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Bioactive lipids act as important 
signalling molecules both in the 
central nervous system and the 
periphery. Bioactive lipids are 
produced by multistep enzymatic 
pathways and after they exert 
their effect by activating their 
specific receptors, they are rapidly 
enzymatically degraded. Altered 
lipid signalling is linked to the 
pathology of several serious diseases. 
In the present study, functional 
autoradiography was applied in a 
novel way to examine the enzymatic 
pathways that synthesize and 
degrade signalling lipids in brain 
sections.
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ABSTRACT 
 
Lipids have recently been recognized as an important class of signalling molecules both in 
the central nervous system and the periphery. Bioactive lipids are produced by multistep 
enzymatic pathways from their membrane phospholipid precursors. After they exert their 
effect by activating their specific receptors, they are rapidly enzymatically degraded.  
Lysophospholipids and endocannabinoids (eCBs) represent two groups of bioactive 
lipids. Lysophosphatidic acid (LPA) is a structurally simple lysophospholipid that mainly 
mediates its actions through six G protein-coupled receptors (GPCRs) (LPA1

6). 
Endocannabinoids, such as anandamide and 2-arachidonoylglycerol (2-AG), are the body’s 
natural agonists for the two GPCRs (CB1 and CB2) that also recognize ∆9-
tetrahydrocannabinol, the psychoactive component present in marijuana. Both LPA and 
eCBs are involved in the development and function of many organ systems as well as in the 
pathology of several serious diseases, such as atherosclerosis and cancer. 
The main objectives of this study were to devise and optimize the methodology used in 
studying lipid-GPCR signalling and to characterize the enzymatic pathways responsible for 
lipid messenger synthesis and degradation. The principal method used in the current study 
was guanosine-5’-O-(3-[35S]thio)-triphosphate ([35S]GTPγS) autoradiography which is 
applied in a novel way to examine the enzymatic pathways that synthesize and degrade 
signalling lipids in brain sections. 
In the first part of the study, the [35S]GTPγS autoradiography method was characterized 
by mapping rat brain regions with prominent [35S]GTPγS binding under basal conditions. A 
liquid chromatography-tandem mass spectrometric method was developed to permit the 
quantitative determination of LPA species from brain tissue samples. Further studies 
revealed that the enzymatic systems synthesizing and metabolizing lipid mediators were 
well preserved in rodent brain cryosections. When LPA/2-AG degradation was 
pharmacologically blocked, brain sections generated endogenous lipids which were able to 
activate their cognate GPCRs during the autoradiography incubations. It was concluded 
that lipid phosphate phosphatases (LPPs) degrade the signalling pool of LPA in brain 
sections but in addition to LPPs, there seems to be alternative phosphatases present in the 
brain that degrade LPA at the whole brain level. The CB1 receptor-dependent Gi protein 
activity remained unaltered in several brain regions of diacylglycerol lipase (DAGL) 
deficient mice when compared to wild-type mice. Alternative enzymes in addition to 
DAGLs seem to be responsible for synthesizing 2-AG in brain sections. It appears that there 
are separate enzymes in the brain that synthesize/degrade the signalling and non-signalling 
lipid pools. Especially when combined with sensitive analytical methods, [35S]GTPγS 
autoradiography represents a valuable tool for studying the life cycle of bioactive lipids. 
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TIIVISTELMÄ 
 
Bioaktiiviset lipidit kuuluvat hormonien kaltaisiin välittäjäaineisiin keskushermostossa 
sekä muualla elimistössä. Bioaktiiviset lipidit tuotetaan monivaiheisten entsymaattisten 
reittien kautta lähtöaineinaan solukalvon fosfolipidit ja reseptorivälitteisen vaikutuksensa 
jälkeen ne hajotetaan entsymaattisesti.  
Lysofosfolipidit ja endokannabinoidit muodostavat kaksi bioaktiivisten lipidien ryhmää. 
Lysofosfolipideihin kuuluva lysofosfatidihappo (LPA) välittää vaikutuksensa pääasiassa 
kuuden G-proteiinikytkentäisen reseptorin (LPA1-6) kautta. Endokannabinoidit, kuten 
anandamidi ja 2-arakidonyyliglyseroli (2-AG), ovat elimistön kannabinoidireseptorien (CB1 
ja CB2) luonnollisia ligandeja. Kannabinoidireseptorit välittävät myös kannabiksen 
psykoaktiivisia vaikutuksia. Sekä LPA että endokannabinoidit ovat osallisina monissa 
elimistön toiminnoissa ja häiriintynyt LPA:n ja endokannabinoidien signalointi liitetään 
useisiin sairauksiin, kuten ateroskleroosiin ja syöpään.    
Bioaktiivisten lipidien toiminnan ymmärtämiseksi tarvitaan menetelmiä, joilla voidaan 
seurata niin lipidien synteesiä, reseptorivälitteistä signalointia kuin entsymaattista 
hajotustakin. Tässä väitöskirjatyössä kehitettiin ja optimoitiin menetelmiä lipidien 
elinkaaren tutkimiseen sekä selvennettiin entsymaattisia reittejä, jotka tuottavat ja 
hajottavat bioaktiivisia lipidejä aivokudoksessa. Pääasiallisena menetelmänä käytettiin 
guanosiini-5’-O-(3-[35S]thio)-trifosfaatti ([35S]GTPγS)-autoradiografiaa, jolla voidaan tutkia 
G-proteiinivälitteistä viestintää kudosleikkeissä. Tutkimuksessa menetelmää sovellettiin 
uudella tavalla entsyymitoiminnan tutkimiseen. 
Tutkimuksessa [35S]GTPγS-autoradiografiamenetelmää karakterisoitiin paikantamalla 
menetelmälle ominainen taustasitoutuminen rotan aivoleikkeissä. Lisäksi kehitettiin 
nestekromatografia-tandem-massaspektrometrimenetelmä LPA:n määrittämiseksi 
aivokudoksesta. Tutkimuksessa havaittiin, että estämällä LPA:a/2-AG:a hajottavien 
entsyymien toimintaa farmakologisilla entsyymi-inhibiittoreilla, endogeeninen lipidi 
kumuloituu aivoleikkeisiin saaden aikaan reseptoriaktivaation, joka voidaan havaita 
[35S]GTPγS-autoradiografian avulla. Tutkimuksen perusteella lipidifosfaattifosfataasit 
hajottavat aivoleikkeissä reseptorivälitteisesti signaloivaa LPA:a, mutta aivokudoksessa 
toimii myös muita LPA:a hajottavia fosfataaseja. Diasyyliglyserolilipaasi (DAGL)-
poistogeenisten hiirten aivoleikkeissä ei useimmilla aivoalueilla havaittu muutoksia CB1-
reseptorivälitteisessä Gi-proteiiniaktiivisuudessa verrattuna villityypin hiiriin. Lisäksi 
pääteltiin, että DAGL-riippumaton entsymaattinen aktiivisuus synnyttää 2-AG:a 
aivoleikkeissä. Aivoissa vaikuttaa olevan erillisiä entsymaattisia reittejä signaloivan ja ei-
signaloivan lipidijoukon synteesiin/hajotukseen. Erityisesti yhdistettynä analyyttisiin 
menetelmiin, [35S]GTPγS-autoradiografia tarjoaa mahdollisuuden seurata bioaktiivisten 
lipidien koko elinkaarta kudosleikkeissä. 
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 1 Introduction 
 
 
Cells are surrounded by the plasma membrane which is made up of a protein-enriched 
phospholipid bilayer. The plasma membrane acts as a kind of skin protecting the cell from 
substances from the outside environment but it also allows messages from outside the cell 
to be mediated into the cell. Lipids have traditionally been seen as structural components of 
cellular membranes or cellular energy sources without any informational functions. During 
last decades, however, lipids have been recognised as being an important class of signalling 
molecules in both the central nervous system (CNS) and the periphery. Several groups of 
these bioactive lipids act through specific G protein-coupled receptors (GPCRs). Under 
normal physiological conditions, the lifetime of bioactive lipids is tightly regulated. 
Bioactive lipids are produced by multistep enzymatic pathways, which are initiated by the 
de-esterification of membrane phospholipids. After the bioactive lipids have exerted their 
action by activating their specific receptors, they are rapidly enzymatically degraded.  
Lysophospholipids and endocannabinoids (eCBs) represent two important groups of 
bioactive lipids. Lysophospholipids can be divided into lysoglycerophospholipids and 
sphingoid lipids. Lysoglycerophospholipids are simple lipids having three structural 
features: a 3-carbon backbone (glycerol), a single aliphatic hydrocarbon chain and a polar 
headgroup. Lysophosphatidic acid (LPA) is one of the best studied 
lysoglycerophospholipid. LPA mainly mediates its actions through six GPCRs (LPA1

6). 
LPA generally evokes hormone- and growth factor-like responses and these are believed to 
be involved in the development and function of neural and vascular systems as well as in 
the function of immune and reproductive systems. Endocannabinoids are the body’s 
natural agonists for the two GPCRs (CB1 and CB2) that also recognize ∆9-
tetrahydrocannabinol (∆9-THC), the psychoactive component present in marijuana. The two 
most extensively studied eCBs are anandamide and 2-arachidonoylglycerol (2-AG). In the 
CNS, eCBs are involved in neurogenesis as well as in cognition, emotional functions, 
regulation of food intake, and pain sensation. In the periphery, eCBs mediate 
cardiovascular, immune, metabolic, and reproductive functions.  
Since both LPA and eCB signalling systems are involved in the development and 
function of several organ systems, it is not surprising that their dysregulated function 
would be associated with a variety of human diseases. Since lipid receptors are widely 
distributed in the body, use of exogenous receptor agonists and antagonists might induce 
side effects in other sites than their target organs. Another way to affect lipid functions 
would be the pharmacological manipulation of enzymes that synthesize and degrade these 
lipids. By inhibiting the activity of the synthesizing/degrading enzymes, one would predict 
that it would be possible to manipulate the levels of endogenous ligands and subsequent 
GPCR activity.  
Before one can understand lipid signalling and subsequently how this knowledge can be 
exploited for drug discovery purposes, it is essential to have suitable methods to monitor 
each step of the life cycle of bioactive lipids, including biosynthesis, receptor signalling and 
enzymatic degradation. Guanosine-5’-O-(3-[35S]thio)-triphosphate ([35S]GTPγS) 
autoradiography has been classically used to detect agonist-driven activity of the receptor-
G protein axis in tissue sections. In the present study, [35S]GTPγS autoradiography has been 
applied in studies of enzymatic pathways that synthesize and degrade signalling lipids in 
rodent brain sections. In brain sections, the receptor G protein-axis as well as enzymatic 
systems remain functional in the right anatomical context. Especially when combined with 
sensitive analytical methods, [35S]GTPγS autoradiography represents a valuable tool for 
studying the regulation of lipid signalling. 
 
2 
 
 
2  Review of the Literature 
 
2.1 G PROTEIN-MEDIATED SIGNALLING 
 
2.1.1 The family of G protein-coupled receptors 
In order to function properly, cells require a machinery that will permit the passage 
messages through the plasma membrane. The family of membrane-bound G protein-
coupled receptors (GPCRs) constitutes one of the largest families of proteins coded by the 
mammalian genome (Fredriksson et al. 2003). GPCRs mediate the signal of a diverse set of 
endogenous ligands such as neurotransmitters, hormones and peptides but detect also 
signals of external origin, acting as sensory receptors for odorants, taste molecules and 
photons of light (Pierce et al. 2002, Maudsley et al. 2005). The total number of human 
GPCRs is estimated to be close to one thousand; about half of them are chemosensory 
receptors and one third (~ 370) represent receptors for endogenous ligands (endoGPCRs) 
(Vassilatis et al. 2003). GPCRs are ubiquitously expressed throughout the body but the 
majority of human GPCRs and endoGPCRs are expressed in the brain (Vassilatis et al. 
2003).  
GPCRs consist of seven α-helical transmembrane domains forming three interhelical 
loops on both sides of the membrane, an extracellular N-terminus, and an intracellular C-
terminus (Latek et al. 2012). Due to the structure formed by a polypeptide passing through 
the plasma membrane seven times, GPCRs are often called seven-transmembrane receptors. 
One common classification (so-called GRAFS system) divides GPCRs into five groups, i.e. 
glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin (Fredriksson et al. 2003, 
Bjarnadottir et al. 2006). The rhodopsin family is the largest family of GPCRs and it includes 
receptors for odorants and endogenous small ligands. On the bases on sequence similarity, 
the rhodopsin family can be further divided into four subclasses (α, β, γ and δ) 
(Fredriksson et al. 2003). The subclasses not only differ between their preferred ligand but 
also in location of their ligand binding domain (Bjarnadottir et al. 2006). The crystal 
structures of 16 members of the rhodopsin family have been resolved (Stevens et al. 2013); 
the pioneering reports described the rhodopsin (Palczewski et al. 2000) and β2-adrenergic 
receptors (Rasmussen et al. 2007, Cherezov et al. 2007). 
At least one third, according to some estimations nearly half, of the currently marketed 
pharmaceutical drugs target GPCRs but there is still potential for drug companies to target 
GPCR signalling. There are receptors that exhibit the heptahelical conformation, the 
hallmark of the GPCRs, but for which there is no known natural ligand; these are called 
orphan receptors. Among the rhodopsin GPCR family, about 67 receptors remain classified 
as orphans and “de-orphanizing” these receptors would be an important goal for drug 
discovery purposes (Civelli et al. 2013).   
 
2.1.2 Signalling via G proteins 
The binding of the ligand induces a conformational change in the receptor protein allowing 
it to interact with other proteins. One feature defining GPCRs is their ability to interact with 
heterotrimeric guanine nucleotide-binding proteins (G proteins). Small, monomeric G 
proteins also exist but they do not couple to GPCRs (Csepanyi-Kömi et al. 2012).  
Heterotrimeric G proteins consist of three subunits, α, β and γ. A substantial number of 
mammalian genes encode G protein subunits (16 genes for α subunit, 5 genes for β subunit, 
12 genes for γ subunit) (Oldham & Hamm 2008). In the resting state, the α subunit of the G 
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protein binds guanosine diphosphate (GDP), and the Gα-GDP is tightly associated with the 
Gβγ-complex. After agonist ligand binding, the receptor adopts a conformation which 
allows it to interact with a G protein, resulting in the exchange of GDP for guanosine 
triphosphate (GTP) in the α subunit. As a consequence, the GTP-bound Gα dissociates from 
the Gβγ complex, enabling both subunit complexes to regulate a variety of effectors 
(Oldham & Hamm 2008, Tuteja 2009). The system returns to its resting state due to the 
activity of guanosine triphosphatase (GTPase) which is an intrinsic part of the α subunit; 
this enzyme hydrolyzes GTP back to GDP. The guanine nucleotide exchange cycle is 
presented in Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The guanine-nucleotide exchange cycle. (A) When agonist is not bound, the receptor 
is uncoupled from the G protein. (B) Binding of an agonist induces a conformational change in 
the receptor and this results in its coupling to the G protein. The G protein is activated and the 
bound GDP is exchanged for GTP. (C) The α subunit of the G protein dissociates from the βγ 
complex and both subunits interact with downstream signalling elements. The α subunit 
hydrolyses bound GTP back to GDP, agonist dissociates from the receptor and the system 
returns to the resting state (modified from Sovago et al. 2001). 
 
 
Based on the amino acid sequence of the α subunits, G proteins can be divided into four 
subfamilies, Gi, Gs, Gq, and G12, and the four Gα subfamilies can be further divided into 
subtypes (Figure 2) (Cabrera-Vera et al. 2003). In addition, five β subunits and twelve γ 
subunits have been identified (Malbon 2005). The majority of endoGPCRs couple to Gi type 
of G proteins (Wong 2003). The type of the α subunit determines the sunsequent 
downstream response (Malbon 2005). Classically, αs activates and αi inhibits adenylate 
cyclase. Adenylate cyclase converts adenosine triphosphate (ATP) into cyclic adenosine 
monophosphate (cAMP) which serves as a second messenger that can activate protein 
kinase A and many other downstream effectors. The αq class proteins activate 
phospholipase Cβ (PLCβ) that catalyzes the formation of diacylglycerol (DAG) and 
inositol-1,4,5-trisphosphate (IP3) that regulate protein kinase C activity and intracellular 
calcium levels, respectively. The α12 class can stimulate Rho guanine nucleotide-exchange 
factors.  
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     Gi                 αi1, αi2, αi3, αoA, αoB, αt1, αt2, αgust, αz  
    
     Gs    αs, αsXL, αolf  
  α     
     Gq    αq, α11, α14, α15/16 
G protein  β  
     G12    α12, α13  
  γ 
   
Figure 2. Illustration of subunits of heterotrimeric G proteins (based on Cabrera-Vera et al. 
2003, Malbon 2005). 
 
 
In addition to the heterotrimeric G proteins, GPCRs interact with other proteins, called 
GPCR interacting proteins (GIPs) (Bockaert et al. 2010). GIPs are believed to control GPCR 
subcellular localization and the fine-tuning of GPCR signalling. Desensitization is a 
mechanism to dampen GPCR signalling at the receptor level (Maudsley et al. 2005). This 
process starts with phosphorylation of either resting or agonist-stimulated receptors by 
kinases. β-Arrestins (type 1 and 2) are GIPs that bind to agonist-occupied, phosphorylated 
GPCRs (Shenoy et al. 2011, Shukla et al. 2011). β-Arrestins desensitize receptors by 
sterically preventing G protein coupling and also promote the internalization, endocytosis 
and recycling/degradation of GPCRs. In addition, β-arrestins can initiate signalling that is 
independent of G proteins via scaffolding signalling molecules in close proximity to an 
activated GPCR.  
On the other hand, G proteins can be activated by other proteins distinct from GPCRs. 
These proteins, called activators of G protein signalling (AGS), can regulate heterotrimeric 
G protein signalling in the absence of GPCRs (Sato et al. 2006, Blumer et al. 2007). The third 
group of compounds, regulators of G protein signalling (RGS), can accelerate the GTPase 
activity of the G protein α-subunit and through this mechanism they can attenuate GPCR 
signalling (Neubig & Siderovski 2002). In summary, regulation of GPCR signalling is a 
complex process, in which several different proteins may be involved in addition to the 
classical cascade mediated by GPCR-heterotrimeric G protein axis. 
 
2.1.3 Functional diversity of GPCR ligands 
According to classical view, agonist (“key”) is a molecule that binds to a receptor (“lock”) 
and induces a conformational change in the receptor protein, which leads to stimulation of 
G protein activity. A more advanced receptor theory postulates that GPCRs exist in a 
dynamic equilibrium between inactive (R) and active (R*) states (Samama et al. 1993). 
According to this model, agonists shift the equilibrium toward the activated states. 
Agonists can be further divided into full and partial agonists; full agonist stabilizes the R* 
conformation and generates maximal response (full efficacy) whereas partial agonists have 
lower intrinsic efficacy, thus producing a sub-maximal response. Neutral antagonists bind to 
both R and R* and do not affect the basal equilibrium. They have no stimulating effect itself 
but they block agonists from binding. A constitutive receptor activity is a state where the 
receptors exist in their active conformation in the absence of any ligand (Lefkowitz et al. 
1993). Inverse agonists bind preferentially to inactive states and decrease the level of 
constitutive activity (Samama et al. 1994). In nonconstitutively active systems, inverse 
agonists act as antagonists. So called protean agonists are ligands that act as partial agonists 
in some systems and as inverse agonists in others (Kenakin 2001).  
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Furthermore, the term orthosteric ligand refers to a ligand that binds to the natural ligand-
binding site (orthosteric site) on the receptor and thus directly competes with the natural 
ligand for receptor binding (Kenakin & Miller 2010). In contrast, allosteric ligands are ligands 
that bind at a site different from the orthosteric binding site but they can still influence the 
functional properties of the receptor. Bitopic ligands have both orthosteric and allosteric 
properties.  
The majority of the current drug molecules targeting GPCRs bind to an orthosteric site of 
the receptor. These drugs either activate receptor (agonists), block the binding of the 
natural agonist (neutral antagonists), or block constitutive receptor activity (inverse 
agonists). Another possible way in which a drug can influence GPCR function would be via 
so called allosteric modulation i.e. in that case the drug would either inhibit or potentiate an 
orthosteric ligand’s binding affinity and/or modulate its signalling efficacy (Kenakin 2010). 
Allosteric modulators can also mediate receptor activation in their own right either via G 
proteins or in a G protein-independent manner (via β-arrestins). When compared to 
orthosteric ligands, allosteric modulators would provide a more selective effect e.g. they 
would act on only a certain receptor subtypes since they target unique regions of the 
receptor.   
 
2.1.4 Lipids as ligands for GPCRs 
Lipid-structured mediators can act in either an intercellular or intracellular manner. The 
intercellular lipid mediators include hormones and hormone-like signallig molecules that 
act via specific receptors, generally either via GPCRs or nuclear receptors (Shimizu 2009, 
Evans & Hutchinson 2010). Intracellular lipid mediators, instead, refer to the second 
messengers such as DAG and IP3.  
The first bioactive lipids that were recognized to signal via GPCRs were the 
cyclooxygenase (COX) products of arachidonic acid metabolism, the prostaglandins and 
thromboxane (Coleman et al. 1994). The prostaglandins and the COX enzymes are perhaps 
the most well-known and most widely utilized lipid targets; the classical COX-inhibitor, 
aspirin, has been on the market for more than 110 years. According to current knowledge, a 
number of bioactive lipids such as leukotrienes, prostanoids, platelet-activating factor, 
lysophospholipids, and endocannabinoids, act via GPCRs and regulate essential cellular 
functions and immune responses (Howlett 2005, Shimizu 2009) (Table 1). In addition, other 
lipids, such as bile acids and steroids as well as short and long chain fatty acids, have been 
reported to bind to GPCRs, but additional studies are still needed to confirm these lipid-
GPCR interactions (Shimizu 2009). 
After the cloning of the cannabinoid CB1 receptor (Devane et al. 1988), several GPCRs for 
intercellular lipid mediators have been cloned. The classification of lipid GPCRs recognizes 
more than 30 receptors that belong to the rhodopsin family of GPCRs (Howlett 2005, Bäck 
et al. 2011, Ye et al. 2009, Brink et al. 2004, Woodward et al. 2011, Chun et al. 2010, Pertwee 
et al. 2010) (Table 1, Figure 3). A few specific families of lipid GPCRs have appeared; for 
example the endothelial differentiation gene (Edg) family consists of three receptors for 
lysophosphatidic acid (LPA1

3) and five receptors for sphingosine 1-phosphate (S1P1

5). 
Members of this family are 40% homologous with the cannabinoid receptors (CB1 and CB2) 
(Shimizu 2009). In addition to the identified lipid receptors, some of the GPCRs found in 
the phylogenetic tree still remain orphans (Figure 3).  
Crystallography studies have revealed differences in the properties of GPCRs e.g. in the 
ligand binding pockets between different GPCR subfamilies, reflecting diversity of the 
endogenous ligands (Katritch et al. 2013, Rosen et al. 2013). Generally, the rhodopsin GPCR 
family bind their ligands from the extracellular milieu. At present, the crystal structure for 
one lipid GPCR, the S1P1 receptor, has been resolved (Hanson et al. 2012). The structure of 
S1P1 receptor reveals a unique configuration of the extracellular loops and the N terminus; 
the N terminus has a well-ordered α-helix on top of the receptor, which in conjuction with 
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the extracellular loops occludes access to the ligand binding pocket from the extracellular 
environment. Instead, there is a large gap between helices I and VII that provides direct 
lateral access of the ligand into the binding pocket from the lipid bilayer. Though the 
crystal structures of other lipid GPCRs have not been resolved, it is believed that also 
endogenous cannabinoids gain access to the cannabinoid receptors via the lipid bilayer 
(Hurst et al. 2010, Hurst et al. 2013).  
 
 
Table 1. Lipid GPCRs, their endogenous ligands and primary biological functions (according to 
Howlett 2005, Bäck et al. 2011, Ye et al. 2009, Brink et al. 2004, Woodward et al. 2011, Chun 
et al. 2010, Pertwee et al. 2010).  
Receptor Endogenous ligands Biological functions 
Leukotriene and lipoxin   
CysLT1, CysLT2 Leucotrienes C4, D4 and E4  
(LTC4, LTD4 and LTE4, respectively)  
 
Inflammation, chemotaxis, 
immune regulation, smooth 
muscle contraction 
 
BLT1, BLT2 Leucotriene B4 (LTB4) 
FPR2/ALX Lipoxin A4 (LXA4) 
Oxoeicosanoid    
5-oxo-ETE/OXE 5-oxo-6,8,11,14-eicosatetraenoic 
acid (5-oxo-ETE), 
hydroperoxyeicosatetraenoic acid 
(5-HPETE), hydroxyeicosatetraenoic 
acid (5-HETE) 
 
  
 
 Chemotaxis 
  
Prostanoids    
DP1, DP2/CRTH2 Prostaglandin D2 (PGD2)  
 
Fever, pain, inflammation, EP14 Prostaglandin E2 (PGE2) 
FP Prostaglandin F2α (PGF2α)  vasodilatation 
 
 IP Prostacyclin (PGI2) 
TP Thromboxane A2 (TXA2) Platelet aggregation, 
vasoconstriction 
Platelet-activating factor 
(PAF) 
  
PAF PAF and PAF-like lipids Inflammation, chemotaxis, 
platelet-activating mediator 
Lysophospholipid   
LPA16 Lysophosphatidic acid (LPA) Cell proliferation, differentiation, 
migration, adhesion, 
morphogenesis S1P15 Sphingosine 1-phosphate (S1P)  
Cannabinoid   
CB1, CB2 2-arachidonoylglycerol (2-AG), 
anandamide 
Brain function, immune 
regulation, analgesia 
 
The life cycle of bioactive lipids can be divided into three main parts: synthesis from 
membrane phospholipids, receptor stimulation and rapid enzymatic hydrolysis. 
Traditionally, classical water-soluble neurotransmitters, hormones etc. are pre-synthesized 
and stored in vesicles before their release from the cell. Due to their hydrophobic nature, 
bioactive lipids are not stored in the vesicles but instead are produced locally only when 
needed, “on demand”. After their biosynthesis and action on their specific receptors, 
bioactive lipids are usually degraded enzymatically. The synthesis, receptor activation and 
metabolism of lipid mediators are tightly regulated under normal physiological conditions, 
and enzyme and/or receptor dysfunction can lead to several disease states.   
Pharmacological means to affect lipid GPCR function include not only exogenous 
receptor ligands/allosteric modulators but also compounds that target the enzymes that 
synthesize or degrade endogenous lipid ligands. Since lipids are synthesized on demand in 
7 
 
 
a site-dependent manner, pharmacological inhibition of the enzymes that degrade these 
lipids would be anticipated to lead to local accumulation of endogenous ligands and 
subsequent GPCR activation. This approach would make it possible to avoid the side-
effects associated with exogenous agonists that target the receptors in all parts of the body. 
Conversely, inhibition of lipid synthesizing enzymes would decrease the levels of the 
endogenous agonist, and in this way, evoke a reduction in GPCR activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Phylogenetic tree of GPCRs including established lipid GPCRs and some orphan 
receptors (Reprinted from Shimizu 2009 with permission from Annual Reviews, Inc.).  
 
 
 
 
2.2 OVERVIEW OF LYSOPHOSPHATIDIC ACID SIGNALLING  
2.2.1 Definition of lysophospholipids 
In the early 1900s, lysophospholipids were first recognized in a study investigating a snake 
venom that acted on lecithin (from Greek “lekithos” meaning egg yolk, later used as 
synonym for phosphatidylcholine (PC)) to produce lysolecithin, where the “lyso”-prefix 
referred to the hemolytic effect on red blood cells (Chun 2007). Lysophospholipids can be 
divided into lysoglycerophospholipids and sphingoid lipids. Lysoglycerophospholipids are 
enzymatically synthesized from membrane phospholipids and they display three structural 
features: a 3-carbon backbone, a single aliphatic hydrocarbon chain and a polar head group. 
A single carbon chain can vary in its length and saturation. Sphingoid lipids, instead, are 
synthetized by the sphingosine kinase-catalyzed phosphorylation of sphingosine (Pyne et 
al. 2009). Since lysophospholipids are rather simple in their structure they are able to 
interact with a diverse array of biomolecular targets, including both membrane and nuclear 
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receptors and enzymes (Parrill 2008). The two best characterized lysophospholipids are 
LPA and S1P (Figure 4). Other lysophospholipids include lysophosphatidylcholine (LPC), 
sphingosylphosphorylcholine (SPC), lysophosphatidylserine (LPS), 
lysophosphatidylethanolamine (LPE), and lysophosphatidylinositol (LPI) (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Chemical structures of lysophospholipids. For S1P and SPC, R = (CH2)12CH3, for others, 
R = acyl with a variable chain length and unsaturation.  
 
Lysophospholipids mediate the majority of their responses via specific GPCRs. There are 
currently 11 bona fide GPCRs identified for lysophospholipids (LPA1

6 and S1P1

5) and 10 
receptor null-mice for lysophospholipid GPCRs have been described (LPA1

5 and S1P1

5) 
(Choi & Chun 2013). In addition to LPA and S1P receptors, there are potential receptors for 
other lysophospholipids among the large group of orphan GPCRs in the human genome. 
Orphan receptors G2A, GPR4, ORG1 and TDAG8 were first claimed to be activated by 
LPC, SPC and/or psychosine, but according to the current view, these receptors act as 
proton-sensing receptors and are not directly activated by lysophospholipids (Seuwen et al. 
2006). Relatively strong evidence has been provided for the designation of GPR55 as an LPI 
receptor (Oka et al. 2007, Pertwee et al. 2010, Pineiro & Falasca 2012).  
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Lysophospholipid GPCRs are widely expressed both in the brain and the periphery. 
Lysophospholipids regulate a wide variety of cellular responses, being involved in the 
development of organ systems, such as nervous, vascular and reproductive systems, but 
they also enhance cancer growth and metastasis, inflammation and the development of 
atherosclerotic plaques (Mutoh et al. 2012). Their structure, wide expression pattern, and 
involvement in so many processes in the body make lysophospholipids attractive drug 
targets. The first drug on the market affecting lysophospholipid signalling is the 
immunosuppressive compound, fingolimod (FTY720, Gilenya®), that was approved by 
Food and Drug Administration in 2010 as the first oral therapy for multiple sclerosis 
(Brinkmann et al. 2010, Chun & Brinkmann 2011). In the body, fingolimod is 
phosphorylated by endogenous sphingosine kinases, resulting in the formation of the 
bioactive fingolimod-phosphate, which acts as an agonist for S1P1 and S1P3

5 receptors.  
 
2.2.2 LPA and its physiological roles 
Different molecular species of LPA exist in vivo. The acyl group of LPA can differ in length 
and its degree of unsaturation; there are saturated and mono- and poly-unsaturated 
variants of either sn1 or sn2 regioisomers. As a signalling molecule, the term LPA generally 
refers to 1-acyl-2-hydroxy-sn-3-phosphate (Figure 4). 
It was long believed that the main source of LPA was blood. Early work indicated that 
LPA was present in serum and originated from activated platelets (Eichholtz et al. 1993). 
Currently it is known that in addition to blood, LPA can be found in other body fluids such 
as saliva (Sugiura et al. 2002), seminal plasma (Hama et al. 2002), and bronchoalveolar 
lavage fluid (Tager et al. 2008). The serum LPA is bound to albumin, gelsolin and other 
proteins which stabilize it in these hydrophilic environments and possibly protect it from 
rapid degradation (Tigyi & Miledi 1992, Goetzl et al. 2000). In addition to body fluids and 
platelets, several cell types, including adipocytes and ovarian cancer cells, can produce and 
release LPA (Mills et al. 2002, Federico et al. 2012).  
LPA generally evokes hormone- and growth factor-like responses. Cells can respond in 
many different ways to LPA; LPA is most often associated with proliferative responses, but 
it also stimulates cell motility and migration, cytoskeletal reorganization, and process 
retraction (Moolenaar et al. 2004). Cellular migration plays central role in embryonic 
development and on the other hand, in the conversion of tumours so that they acquire an 
invasive and metastatic phenotype. 
Significant amounts of LPA have been detected in the brain tissue (Sugiura et al. 1999, 
Nakane et al. 2002). In the brain, LPA has been identified in neural progenitors, primary 
neurons, oligodendrocytes, astrocytes, microglia, and brain endothelial cells, e.g. being 
involved in neurogenesis and myelination (Ye et al. 2002). In several types of primary 
neurons, LPA has been demonstrated to induce morphological changes, such as neurite 
retraction and growth cone collapse as well as to regulate migration, cell death/survival, 
synapse formation, and synaptic transmission (Ye et al. 2002, Pilpel & Segal 2006, Choi & 
Chun 2013). 
 
2.2.3 LPA receptors 
Early work indicated that LPA was a constituent of a mysterious smooth muscle-
stimulating substance, Darmstoff (Vogt 1963). Further studies suggested that LPA could be 
involved in the regulation of blood pressure but the mechanism of this action was not clear 
(Sen et al. 1968, Tokumura et al. 1978). Later, signalling cascades mediated by LPA were 
shown to involve G proteins (van Corven et al. 1989). Currently, six LPA receptors 
belonging to the rhodopsin GPCR family have been identified (Table 2). The first LPA 
receptor was cloned in 1996 from the ventricular zone of the developing mouse cerebral 
cortex and originally named the ventricular zone gene-1 (Vzg-1) (Hecht et al. 1996). This 
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receptor, currently called LPA1, belongs to the Edg family. In addition to LPA1, two other 
Edg members (LPA2, LPA3) have been described (An et al. 1998, Bandoh et al. 1999). The 
LPA1

3 receptors share 5057% amino acid identity with each other. In addition to the Edg 
family, another non-Edg group of GPCRs has been claimed to act as LPA receptors (LPA4

6) 
(Noguchi et al. 2003, Kotarsky et al. 2006, Lee et al. 2006, Pasternack et al. 2008, Lee et al. 
2009). LPA4

6 are closely related to the subfamily of P2Y purinergic receptors and share only 
2024% amino acid identity with LPA1

3. Evidently, LPA receptors have evolved via two 
distinct lineages. Additional GPCRs for LPA have also been putatively described in the 
literature (Tabata et al. 2007, Murakami et al. 2008, Oka et al. 2010) but further studies will 
be needed to clarify if these receptors truly mediate the biological effects of LPA.  
In addition to G protein-mediated pathways, LPA-stimulated GPCR activation can lead 
to activation of nuclear factor-κB pathway e.g. via β-arrestins (Sun & Yang 2010). LPA has 
also been demonstrated to activate the peroxisome proliferator-activated receptor γ 
(PPARγ) (McIntyre et al. 2003). The PPARγ acts as a transcription factor e.g. controlling 
genes that are involved in glucose and fatty acid metabolism and in adipocyte 
differentiation. LPA has been reported to displace the full agonist, the antidiabetic agent, 
rosiglitazone, from PPARγ (Parrill 2008). The relevance of LPAPPARγ signalling still 
remains somewhat controversial.  
 
 
Table 2. Confirmed GPCRs for LPA, their expression patterns and signalling pathways.   
  
Receptor Other  
names 
Primary expression 
loci in mice 
G protein 
coupling 
Downstream 
responses 
References 
LPA1 Edg2,  
Vzg-1 
Brain, uterus, testis, 
lung, small intestine, 
heart, stomach, kidney, 
spleen, thymus, placenta, 
skeletal muscle 
Gi, Gq,  
G12 
Inhibition of AC, 
activation of Ras, 
PI3K, PLC, Rho 
Hecht et al. 
1996, Choi et 
al. 2010 
LPA2 Edg4 Kidney, uterus, testis, 
lung, stomach, spleen, 
thymus, brain, heart 
Gi, Gq,  
G12 
Inhibition of AC,  
activation of Ras, 
PI3K, PLC, Rho 
An et al. 1998, 
Choi et al. 
2010 
LPA3 Edg7 Testis, kidney, lung, 
small intestine, heart, 
stomach, spleen, brain, 
thymus 
Gi, Gq Inhibition of AC,  
activation of Ras, 
PI3K, PLC 
Bandoh et al. 
1999, Choi et 
al. 2010 
LPA4 GPR23,  
P2Y9 
Heart, skin, thymus, 
ovary, developing brain, 
embryonic fibroblasts 
Gi, Gq, G12, 
Gs 
Inhibition of AC 
activation of AC, 
Ras, PI3K, PLC, Rho  
Noguchi et al. 
2003, Lee et al. 
2007, Choi et 
al. 2010 
LPA5 GPR92 Widely expressed, such 
as embryonic brain, small 
intestine, skin, spleen, 
stomach, thymus, lung, 
heart, liver, embryonic 
stem cells 
Gq, G12 Activation of PLC 
and Rho 
Kotarsky et al. 
2006, Lee et al. 
2006, Choi et 
al. 2010 
LPA6 P2Y5 In humans: hair follicle Gi, Gs, G12  
 
Inhibition of AC,  
activation of AC, 
Ras, PI3K, PLC, Rho 
Lee et al. 2009, 
Pasternack et 
al. 2008 
Abbreviations: AC, adenylate cyclase; PI3K, phosphatidylinositol-3-kinase; PLC, phospholipase 
C. 
  
Each LPA GPCR displays a distinct ligand selectivity profile for the various LPA species, 
e.g. LPA3 is more potently activated by an LPA with an acyl chain at the sn-2 position 
(Bandoh et al. 2000). Generally, LPAs with unsaturated fatty acids are more potent in 
activating LPA receptors than LPAs with saturated fatty acids (Bandoh et al. 2000, Fujiwara 
et al. 2005). LPA signalling is complex due to the large number of LPA species, receptors 
and signalling partners. Furthermore, different cells can express different receptors but 
some cells and tissues express several different LPA receptor subtypes (Moolenaar et al. 
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2004). The LPA-induced response largely depends on the cell in question, e.g. LPA 
increases the survival of certain cancer cells by protecting them from apoptosis (Meng et al. 
2005), but on the other hand, it has been reported to promote apoptosis of hippocampal 
neurons (Ye et al. 2002).  
All the six identified LPA receptors are expressed at varying levels in the different types 
of cells in the CNS, especially during embryonic development and/or postnatal life. The 
principal LPA receptor in the brain is LPA1, and the major site of its expression is the white 
matter tracts of the developing nervous system (Choi et al. 2010). During embryonic stage, 
the LPA1 receptor is highly expressed in the ventricular zone where the neural progenitor 
cells are located, playing a role in cortical development. During postnatal life, LPA1 is 
located within oligodendrocytes, the myelinating cells of the CNS, as demonstrated by in 
situ hybridization (Weiner et al. 1998, Stankoff et al. 2002) and immunohistochemistry 
(Handford et al. 2001, Cervera et al. 2002). LPA1 is also expressed in astrocytes, microglia, 
and neurons. In mice, LPA1 expression peaks at 35 weeks after birth and diminishes 
thereafter (Contos & Chun 2001). In the healthy adult mouse nervous system, the LPA1 
receptor is weakly expressed but is upregulated following spinal cord or brain injury 
(Goldshmit et al. 2010).  
Knockout (KO) mice for five LPA receptors (LPA1

5) have been reported. In the LPA1-
KO, the brain development was disturbed as evidenced by a smaller brain size with 
reduced cortical width and cerebral wall thickness (Contos et al. 2000). Combined with a 
defect in the suckling behaviour due to impaired olfaction, these disabilities resulted in 50% 
neonatal lethality. In the LPA1 receptor knockout mice, altered levels of neurotransmitters 
(serotonin, gamma-aminobutyric acid (GABA), glutamate) have been detected, indicating 
that LPA might have a role in modulating synaptic transmission (Harrison et al. 2003, 
Roberts et al. 2005). LPA3-deficient female mice showed delayed embryo implantation, 
altered embryo spacing, and reduced litter size (Ye et al. 2005). Defects in prostaglandin 
levels were also observed indicating co-operation between the LPA3 receptor and 
prostaglandin signalling in the embryo implantation. LPA2 (Contos et al. 2002) and LPA5 
(Lin et al. 2012) knockout mice were born normally and displayed no phenotypic 
abnormalities. Conflicting data appear with LPA4 knockouts; a normal phenotype was 
originally reported (Lee et al. 2008) but later, defects in blood vessel and lymphatic vessel 
formation have been observed (Sumida et al. 2010). 
 
2.2.4 Biosynthesis of LPA  
Biosynthesis of LPA occurs through multi-step enzymatic pathways. LPA is generated 
locally in specific tissues, both intracellularly and extracellularly. It is postulated that 
intracellular LPA mainly acts as an intermediate for phospholipid synthesis whereas 
extracellular LPA mediates signalling functions (Okudaira et al. 2010). Two main routes for 
LPA production have been postulated in the literature; in the first pathway, LPA is 
produced from lysophospholipids by autotaxin (ATX) and in the second pathway by 
deacylation of phosphatidic acid (PA). 
 
 
LPA synthesis by autotaxin 
 
Extracellularly, LPA is generated from lysoglycerophospholipids, such as LPC, by 
enzymatic removal of the polar headgroup (Figure 5). The principal enzyme for the 
generation of circulating LPA has been claimed to be ATX. ATX was originally detected as 
an autocrine motility factor isolated from the conditioned medium of cancer cells (Stracke 
et al. 1992). Ten years later, ATX was observed to act as a secreted lysophospholipase D 
(Umezu-Goto et al. 2002, Tokomura et al. 2002). Structurally ATX belongs to the nucleotide 
pyrophosphate/phosphodiesterase family of enzymes, which hydrolyse pyrophosphate or 
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phosphodiester bonds of several molecules, typically ATP and adenosine diphosphate 
(ADP). The main substrate for ATX is LPC, but ATX can also hydrolyse SPC to S1P (Clair et 
al. 2003). ATX does not hydrolyse compounds with a double acyl chain, e.g. PC, and 
therefore it is not identical in action to classical phospholipase D (PLD). The ATXLPA axis 
shows feedback inhibition as the biosynthesis product LPA inhibits ATX activity (van 
Meeteren et al. 2005). ATX is activated by divalent cations such as Co2+, Zn2+, Mn2+, and Ni2+ 
(Lee et al. 2001). 
ATX is abundant in the blood and other biological fluids, and is also expressed in the 
brain as well as in the kidney and lymphoid organs (Okudaira et al. 2010). Several findings 
suggest that ATX is the main enzyme generating circulating LPA. It has been reported that 
plasma LPA levels correlate with the serum ATX activity (Hosogaya et al. 2008). Depletion 
of ATX completely prevents LPA production in the serum (Tanaka et al. 2006, Tsuda et al. 
2006) whereas ATX overexpression in transgenic mice increases LPA plasma levels 
(Pamuklar et al. 2009). Heterozygous ATX-knockouts develop normally but have 50% 
lower plasma LPA concentrations when compared to the corresponding wild-type mice 
(Tanaka et al. 2006). Importantly, the homozygous ATX knockout in mice is embryonically 
lethal, due to the failure in the maturation of vessels in autotaxin-null embryos, indicating 
that the ATXLPA axis is an essential component in the blood vessel formation during 
development (Tanaka et al. 2006). LPA receptor knockout animals show less severe 
phenotype than ATX knockout animals, which may reflect that ATX also acts on LPA-
independent pathways or via yet unidentified LPA receptors. Crystal structures of ATX as 
well as the ATXLPA complex have been resolved (Nishimasu et al. 2011, Hausmann et al. 
2011). It has been postulated that in addition to generating LPA, ATX might behave as a 
lipid-carrier protein that transfers LPA directly to the LPA receptors (Nishimasu et al. 
2011).  
 
Other pathways for LPA generation  
 
In the intracellular milieu or on the plasma membrane, LPA is mainly generated via a 
pathway in which PA is first generated from phospholipids or from DAG and then 
deacylated by phospholipase A1/A2 (PLA1/PLA2, respectively) (Figure 5). PLA1 produces 2-
acyl-lysophospholipids whereas PLA2 produces 1-acyl-lysophospholipids and is also 
involved in the production of prostaglandins and the PAF (Aoki et al. 2008). Additional 
pathways for LPA generation include acylation of glycerol 3-phosphate by 
glycerophosphate acyltransferase (GPAT) or phosphorylation of monoacylglycerol (MAG) 
by monoacylglycerol kinase (MAGK) (Tigyi & Parrill 2003, Moolenaar et al. 2004, Bektas et 
al. 2005, Okudaira et al. 2010) (Figure 5).   
The intracellular LPA synthesis occurs in the endoplasmic reticulum or in mitochondria. 
Intracellularly generated LPA likely serves as a precursor for glycerophospholipid 
synthesis rather than for signalling purposes. Intracellularly produced LPA might play a 
role in activating the nuclear receptor PPARγ (Zhang et al. 2004). The biosynthetic and 
degradative pathways for LPA have also been detected in the nuclear membrane and/or 
within the nucleus of cells (Baker & Chang 1999, Baker & Chang 2000). Nuclear localization 
may protect LPA from the otherwise rapid degradation.  
There are several isozymes for both PLA1 and PLA2. Among PLA1 isozymes, membrane-
bound PA-selective PLA1α and β (mPA-PLA1α and β), also called LIPH and LIPI, 
respectively, hydrolyse PA producing 2-acyl-lysophosphatidylserine and 2-acyl-LPA, 
respectively (Aoki 2004, Aoki et al. 2008). Interestingly, evidence has been provided that 
mPA-PLA1α/LIPH is expressed in hair follicles. Deletion in the gene encoding mPA-
PLA1α/LIPH cause hair growth defects in humans (Kazantseva et al. 2006). Defects in hair 
growth have also been detected when the gene encoding the LPA6 receptor is disrupted 
(Pasternack et al. 2008, Shimomura et al. 2008). These observations and the co-localization 
of PLA1α/LIPH and the LPA6 receptor in hair follicles indicate that LPA produced by mPA-
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PLA1α/LIPH and signalling via the LPA6 receptor plays a role in the regulation of hair 
growth (Inoue et al. 2011).  
 
 
Pharmacological inhibition of LPA generation 
At present, the development of pharmacological inhibitors of LPA-generating enzymes has 
focused on ATX. A few pharmacological inhibitors of ATX activity have been described 
including lipid analogs (e.g. cyclic phosphatidic acids), metal chelators (L-histidine, 
ethylenediaminetetraacetic acid (EDTA)) and nonlipid small molecules (Jankowski 2011). 
One of the first small molecular inhibitors is S32826 that inhibits ATX in nanomolar range, 
shows ATX inhibition in cellular models but is unstable in vivo (Ferry et al. 2008). More 
recently, thiazolidinediones with a boronic acid moiety (e.g. HA130 and HA155) (Albers et 
al. 2010, Albers et al. 2011) as well as compound PF-8380 (Gierse et al. 2010) were reported 
to inhibit ATX in nanomolar range and to reduce LPA levels in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Enzymatic pathways for the biosynthesis and degradation of LPA. Abbreviations: ATX, 
autotaxin; DAG, diacylglycerol; DAGK, diacylglycerol kinase; GP, glycerol phosphate; GPAT, 
glycerophosphate acyltransferase; LPAAT, lysophosphatidic acid acyltransferase; LPA, 
lysophosphatidic acid; LPC, lysophosphatidylcholine; LPL, lysophospholipase; LPP, lipid 
phosphate phosphatase; MAG, monoacylglycerol; MAGK, monoacylglycerol kinase; PA, 
phosphatidic acid; PLA, phospholipase A; PLD, phospholipase D (Based on Okudaira et al. 
2010). 
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2.2.5 Enzymatic degradation of LPA   
The lifetime of the signalling pool of LPA is thought to be controlled by enzymatic 
degradation. Although the degradation terminates LPA signalling as such, the degradation 
products can be used as precursors for other signalling lipids. The principal pathway for 
LPA degradation is believed to be enzymatic removal of the phosphate group producing 
MAG (Figure 5).  
 
Dephosphorylation via lipid phosphate phosphatases  
 
LPA is rapidly dephosphorylated by a family of integral membrane proteins known as lipid 
phosphate phosphatases (LPPs), originally named PAP2 (Pyne et al. 2004, Sigal et al. 2005, 
Brindley & Pilquil 2009). The PAP1 family of phosphatases (also known as lipins), instead, 
selectively dephosphorylate PA during lipid biosynthesis (Brindley et al. 2009). LPPs 
belong to a larger family of proteins that include sphingosine phosphate phosphatases, 
sphingomyelin synthases as well as other less well characterized proteins (Sigal et al. 2005). 
In addition to LPA, LPP substrates include PA, S1P, and ceramide 1-phosphate (C1P), 
producing diacylglycerol, sphingosine, and ceramide (Waggoner et al. 1996). 
The LPP family comprises four members (LPP1, LPP2, LPP3 and the splice variant 
LPP1a) (Waggoner et al. 1996, Kai et al. 1997, Roberts et al. 1998). It has been demonstrated 
that LPP1 and LPP3 hydrolyse LPA and PA more effectively than C1P or S1P, whereas 
LPP2 most readily hydrolyses LPA and S1P (Pyne et al. 2004). LPP1 and LPP3 are widely 
expressed in human tissues whereas LPP2 expression is more restricted (Sigal et al. 2005). 
All the enzyme subtypes are expressed in the brain, with LPP1 and LPP3 being the most 
extensive (Kai et al. 1997, Hooks et al. 1998, Sigal 2005). At the subcellular level, LPPs have 
been localized to the endoplasmic reticulum and plasma membrane, and possibly to other 
endomembrane compartments, such as the Golgi apparatus. LPPs are characterized by six 
membrane spanning domains with three extracellular loops with the active site facing the 
extracellular side of the plasma membrane or the luminal side of intracellular membranes 
(Zhang et al. 2000b). The hallmarks of the LPP activity are that it does not require Mg2+ and 
it is resistant to the alkylating agent, N-ethylmaleimide (NEM) (Jamal et al. 1991).  
There is evidence to indicate that LPP-catalysed degradation of LPA can regulate LPA 
signalling. For example, over-expression of LPP3 in ovarian cancer cells reduced tumour 
growth in vitro and in vivo (Tanyi et al. 2003a). LPP activity decreased LPA accumulation in 
platelets (Smyth et al. 2003) and in pre-adipocytes (Simon et al. 2002). Knockout studies of 
all the LPP subtypes have been described. A study with LPP1-KO mice indicated that LPP1 
plays a role in regulating the degradation of circulating LPA in vivo (Tomsig et al. 2009). 
However, in that study there was no disruption of the LPP1 encoding gene in the brain, a 
phenomenom for which the authours could not supply a plausible explanation. In fact, 
LPP1 knockout mice showed a normal phenotype. In contrast, the knockout of LPP3 
proved to be embryonically lethal (Escalante-Alcade et al. 2003). In vitro studies using cell 
lines lacking LPP3 link LPP3 to early neural development (Sanchez-Sanchez 2012). LPP2 
knockout mice exhibit no obvious phenotypic defects (Zhang et al. 2000a).  
Plasticity-related genes (PRGs) are a group of recently identified, brain-specific 
membrane proteins that were originally proposed to act as LPA phosphatases (Bräuer & 
Nitsch 2008, Strauss & Bräuer 2013). Among the family of PRGs, PRG-1 shares close 
homology to the LPPs, having three conserved integral membrane domains facing the 
extracellular side of the plasma membrane, a feature that enables LPPs to dephosphorylate 
their lipid substrates. However, the catalytic residues responsible for LPP activity are not 
fully conserved in PRGs (Bräuer & Nitsch 2008) suggesting that PRGs might not act as LPA 
phosphatases. Instead, PGR-1 was recently demonstrated to be active at the postsynaptic 
side of the excitatory glutamatergic synapse where it may mediate the uptake of bioactive 
lipids (Trimbuch et al. 2009). PRG-1 was found to effectively control the levels of LPA in the 
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synapse though its mechanism of action seems to be more transporter-like than 
dephosphorylating.   
 
Other pathways for LPA degradation 
In comparison to dephosphorylation, the other pathways for LPA metabolism are less well 
characterized. The other known pathways include the de novo formation of PA by 
lysophosphatidic acid acyltransferase (LPAAT) and the lysophospholipase-catalyzed 
hydrolysis of the acyl group to form glycerol phosphate (GP) (Tigyi & Parrill 2003) (Figure 
5). The LPAAT enzymes transfer an acyl group from acyl-coenzyme A to LPA to form PA. 
Several members of the LPAAT family have been sequenced including both 
transmembrane and membrane associated proteins (Tigyi & Parrill 2003). A majority of the 
characterized lysophospholipases act on LPC. Neuropathy target esterase (NTE) is a 
membrane-bound serine hydrolase that is localized within neurons and it has been shown 
to act as a lysophospholipase, hydrolyzing LPC (Quistad et al. 2003, van Tienhoven et al. 
2002, Vose et al. 2008). The NTE-related esterase was reported to hydrolyze both LPC and 
LPA (Kienesberger et al. 2008). However, very little is known about the role of these 
enzymes in vivo, especially the possibilities to act as regulators of LPA receptor signalling. 
 
Pharmacological inhibition of LPA degradation 
 
Thus far, only a few pharmacological inhibitors for LPA degradation have been described. 
General phosphatase inhibitors such as vanadate have been used to inhibit LPPs (English et 
al. 1999, Simon et al. 2002, Gaveglio et al. 2011). Increased LPA levels were observed in 
vanadate-treated adipocytes when compared to control cells (Simon et al. 2002). 
Propranolol, better known as a β-adrenoceptor blocking agent, only modestly inhibits LPPs 
(Roberts et al. 1998, Holinstat et al. 2007). Fluorophosphonate analogs of PA have been 
claimed to specifically inhibit LPP1 (Smyth et al. 2003).   
 
2.2.6 LPA signalling as a therapeutic target 
Direct activation/inhibition of LPA receptors 
 
LPA signalling regulates several functions in the body, and it has been reported to be 
involved in the pathology of several common diseases (Table 3). LPA plays both positive 
and negative roles in different disease processes and depending on the expression of the 
different receptors in various cell types, LPA may exert either a protective or detrimental 
effect (Table 3). Currently, there are no drugs on the market targeting LPA signalling 
(Gotoh et al. 2012). The diversity of LPA signalling makes the LPA-targeting drug 
discovery challenging; there are several LPA species that activate several LPA receptor 
subtypes (and additional receptors will likely be identified in the future) that are widely 
distributed in tissues and act on overlapping targets. First, one needs to decide whether 
enhancing or reducing LPA activity is needed to achieve a therapeutic response, and tissue-
selectivity should be obtained to avoid harmful side effects. Generally, the inhibition of 
LPA signalling might be beneficial in cancer and in atherosclerosis as well as in the 
treatment of neuropathic pain and obesity. In contrast, LPA agonism might be beneficial in 
schizophrenia and reproductive disorders.  
Several LPA receptor agonists or antagonists have been reported, but most show only 
modest selectivity and a relative lack of in vivo validation (Tamaryua et al. 2004, Mutoh et 
al. 2012). Due to the large number of LPA receptors, it is difficult to achieve selectivity for a 
certain subtype; moreover, there are few cell types where only one LPA receptor subtype is 
endogenously expressed. Some promising results have been obtained with the LPA1/3 
receptor-selective antagonist, VPC-12249, which conferred protection against the renal 
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ischemia-reperfusion injury in a mouse model (Okusa et al. 2003). Another LPA1/3 receptor-
selective antagonist, Ki16425 (Ohta et al. 2003), was able to inhibit breast cancer cell 
proliferation and metastasis in mice (Boucharaba et al. 2006) and it also blocked nerve 
injury-induced neuropathic pain (Ma et al. 2009). Recently, compound AM095 was reported 
to be an orally bioavailable, LPA1 receptor-selective antagonist (200-fold selectivity over 
LPA1 versus LPA3), showing anti-fibrotic properties in rodents. It is currently in preclinical 
development to treat lung and skin fibrosis (Swaney et al. 2011).  
 
 
Table 3. Examples of alterations in LPA signalling during diseases.  
 
Disease Examples of reported effects  
CNS diseases  
Alzheimer’s disease Hallmarks of Alzheimer’s disease include extracellular accumulation of β-
amyloid peptide and hyperphosphorylated Tau protein in brain (Minati et al. 
2009). LPA induces increased production of β-amyloid in mouse 
neuroblastoma cells (Shi et al. 2013). Increased Tau protein phosphorylation 
has been detected in human neuroblastoma cells during LPA-induced neurite 
retraction (Sayas et al. 1999). 
Nerve injury-induced 
conditions 
LPA in the blood may enter the brain during CNS injury and evoke 
pathological events. Upregulation of LPA receptors has been observed in 
injured tissues and in reactive astrocytes in mice (Goldshmit et al. 2010) and 
post-mortem human brain (Frugier et al. 2011). The hemorrhagic brain injury 
results in the elevations of LPA levels in the cerebrospinal fluid in piglets 
(Tigyi et al. 1995). 
Neuropathic pain LPA plays a role in initiating neuropathic pain (Ueda 2011). LPA5 receptor 
knockout mice are protected from neuropathic pain (Lin et al. 2012). LPA 
causes activation of peripheral nociceptor endings (Renbäck et al. 2000) and 
induces demyelination, an aspect of chronic neuropathic pain, through the 
ATXLPA1 receptor axis in mice (Nagai et al. 2010). 
Schizophrenia LPA1 knockout mice strains show a schizophrenia-like phenotype (Harrison et 
al. 2003, Roberts et al. 2005). 
   
Other diseases  
Atherosclerosis LPA promotes the development of intimal hyperplasia by inducing platelet 
activation and is found in the lipid-rich core of atherosclerotic plaques in 
humans and rodents (Siess et al. 1999, Smyth et al. 2008, Bot et al. 2013). 
In atherosclerotic lesions, LPA induces endothelial dysfunction, monocyte 
attraction and adhesion, low density lipoprotein uptake, and proinflammatory 
cytokine release (Schober & Siess 2012). 
On the other hand, LPA seems to play a protective role under ischemic 
conditions by protecting rat mesenchymal stem cells from hypoxia-induced 
apoptosis (Chen et al. 2008, Liu et al. 2009a). 
Airway disease In mouse models, exogenous LPA promotes inflammatory responses in lung 
epithelial cells and endogenous LPA levels in the bronchoalveolar lavage 
(BAL) increase in lung inflammatory diseases, such as asthma, fibrosis and 
acute lung injury (Zhao & Natarajan 2013).  
Cancer LPA accumulation has been identified in the ascites and blood of ovarian 
cancer patients (Xu et al. 1998, Yoon et al. 2003). LPA stimulates ovarian 
cancer cell proliferation and protects them from apoptosis (Xu et al. 1995, 
Meng et al. 2005, Ren et al. 2006). LPA regulates ovarian cancer cell motility 
and metastasis (Boucharaba et al. 2006).     
LPA is involved also in other cancers including breast, gastric, colon, 
prostate, pancreas, liver, and brain (glioma) (Lin et al. 2010). LPA has 
angiogenic properties in breast cancer (Boucharaba et al. 2009).  
Fibrosis LPA1 receptor signalling has been implicated in the development of renal, 
pulmonary and liver fibrosis (Pradere et al. 2008). In patients with pulmonary 
fibrosis, LPA levels are elevated in BAL, and LPA1 is highly expressed in lung 
fibroblasts (Tager et al. 2008). 
Ischemic stroke LPA levels in plasma are increased in patients with ischemic cerebrovascular 
disease (Li et al. 2008). 
      Continued 
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Table 3. Examples of alterations in LPA signalling during diseases. Continued  
 
Disease Examples of reported effects  
Obesity Reduction in brown adipose tissue may lead to the development of obesity; 
LPA decreases the differentiation of mouse brown adipocyte cells (Federico et 
al. 2012). LPA1 receptor knockout protects from weight gain in mice on a 
high fat diet (Dusaulcy et al. 2009). 
Reproductive disorders LPA receptors are expressed in both the testis and ovary and other 
reproductive tissues (Ye 2008). In humans, LPA4 expression is highest in the 
ovary in comparison with other tissues (Noguchi et al. 2003, Ye 2008). LPA3 
knockout mice suffer interference in timing and spacing of embryo 
implantation (Ye et al. 2005). The timing impairment is caused by the 
disruption of prostaglandin signalling. LPA1/2/3 triple knockout mice show 
reduced sperm production and lowered mating activity, followed by age-
related azoospermia (Ye 2008). 
Rheumatoid arthritis Significant amounts of LPA, autotaxin and its substrate LPC are present in the 
synovial fluid of patients with rheumatoid arthritis (RA). LPA enhances COX2 
expression and prostaglandin E2 production in human RA synovial cells; these 
actions are inhibited by Ki16425 (Nochi et al. 2008).  
Wound healing Topical LPA promotes dermal wound healing (Demoyer et al. 2000, Balazs et 
al. 2001). Following injury, fibroblasts proliferate and migrate to the wound 
site; thus modulation of the proliferation and migration of fibroblasts might 
be an effective strategy for regulating wound healing. LPA induces the 
proliferation of human fibroblasts (Jang et al. 2003). LPA enhances wound 
healing in aged rats by inducing DNA synthesis, proliferation and migration of 
senescent cells (Rhim et al. 2010).  
 
 
Pharmacological inhibition of LPA biosynthesis or degradation 
 
In addition to receptor agonists and antagonists, another possible way to affect LPA 
signalling is to develop compounds that affect LPA biosynthesis or degradation. Generally, 
the inhibition of ATX would be beneficial if one wishes to decrease LPA levels, whereas the 
inhibition of LPPs and other degradative enzymes would be anticipated to elevate LPA 
levels. 
The ATXLPA receptor signalling axis provides a promising opportunity especially for 
cancer therapy (Gotoh et al. 2012). Many malignant cancers, such as breast cancer, 
lymphoma and glioblastoma, express high ATX levels (Yang et al. 2002, Baumforth et al. 
2005, Kishi et al. 2006). ATX has been indicated to enhance metastatic and invasive 
potential of tumour cells, which likely is caused by the role of ATX in blood vessel 
formation. ATX can promote tumour cell motility and metastasis through LPA production, 
and it is claimed to be among the 40 most up-regulated genes in highly metastatic cancers 
(Euer et al. 2002). In transgenic mice, increased expression of either ATX or LPA1

3 receptors 
is sufficient to induce invasive and metastatic breast cancers (Liu et al. 2009b). In melanoma 
cells, ATX-stimulated motility was suppressed by Ki16425 (Hama et al. 2004).   
In addition to cancer, increased ATX activity has been observed in several other diseases. 
ATX has been reported to be upregulated in the brains of Alzheimer’s disease patients 
(Umemura et al. 2006). The ATX-synthesized LPA has been demonstrated to induce 
neuropathic pain (Nagai et al. 2010). In atherosclerotic lesions, low density lipoprotein 
oxidation generates LPC that is converted by ATX to LPA, which then recruits monocytes 
and triggers inflammation (Schober & Siess 2012). Increased lysoPLD activity has been 
observed in pregnant women in the third trimester of pregnancy and there is an extended 
increase in women expecting a preterm delivery (Tokumura et al. 2002). The ATXLPA axis 
has been shown to be up-regulated in inflammatory conditions such as rheumatoid arthritis 
(Kehlen et al. 2001) and ATX levels are high in liver fibrosis (Nakagawa et al. 2011). Since 
both LPA and ATX are present in various biological fluids, they could also be used as 
biomarkers to predict the presence of certain cancers and other diseases.  
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In contrast to ATX, LPP activity has been demonstrated to be low in several cancer cells 
e.g. the LPP expression is decreased in the majority of ovarian cancers (Tanyi et al. 2003b), 
whereas over-expression of LPP3 in ovarian cancer cells reduces tumour growth in vitro 
and in vivo (Tanyi et al. 2003a). It has been proposed that the combined effect of low LPP 
expression and high ATX expression in tumours makes them hypersensitive to growth-
stimulating factors (Samadi et al. 2011). LPA-independent actions of LPPs in cancer cells 
have also been reported. Unexpectedly, an increased LPP3 expression was observed in 
glioblastoma tumours and glioblastoma cell lines whereas LPP3-knockdown inhibited 
tumour growth (Chatterjee et al. 2011). These findings indicate that LPP3 can amplify the 
activities of β-catenin and cyclin-D1, known enhancers of cell cycle progression. On the 
other hand, LPP1 overexpression causes several abnormalities in mice including reduced 
body size and impaired spermatogenesis but there are no alteration in LPA levels in the 
blood (Yue et al. 2004). Recently, inactivation of the gene encoding LPP3 enhanced 
neointima formation in response to arterial injury in vivo, which was considered as 
evidence for a protective role for LPP3 in the atherotrombotic disease (Panchatcharam et al. 
2013).  
At present, there are relatively few reports describing pharmacological ATX inhibitors 
that are active in vivo. Intravenously injected compound HA130 reduces LPA levels in mice 
(Albers at al. 2010). Compound PF-8380 is able to block inflammation-induced LPA 
synthesis and reduces inflammatory hyperalgesia with the same efficacy as naproxen in 
rats (Gierse et al. 2010). The pharmacological inhibitors of LPPs reported so far include 
general phosphatase inhibitors and fluorophosphonate analogs, whose in vivo 
bioavailability is limited, and propranolol, that exerts significant other (detrimental) actions 
at the concentrations required to block LPPs. Much of work still needs to be done to 
develop specific and potent inhibitors capable of influencing LPA levels in vivo. 
 
 
2.3 OVERVIEW OF THE ENDOCANNABINOID SYSTEM 
The endocannabinoid (eCB) system comprises of two G protein-coupled cannabinoid 
receptors, their natural ligands (the eCBs), and the synthetic and degradative enzymes 
regulating the ligand levels. The eCB system regulates a wide variety of functions both in 
the CNS and periphery. In the CNS, eCBs are involved in synapse formation and 
neurogenesis as well as in cognition, memory, emotional functions, regulation of food 
intake, and pain sensation. In the periphery, eCBs mediate cardiovascular, immune, 
metabolic, and reproductive functions. 
2.3.1 Cannabinoid receptors and their natural ligands  
Cannabis has long been used for its hedonistic properties but also for the self-medication of 
several diseases and to ease pain. The Cannabis sativa plant has been demonstrated to 
contain around 70 compounds termed phytocannabinoids. The isolation of the main 
psychoactive compound, ∆9-tetrahydrocannabinol (∆9-THC) (Gaoni & Mechoulam 1964), 
initiated the rational research in this field. Later, two GPCRs mediating cannabinoid 
responses were cloned and named CB1 and CB2 (Devane et al. 1988, Munro et al. 1993). The 
human CB1 and CB2 receptors share 44% overall amino acid identify (Munro et al. 1993). 
Both CB1 and CB2 are mainly coupled with Gi proteins. In addition to CB1 and CB2, other 
cannabinoid receptors have been proposed, such as the orphan receptor GPR55 (Ryberg et 
al. 2007, Lauckner et al. 2008). Since studies with GPR55 show contradictory results, GPR55 
has not been generally accepted as a cannabinoid receptor (Pertwee et al. 2010, Henstridge 
et al. 2011). Instead, it has been suggested that LPI may be the specific ligand for GPR55 
(Oka et al. 2007, Pertwee et al. 2010, Pineiro & Falasca 2012). 
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The CB1 receptor is mainly expressed in the brain and spinal cord and it is one of the 
most abundant GPCRs in the brain (Herkenham et al. 1991). CB1 is mainly responsible for 
the neurobehavioral effects of ∆9-THC (Zimmer et al. 1999). In the rat brain, CB1 is highly 
expressed in basal ganglia and moderately in the hippocampus, cerebellum and neocortex 
(Herkenham et al. 1991). In the brain, the majority of the CB1 receptors have been shown to 
be localized presynaptically on both GABAergic interneurons and glutamatergic neurons, 
but more intensively on the former nerves (Katona et al. 1999, Hajos et al. 2000, Hajos et al. 
2001, Katona et al. 2001). CB1 is also expressed in the periphery, such as in the lungs, small 
intestine and reproductive organs (Sugiura & Waku 2002). A functional CB1 receptor has 
also been found in the preimplantation embryo (Paria & Dey 2000). CB1 receptor knockout 
mice are healthy and fertile but do suffer an elevated mortality rate and reduced locomotor 
activity (Zimmer et al. 1999). Aged CB1 receptor knockout mice also show deterioration in 
cognitive functions (Albayram et al. 2011, Albayram et al. 2012).     
The CB2 receptor is mainly expressed in peripheral tissues, especially the immune 
system, including white blood cells in the spleen, tonsils, and thymus (Munro et al. 1993, 
Atwood & Mackie 2010), being involved in the regulation of immune responses. There is 
also evidence that neurons (Skaper et al. 1996, Van Sickle et al. 2005, Ashton et al. 2006, 
Gong et al. 2006) as well as microglia and astrocytes (Benito et al. 2003, Esposito et al. 2007) 
can express CB2. CB2 has been postulated to play a role in the brain especially during 
neuroinflammation and brain injury but its role in the healthy brain remains unclear 
(Atwood & Mackie 2010). The CB2 receptor knockout mice are healthy and fertile (Buckley 
et al. 2000, Buckley 2008).  
Cloning of the cannabinoid receptors initiated the search for their natural ligands, 
termed eCBs. The first endogenous cannabinoid identified was arachidonoylethanolamide 
(anandamide, AEA) (Devane et al. 1992). Later, 2-arachidonoylglycerol (2-AG) was 
identified in the canine gut (Mechoulam et al. 1995) and rat brain (Sugiura et al. 1995). At 
present, AEA and 2-AG (Figure 6) remain the best characterised and most widely studied 
endocannabinoids. There are other putative endocannabinoids, e.g. 2-arachidonoyl glyceryl 
ether (noladin ether) (Hanus et al. 2001), O-arachidonoyl ethanolamine (virodhamine) 
(Porter et al. 2002), and N-arachidonoyldopamine (Huang et al. 2002). It remains uncertain 
whether noladin ether is a true endocannabinoid; e.g. some research groups have not been 
able to detect this compound in the brains of several mammalian species (Oka et al. 2003). 
Exogenous cannabimimetic compounds include classical cannabinoids, non-classical 
cannabinoids, and aminoalkylindoles (Pertwee et al. 2010). Cannabidiol, instead, is a 
phytocannabinoid that has no agonist activity at cannabinoid receptors and lacks any 
psychotropic effects (Mechoulam & Parker 2013). 
 
 
 
 
 
 
 
Figure 6. Chemical structures of the two principal endocannabinoids. 
 
 
Both AEA and 2-AG have been detected in several brain regions as well as in the 
periphery. Endocannabinoid signalling plays a role in several important processes during 
neuronal development (Berghuis et al. 2007, Keimpema et al. 2010, Argaw et al. 2011) as 
well as in adult neurogenesis (Goncalves et al. 2008). In the brain, 2-AG concentrations are 
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approximately 200-fold higher than those of AEA (Bisogno et al. 1999). It has been noted 
that 2-AG is rapidly generated in rat brain after decapitation (Sugiura et al. 2001), a fact that 
needs to taken into account when determining post-mortem tissue 2-AG levels. 2-AG acts 
as a potent full agonist at CB1 and CB2 receptors whereas AEA acts as a partial agonist for 
both receptors (Gonsiorek et al. 2000, Savinainen et al. 2001, Sugiura 2009). In the CNS, 2-
AG is believed to be the physiologically relevant ligand for the CB1-mediated synaptic 
signalling (Hashimotodani et al. 2007) but AEA may also mediate certain forms of synaptic 
homeostasis and plasticity (Gerdeman et al. 2002, Kim & Alger 2010). The actions of AEA 
and 2-AG in the brain are local, partly due to the hydrophobic nature of these compounds 
and poor solubility in the hydrophilic extracellular tissue fluid. In addition to the partial 
agonistic properties for the CB receptors, AEA acts as a full agonist for the transient 
receptor potential vanilloid type-1 (TRPV1) receptor that is a non-selective cation channel 
belonging to the larger family of TRP channels (Zygmunt et al. 1999).      
2.3.2 Biosynthesis and response of eCBs 
Generally, endocannabinoids are synthesized on demand from plasma membrane 
phospholipid precursors and released from cells immediately after their production. The 
levels of eCB precursors depend on the expression and activity of the biosynthetic and 
degrading enzymes, and also on the diet and its content of arachidonic acid (AA) and its 
precursor linoleic acid (DiMarzo & Petrosino 2007, Katona & Freund 2012).  
The principal eCB function is the modulation of synaptic activity through retrograde 
signalling. In postsynaptic neurons, eCB synthesis is triggered by an increase in 
intracellular calcium concentrations induced by cell depolarization or stimulation of Gq 
protein-coupled receptors (Kano et al. 2009). After their production, eCBs move across the 
synaptic cleft in a retrograde manner, activate presynaptic CB1 receptors and suppress 
neurotransmitter release (Figure 7). Most often, the presynaptic CB1 receptor activity 
suppresses GABAergic and glutamatergic transmission causing depolarization-induced 
suppression of inhibition (DSI) or depolarization-induced suppression of excitation (DSE). 
The ratio of DSI and DSE determines the net effect of this fine tuning of neurotransmission 
(Kano et al. 2009, Piomelli 2003). It should be noted that neurotransmission is often a 
heterosynaptic process. The mechanism by which the lipophilic eCBs move through the 
extracellular space from the postsynaptic side to the presynaptic side is not known.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Illustration of retrograde eCB signalling (modified from Sugiura 2009).  
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Although retrograde signalling is believed to be the principal mechanism of eCB action, 
alternative ways of signalling have been proposed. It has been postulated that eCBs may 
signal in an autocrine manner or alternatively via astrocytes to modulate synaptic function 
(Castillo et al. 2012). In addition to the cannabinoid receptors, there is evidence indicating 
that AEA-activated TRPV1 channels may participate in eCB signalling (De Petrocellis & Di 
Marzo 2010). In addition to their signalling functions, eCBs have been claimed to exert 
supplemental effects. A detectable amount of 2-AG is present in a non-stimulated brain 
without permanent activation of CB1 receptors, indicating that not all of the 2-AG present is 
used for cannabinoid signalling (Tanimura et al. 2010, Gao et al. 2010). It has been 
speculated that a pool of 2-AG might be presynthesised and kept waiting to be released 
after an appropriate stimulus (Min et al. 2010a, Alger & Kim 2011, Di Marzo 2011). Since 2-
AG acts at the crossroads of multiple biochemical pathways in lipid metabolism, it is likely 
that a proportion of 2-AG generated in the brain serves as a lipid intermediate in these 
pathways (Piomelli 2003). Although the signalling pool of 2-AG is apparently circulating 
between post- and presynaptic neurons, another pool might be present in other cell types, 
such as astrocytes and microglia, and not be involved in retrograde signalling.  
 
Biosynthesis of AEA 
 
At least four different synthetic mechanisms for AEA have been proposed (Di Marzo 2011). 
The most important pathway for AEA generation is thought to be the release from N-
arachidonoylphosphatidylethanolamine (NArPE), which is first formed from 
phosphatidylcholine and phosphatidylethanolamine, by N-acyltransferase. N-
acylphosphatidylethanolamine-specific PLD (NAPE-PLD) converts NArPE into 
anandamide (and PA). In the brain, NAPE-PLD has been demonstrated to be localized in 
different strucrures, e.g. hippocampus and cerebellum (Egertova et al. 2008, Cristino 2008). 
Other routes for AEA generation from NArPE have been proposed such as conversion by 
the sequential actions of the α/β-hydrolase domain-containing protein 4 and 
glycerophosphodiesterase-1 or by the soluble PLA2 followed by conversion into 
anandamide by a lyso-PLD (Di Marzo 2011). In addition, generation by sequential actions 
of a PLC and a phosphatase has been proposed. 
 
Biosynthesis of 2-AG 
 
The primary precursor for 2-AG is believed to be DAG generated from 
phosphatidylinositols by the action of PLCβ or from PA by phosphatases (Sugiura et al. 
2006, Bisogno 2008). DAG is further hydrolyzed by the sn-1-specific DAG lipase (DAGL) to 
generate 2-AG (Oudin et al. 2011, Reisenberg et al. 2012) (Figure 8).  
Two isoforms of the Ca2+-sensitive, sn-1-selective DAGLs generating 2-AG have been 
cloned and named as DAGLα and DAGLβ (Bisogno et al. 2003). DAGLα and -β have arisen 
from a gene duplication event and they are very closely related. The main difference 
between the enzymes is the presence of a C-terminal tail in DAGLα that is absent from 
DAGLβ. The two isoforms are expressed differentially in different cells; DAGLα is highly 
expressed in the CNS when compared to other tissues whereas DAGLβ possesses a broader 
but somewhat lower expression pattern (Bisogno et al. 2003). In the adult brain, DAGLs are 
expressed in the same brain regions as the CB1 receptor, DAGLα more intensively than 
DAGLβ (Bisogno et al. 2003, Yoshida et al. 2006). DAGLα is concentrated in the heads of 
dendritic spines located postsynaptically opposite to presynaptic glutamatergic axons 
expressing CB1 in several brain regions, such as the hippocampus (Katona et al. 2006), 
striatum (Uchigashima et al. 2007), and prefrontal cortex (Lafourcade et al. 2007). However, 
in the developing mouse brain DAGLα and DAGLβ are expressed in a specific and 
restricted manner in the same axonal tracts and in the same growth cones as CB1 (Berghuis 
et al. 2007) indicative of a loss of DAGLs from axons during development.  
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There is convincing evidence that DAGLα is the major enzyme involved in the 
biosynthesis of 2-AG used in retrograde synaptic signalling. Overexpression of DAGLα 
results in a significant increase in basal 2-AG levels whereas knockdown of DAGLα by 
RNA interference can reduce 2-AG levels (Jung et al. 2007). It was observed that the 
retrograde synaptic suppression was absent in several brain regions of DAGLα-knockout 
mice whereas it remained intact in the brains of DAGLβ-knockout mice (Tanimura et al. 
2010, Gao et al. 2010, Yoshino et al. 2011). Furthermore, there were up to 80% reductions in 
2-AG levels in DAGLα-KO mice brain whereas in the brains of DAGLβ-KO mice, the 2-AG 
levels remained unaltered (Tanimura et al. 2010, Yoshino et al. 2011), or were reduced up to 
50% (Gao et al. 2010). With the exception of a slight decrease in body weight, the 
phenotypes of the DAGLα-KO and DAGLβ-KO animals were found to be normal when 
compared to wild-type (WT) animals (Gao et al. 2010). The role of DAGLβ seems to be 
more important in peripheral tissues; it was demonstrated that DAGLβ inactivation lowers 
2-AG levels in mouse peritoneal macrophages, indicating that DAGLβ is involved in the 
regulation of inflammatory responses in macrophages (Hsu et al. 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Enzymatic pathways for 2-AG biosynthesis and degradation. The principal pathway is 
presented with thick arrow. Abbreviations: 2-AG, 2-arachidonoylglycerol; ABHD, α/β-hydrolase 
domain-containing protein; COX, cyclooxygenase; DAG, diacylglycerol; DAGL, diacylglycerol 
lipase; LOX, lipoxygenase; LPA , lysophosphatidic acid; LPI, lysophosphatidyl inositol; MAGL, 
monoacylglycerol lipase; MAGK, monoacylglycerol kinase; PA, phosphatidic acid; PLA, 
phospholipase A; PLC, phospholipase C. 
 
 
Although DAGLα evidently generates the majority of 2-AG for retrograde synaptic 
signalling, evidence has been provided to show that DAGLα is not involved in the 
hippocampal DSI (Min et al. 2010b). It is noteworthy that in some brain regions, highly 
enriched in CB1 receptors (such as the substantia nigra), DAGLα is only sparsely expressed, 
as evidenced by the weak labelling with the DAGLα antibodies in immunohistochemical 
studies (Uchigashima et al. 2007, Kano et al. 2009, Tanimura et al. 2010). This is considered 
as support for the existence of alternative biochemical routes that could generate CB1 
receptor-activating eCBs in those brain regions with sparse DAGLα expression. In addition 
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to neurons, it has been demonstrated that mouse microglia (Walter et al. 2003, Witting et al. 
2004, Carrier et al. 2004) as well as astrocytes (Walter et al. 2004) have the capacity to 
produce 2-AG. Additional pathways for 2-AG generation include the release from sn-2-
arachidonic acid-containing phospholipids by sequential actions of phospholipase A1 
(PLA1) and lyso-PLC or by phosphatase-mediated conversion from 2-arachidonoyl-LPA 
(Nakane et al. 2002, Sugiura et al. 2006, Bisogno 2008) (Figure 8).  
 
Pharmacological inhibition of eCB biosynthesis 
 
Only a limited number of pharmacological inhibitors for eCB-generating enzymes are 
currently available. At present, the search has focused on inhibitors of DAGLs. In 
experimental settings, tetrahydrolipstatin (THL, also known as orlistat) and RHC80267 
have been used to inhibit DAGLs (Bisogno et al. 2003). These inhibitors, however, are 
poorly selective for DAGLs and they have additional enzyme targets. More recently, some 
fluorophosphonate compounds, such as O-3841, O-3640, O-5596, and O-7460 (Bisogno et al. 
2006, Bisogno et al. 2009, Bisogno et al. 2012) as well as the THL-analog OMDM-188 (Ortar 
et al. 2008) have been reported as being selective DAGL inhibitors but none of these 
inhibitors can discriminate between the α and β isoforms. Recently, some triazole urea 
compounds (KT109, KT172) were reported to selectively inhibit DAGLβ (Hsu et al. 2012). 
 
2.3.3 Enzymatic degradation of eCBs 
Soon after their generation, eCBs are initially removed from the extracellular space by 
cellular uptake and then degraded by hydrolytic enzymes (Blankman & Cravatt 2013). The 
hydrolysis of eCBs generally terminates their function but the hydrolysis products can also 
be used as precursors for other signalling molecules. 
The mechanism by which eCBs are moved across the plasma membrane has remained 
elusive. It is not clear if eCBs are taken up by cells via a plasma membrane transporter, by 
endocytosis or simply by passive diffusion. Furthermore, it is unclear whether AEA and 2-
AG have the same or distinct uptake mechanisms. Several AEA carrier proteins have been 
proposed, such as fatty acid binding proteins, heat shock protein 70, albumin and the fatty 
acid amide hydrolase (FAAH)-like AEA transporter (Fowler 2012a), but more studies will 
be needed to elucidate the involvement of these proteins in eCB uptake. 
 
 
AEA degradation  
 
The primary enzyme catalyzing the hydrolysis of AEA is FAAH (Deutsch & Chin 1993). 
FAAH belongs to the family of serine hydrolases, and it hydrolyzes AEA into AA and 
ethanolamine (Long & Cravatt 2011). FAAH has been well characterized and its crystal 
structure has been resolved (McKinney & Cravatt 2005). FAAH is abundantly expressed in 
the brain; it is located intracellularly mainly in postsynaptic neurons (Egertova et al. 1998, 
Gulyas et al. 2004).  
Especially in the periphery, additional enzymes capable of hydrolyzing AEA have also 
been described, e.g. N-acylethanolamine-hydrolyzing acid amidase (Tsuboi et al. 2007) and 
FAAH-2. This latter enzyme is expressed in primates and some related mammals, but not 
in lower placental mammals including the mouse and rat (Wei et al. 2006). AEA is also 
metabolized by COX-2 to prostaglandin ethanolamides (Ross et al. 2002, Kozak et al. 2002a) 
and by lipoxygenase (LOX) into 12- and 15-hydroxy AEA (Ueda et al. 1995, Edgemont et al. 
1998). Some cytochrome P450 species can metabolize AEA to the corresponding epoxides 
and hydroxy metabolites in liver microsomes (Bornheim et al. 1995, Snider et al. 2008).  
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2-AG degradation 
 
2-AG is enzymatically hydrolyzed into AA and glycerol (Figure 8). The first enzyme 
implicated as a 2-AG hydrolase was monoacylglycerol lipase (MAGL) (Dinh et al. 2002, 
Dinh et al. 2004, Saario et al. 2004). MAGL is a serine hydrolase that catalyses the hydrolysis 
of monoacylglycerols to their corresponding fatty acids. Originally the gene encoding 
MAGL was cloned from mouse adipose tissue, but MAGL has also been detected in other 
peripheral tissues such as the kidney, ovary, testis and heart (Karlsson et al. 1997). In the 
brain, MAGL is localized in the presynaptic terminals that also express CB1 receptors (Dinh 
et al. 2002, Gulyas et al. 2004). Studies have suggested MAGL as being the main hydrolase 
terminating 2-AG actions in the brain, accounting for ~85% of the total 2-AG hydrolysis 
(Blankman et al. 2007). The crystal structure of MAGL has been resolved by two 
independent laboratories; the enzyme has shown to be a dimer, existing in both a soluble 
form and associated with cell membranes (Bertrand et al. 2010, Labar et al. 2010).   
In addition to MAGL, two novel α/β-hydrolase domain-containing proteins, ABHD6 and 
ABHD12, have been found to be able to hydrolyze the brain 2-AG and, together with 
MAGL, these three serine hydrolases account for ~99% of the brain 2-AG hydrolase activity 
(Blankman et al. 2007). Both ABHD6 and ABHD12 are integral membrane proteins that are 
expressed in several brain regions. The active site of ABHD6 is believed to face the cell 
interior whereas the active site of ABHD12 faces the lumen/extracellular space (Blankman 
et al. 2007). The three 2-AG hydrolases hydrolyse only monoacylglycerols (not di- or 
triacylglycerols or LPA) having different substrate and isomer preferences (Navia-
Paldanius et al. 2012). The three serine hydrolases display different subcellular localization, 
suggesting that they could access and hydrolyze distinct pools of 2-AG. When compared to 
MAGL and ABHD6, ABHD12 is expressed at higher levels in microglia (Fiskerstrand et al. 
2010). 
Under certain conditions, FAAH has been shown to metabolize 2-AG (DiMarzo et al. 
1998, Goparaju et al. 1998). COX-2 and LOX are capable of metabolizing 2-AG to glyceryl 
prostaglandins (Kozak et al. 2000) and to hydroxyeicosatetraenoic acids glyceryl esters 
(Kozak et al. 2002b), respectively (Figure 8). In addition, NTE has been reported be able to 
hydrolyze 2-AG (van Tienhoven et al. 2002). In some cells, including human monocytic 
leukaemia cells, non-specific esterases such as human carboxylesterases 1 and 2 can 
catalyze 2-AG hydrolysis (Rouzer & Marnett 2011). Thus the contribution of a particular 
enzyme to 2-AG metabolism largely depends on the cell in question. 
Pharmacological inhibition of eCB degradation 
The primary enzymes responsible for AEA and 2-AG degradation are considered to be 
FAAH and MAGL, respectively, and the major efforts on inhibitor development have been 
focused on these two targets. 
Since the initial research in the cannabinoid field focused on AEA, studies on the 
pharmacological inhibition of eCB degradation began with FAAH. Several inhibitors of 
FAAH have been described representing both reversible and irreversible mechanisms. 
Irreversible inhibitors include sulfonyl fluorides such as phenylmethylsulfonyl fluoride, 
hexadecylsulfonyl fluoride, methylarachidonoylfluorophosphonate (MAFP) as well as the 
carbamate compound URB597 (Deutsch et al. 1997a, Deutsch et al. 1997b, Kathuria et al. 
2003). The reversible inhibitors include trifluoromethyl ketones such as arachidonoyl 
trifluoromethyl ketone (Koutek et al. 1994). All of these compounds, however, possess 
limited selectivity for FAAH. More recently, some piperidine/piperazine ureas, PF-750, PF-
3845, and PF-04457845 have been claimed to be selective for FAAH over other serine 
hydrolases (Ahn et al. 2007, Ahn et al. 2009, Johnson et al. 2011).  
The search for MAGL inhibitors began soon after that of FAAH inhibitors. Non-specific 
mercuric compounds, fatty acid trifluoromethylketones, sulfhydryl reagents and 
disulphide compounds, and organophosphorus compounds, such as MAFP, irreversibly 
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inhibit MAGL (Fowler 2012b). In the brain, virtually all 2-AG hydrolase activity is sensitive 
to MAFP (Saario et al. 2004). The non-selectivity of these compounds led to attempts to 
develop inhibitors that would selectively target MAGL. The carbamate compound URB602 
was first reported to be a selective pharmacological inhibitor of MAGL (Hohmann et al. 
2005), but further studies called into question its selectivity (Vandevoorde et al. 2007). The 
sulfhydryl reagent N-arachidonoylmaleimide (NAM) is a potent, irreversible and rather 
selective inhibitor of MAGL, blocking ~85% of the brain 2-AG hydrolase activity (Saario et 
al. 2005, Blankman et al. 2007). The carbamate compound JZL184 has been reported to be a 
specific inhibitor of MAGL (Long et al. 2009), but its low potency may limit its use 
(Savinainen et al. 2010, Aaltonen et al. 2013). Recently, compounds ML30 (Morera et al. 
2012), KML29 (Chang et al. 2012) and JJKK-048 (Aaltonen et al. 2013) were reported as 
being selective MAGL inhibitors and of these, JJKK-048 seems to be the most potent and 
MAGL-selective inhibitor currently available.  
 
2.3.4 Endocannabinoid system as a target for drug discovery 
 
Direct activation or inhibition of the eCB system 
 
Cannabis has been used for its medicinal properties for millennia, long before its 
mechanism of action was understood. To date, alterations in the endocannabinoid system 
have been reported in several different diseases in both the CNS and periphery (Pacher et 
al. 2006, Pacher & Kunos 2013) (Table 4). In the CNS, eCBs are generally considered to be 
neuroprotective (Sánchez & García-Merino 2012). One hallmark of the neurodegenerative 
diseases is inflammation and eCBs may relieve symptoms by possessing anti-inflammatory 
properties. In neurodegenerative diseases, there is often down-regulation of CB1 receptors 
but up-regulation of CB2 receptors. The neuroprotective effect is thought to be mediated 
through the activation of CB1 receptors, and the inhibition of inflammatory microglial 
responses through the activation of CB2 receptors. In cancer, the role of eCBs is still 
controversial, but generally eCBs suppress cancer progression (Hermanson & Marnett 
2011). Other well known effects of eCBs are their antinociceptive properties (Karst et al. 
2010) as well as their ability to increase appetite (Matias & Di Marzo 2007).  
The alterations of the eCB system can be either protective or deleterious depending on 
the cell or tissue type (Table 4), and it must be carefully determined whether the activation 
or blocking eCB system would be desired to achieve the therapeutic response (Di Marzo 
2008). In some diseases, the current knowledge is still contradictory, as both both positive 
and negative changes in the eCB system have been reported. On the other hand, the levels 
of AEA and 2-AG might be regulated oppositely in the same disease. The endocannabinoid 
system has been a target of an intensive drug discovery but the challenge has been to obtain 
a selective effect in each organ or tissue and to avoid harmful side-effects especially in those 
brain regions controlling mood and cognitive functions.  
Currently, ∆9-THC (dronabinol) and its synthetic analogue, nabilone, which directly 
activate cannabinoid receptors, are used for the treatment of nausea and vomiting induced 
by radiotherapy or chemotherapy, and for preventing the wasting syndrome, such as 
encountered in patients with acquired immunodeficiency syndrome (Pacher & Kunos 
2013). Sativex®, a preparation consisting of a mixture of cannabidiol and ∆9-THC, is 
licenced for the use in the multiple sclerosis-related spasticity and pain in several countries 
(Karst et al. 2010). The first selective CB1 receptor antagonist/inverse agonist rimonabant 
was briefly on the market for the treatment of obesity in several European countries during 
20062008 but it had to be withdrawn mainly due to its psychiatric side effects, including 
increased anxiety, depression and suicidal intentions (Idelevich et al. 2009). In addition to 
brain-penentrant CB1 antagonists, peripherally restricted antagonists for CB1 receptors are 
under development for the treatment of metabolic disorders (Silvestri & Di Marzo 2012). 
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Peripherally restricted agonists for CB1 receptors would be useful for pain treatment since 
the cannabinoid-induced analgesia has been proven largely to be mediated via CB1 
receptors in peripheral nociceptive afferents (Agarwal et al. 2007). In addition to orthosteric 
ligands, allosteric modulators for cannabinoid receptors (e.g. ORG27569, PSNCBAM-1) 
have been reported (Ahn et al. 2013, Cawston et al. 2013). These compounds have been 
reported to be able to modulate the actions of orthosteric ligands as well as to mediate G 
protein-independent signalling via the β-arrestins.  
 
 
Table 4. Examples of alterations in the eCB system during diseases and/or potential therapeutic 
usefulness of exogenous and endogenous cannabinoids.  
 
Disease Examples of reported effects  
Neurodegenerative 
diseases 
 
Alzheimer’s disease (AD) CB1 receptors are down-regulated in neurons whereas CB2 receptors are up-
regulated particularly in microglia in AD patients (Ramirez et al. 2005, Benito 
et al. 2003). Elevation in eCB levels provides neuroprotection against β-
amyloid peptide toxicity in rats (van der Stelt et al. 2006). 
Amyotropic lateral 
sclerosis (ALS) 
At present, only anti-glutamatergic agents are used in delaying the disease 
progression. Cannabinoids exert anti-glutamatergic and anti-inflammatory 
actions through activation of the CB1 and CB2 receptors, respectively, and 
may have therapeutic potential in the treatment of ALS (Bilsland & 
Greensmith 2008).  
Huntington’s disease (HD) CB1 receptor down-regulation has been detected in the human globus pallidus 
and substantia nigra whereas CB2 receptors are up-regulated in the striatum 
(Glass et al. 2000, Palazuelos et al. 2009). 
Multiple sclerosis (MS) MS is an inflammatory, demyelinating disease. Both CB1 and CB2 receptors 
are expressed in cells (such as microglia and macrophages) that are located 
in human MS plaques (Benito et al. 2007). Cannabinoid agonists have 
remyelinating properties in mice (Arevalo-Martin et al. 2003). Sativex® is 
licensed for the treatment of MS related spasticity and neuropathic pain in 
several countries.  
Parkinson’s disease (PD) Role of the eCB system in the modulation of the dopaminergic system links 
eCBs to PD, in which dopaminergic neurons are destroyed. So far conflicting 
data exist; both increased and decreased striatal eCB levels have been 
reported (Scotter et al. 2010). In a rat model, increased cannabinoid tone 
has been observed in globus pallidus (DiMarzo et al. 2000).  
Mental disorders  
Anxiety and depression Low doses of cannabinoid agonists are anxiolytic in animal models (Zanettini 
et al. 2011). 
Schizophrenia Increased levels of eCBs have been detected in the cerebrospinal fluid 
(Giuffrida et al. 2004) and the blood (De Marchi et al. 2003) of schizophrenic 
patients. Increased levels of 2-AG but decreased levels of AEA have been 
detected in postmortem brains of schizophrenic patients (Muguruza et al. 
2013).  
Region-specific changes in the density of CB1 receptors in brain have been 
observed in schizophrenic patients (Dean et al. 2001, Zavitsanou et al. 2004, 
Newell et al. 2006, Dalton et al. 2011).  
Control of food intake  
Anorexia Exogenous and endogenous cannabinoids increase food intake (Matias & Di 
Marzo 2007, Li et al. 2011). 
eCBs may mediate the rewarding effect of self-starvation in anorexia 
nervosa patients (Monteleone et al. 2005).   
Obesity Hyperactivity of the eCB system in obesity; high eCB levels are found in the 
blood and visceral adipose tissue of obese and hyperglycaemic patients. CB1 
receptor blockade suppresses food intake (Matias & Di Marzo 2007, Li et al. 
2011). 
                                                                      Continued 
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Table 4. Examples of alterations in the eCB system during diseases and/or potential therapeutic 
usefulness of exogenous and endogenous cannabinoids. Continued  
 
Disease Examples of reported effects  
Other diseases  
Cancer Generally, cannabinoids and endocannabinoids inhibit tumour growth by 
inducing apoptosis and inhibiting proliferation and angiogenesis (Hermanson 
& Marnett 2011). Elevated levels of AEA and 2-AG have been reported in 
several types of tumours. An opposite regulation of AEA and 2-AG levels has 
been observed; e.g. AEA levels decrease and 2-AG levels increase in the 
human glioma tissue (Wu et al. 2012).  
The role of CB1 and CB2 receptor expression in relation to disease 
prognosis depends on the cancer type, e.g. a high expression of CB1 
receptors in prostate cancer tumour samples is associated with disease 
severity and poor prognosis (Chung et al. 2009). 
Cardiovascular diseases Increased AEA and 2-AG levels have been detected in coronary artery disease 
patients. CB1 antagonists have been reported to be antiatherosclerotic and to 
reduce several metabolic cardiovascular risk factors (Pacher & Steffens 
2009). 
Drug addiction and 
alcoholism 
Interconnected role of CB1 and opiate receptors; cannabinoids reduce opioid 
withdrawal symptoms in rodent models (Fattore et al. 2005).  
The eCB system is involved in the reinforcing properties of ethanol; in 
rodents, chronic consumption of ethanol increases eCB synthesis and reduces 
CB1 expression in brain regions associated with addiction pathways (Pava & 
Woodward 2012). 
Epilepsy Exogenous cannabinoids have been reported to exert both pro- and anti-
convulsive activities in animal models and humans, depending on the model. 
Endocannabinoids seem to be anti-convulsive via CB1 receptors in mice (Lutz 
2004). 
Glaucoma and retinopathy Cannabinoids decrease intraocular pressure in humans (Tomida et al. 2004). 
Nausea Cannabinoids have anti-emetic properties and are clinically used as anti-
emetics (Todaro 2012). 
Osteoporosis CB2 receptor deficient mice experience accelerated age-related bone loss 
(Ofek et al. 2006). 
Pain Cannabinoids relieve acute and chronic pain, especially neuropathic pain; 
evident both in animal models and human studies (Karst et al. 2010).  
Rheumatoid arthritis (RA) Elevated levels of AEA and 2-AG have been detected in the synovial fluid of 
RA patients (Richardson et al. 2008). 
 
 
Pharmacological inhibition of eCB biosynthesis or degradation 
 
In addition to targeting CB receptors by exogenous ligands and allosteric modulators, eCB-
synthesizing and -degrading enzymes represent attractive targets for drug development (Di 
Marzo 2009). Inhibition of eCB degradation by an enzyme inhibitor would increase eCB 
levels and lead to prolonged activation of CB receptors but only at sites where eCB was 
originally synthesized. In this way, the pharmacological effect woud be more localized 
when compared to exogenous agonists that target CB receptors in all parts of the body. It is 
thought that treatment with enzyme inhibitors would less likely cause psychoactive effects 
than CB receptor agonists. Conversely, one would predict that pharmacological inhibitors 
of eCB-generating enzymes would be useful if one wished to block eCB signalling and to 
treat pathological conditions that involved overactivity of eCB system. The postulated eCB 
transporters would also provide targets for drug development but further studies will be 
required to demonstrate the actual existence of these proteins. 
In order to obtain a specific effect in a certain tissue, it is important that the inhibitor has 
selectivity and does not block other enzymes. Only a limited number of selective 
pharmacological inhibitors for eCB-synthesizing enzymes are currently available. The 
primary enzymes responsible for AEA and 2-AG degradation are considered to be FAAH 
and MAGL, respectively, and the major efforts on inhibitor development have been focused 
on these two enzymes. Since AEA and 2-AG may be regulated in opposite ways in certain 
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diseases and dual FAAH/MAGL blocking may result in unwanted cannabis-like effects 
(including weight gain and impairments in cognition and motor control), the selectivity 
over AEA and 2-AG degrading enzymes is a desired goal in inhibitor development. 
However, due to their chemical properties, e.g. poor stability or poor permeability through 
biological membranes, many of the inhibitors reported in the literature are not suitable for 
in vivo administration. Furthermore, the in vivo data for some recently reported inhibitors 
are publicly not available. Examples of the currently reported in vivo effects of 
pharmacological inhibitors of eCB-synthesizing and -degrading enzymes in rodents are 
listed in Table 5. 
It is noteworthy that continuous treatment of mice with a high dose of JZL184, as well as 
the genetic deletion of MAGL, have been reported to result in 2-AG overflow and 
subsequent CB1 receptor desensitization and functional antagonism of the eCB system 
(Chanda et al. 2010, Sclosburg et al. 2010, Taschler et al. 2011). However, this effect was 
avoided by using lower doses of JZL184 (Busquets-Garcia et al. 2011). Receptor 
desensitization represents a potential problem that needs to be overcome when aiming at 
developing drugs inhibiting 2-AG breakdown.  
 
 
Table 5. Selective inhibitors of eCB-synthesizing and -degrading enzymes and examples of their 
in vivo effects in rodents.  
 
Enzyme Inhibitor In vivo effects in rodents References 
Synthesizing  
enzymes 
   
DAGLα/β O-3841,     
O-3640 
Not suitable in vivo (lack of stability 
and poor permeability through the 
plasma membrane) 
Bisogno et al. 2006 
 O-5596 Reduction in food intake Bisogno et al. 2009 
 O-7460 Reduction in food intake Bisogno et al. 2012 
 OMDM188 Not determined Ortar et al. 2008 
DAGLβ KT109, KT172 Not determined 
 
Hsu et al. 2012 
Degrading  
enzymes 
   
FAAH URB597 Reduction of inflammatory pain,  
anxiolysis 
Kathuria et al. 2003, Naidu 
et al. 2010 
 PF-750 Not determined Ahn et al. 2007 
 PF-3845 Reduction in inflammatory pain Ahn et al. 2009, Booker et 
al. 2012 
 PF-04457845 Reduction in acute inflammatory 
and chronic noninflammatory pain 
Ahn et al. 2011 
MAGL URB602 Enhancement of stress-induced 
analgesia, reduction of 
inflammatory pain, neuroprotection 
in neonatal ischemic brain injury 
Hohmann et al. 2005, 
Guindon et al. 2007, 
Comelli et al. 2007, Carloni 
et al. 2012 
 NAM Potentiation of CB1 receptor-
mediated behavioural effects of  
2-AG 
Burston et al. 2008 
 JZL184 Acute analgesia, reduction of 
inflammatory pain, anti-emesis,  
anxiolysis 
Long et al. 2009, Guindon 
et al. 2011, Kinsey et al. 
2011, Sticht et al. 2012, 
Ghost et al. 2013  
 ML30 Not determined Morera et al. 2012 
 KML29 Not determined Chang et al. 2012 
 JJKK-048 Not determined Aaltonen et al. 2013 
ABHD6 WWL70 Anti-inflammation and 
neuroprotection 
Tchantchou & Zhang 2013 
 
ABHD12 No specific inhibitor described so far 
Abbreviations: ABHD, α/β-hydrolase domain-containing protein; DAGL, diacylglycerol lipase; 
FAAH, fatty acid amide hydrolase; MAGL, monoacylglycerol lipase; NAM, N-
arachidonoylmaleimide. 
 
29 
 
 
Endocannabinoid-independent pathophysiological roles of serine hydrolases  
 
There are recent findings demonstrating that the enzymes degrading eCBs are involved in 
the pathology of several diseases also in a manner independent of eCB signalling. 
Pathophysiological roles of MAGL have been reported in cancer and neurodegenerative 
diseases. MAGL is intensely expressed in aggressive human cancer cells and primary 
tumours (Nomura et al. 2010). MAGL contributes to the cancer pathogenicity by providing 
free fatty acids for the production of bioactive lipids such as LPA and prostaglandins. The 
blockade of MAGL impairs invasiveness and tumorigenicity of several cancer cells; this 
effect is mainly due to the reduction in the levels of these other bioactive lipids, and does 
not involve eCB. Recently it has been demonstrated, that in addition to terminating 2-AG 
signalling, MAGL releases AA to be used as a precursor for the pro-inflammatory 
prostaglandin synthesis in the brain (Nomura et al. 2011). The pharmacological or genetic 
inactivation of MAGL has attenuated neuroinflammation and exerted neuroprotective 
effects in a Parkinson’s disease mouse model (Nomura et al. 2011) and in an Alzheimer’s 
disease mouse model (Chen et al. 2012). These findings thus link the eCB and eicosanoid 
pathways together through MAGL. Thus, MAGL-inhibitors may exhibit antinociceptive 
and anti-inflammatory responses by the simultaneous enhancement of eCB levels and 
reduction of eicosanoid levels in the brain. It is believed that MAGL may play a role in the 
prostaglandin production in the brain but not in the gut, where the cytosolic PLA2 
predominantly releases AA for prostaglandin production. Therefore, MAGL inhibitors 
potentially would not exhibit the gastrointestinal toxicity commonly associated with 
COX1/COX2 inhibitors. In addition, ABHD6 has been reported to be expressed in tumours 
(Li et al. 2009, Max et al. 2009). Mutations in the gene encoding ABHD12 have been 
connected to the neurogenerative disease PHARC (polyneuropathy, hearing loss, ataxia, 
retinis pigmentosa, and cataract) (Fiskerstrand et al. 2010). A knockout of the gene encoding 
ABHD12 induces an age-dependent PHARC-like phenotype in mice but does not increase 
brain bulk levels of 2-AG or other MAGs (Blankman et al. 2013). 
 
 
2.4 FUNCTIONAL AUTORADIOGRAPHY AS A METHOD TO STUDY LIPID 
GPCR SIGNALLING 
2.4.1 General methods to study GPCR activity  
Methods to study GPCR function can be divided into groups depending on which step of 
the GPCR signalling cascade they monitor (Zhang & Xie 2012). Classical receptor binding 
assays can be used to characterize the affinity of a compound in targeting its cognate GPCR. 
Methods that measure either G protein activation or G protein-mediated downstream 
events, such as second messenger generation, are defined as functional assays. In addition, 
some functional assays for G protein-independent signalling exist. 
Traditionally, radioligand binding with receptor-containing membranes has been used to 
identify compounds that target GPCRs (or other receptors). Since the pioneering 
experiments (Lefkowitz et al. 1970), 3H- and 125I-labeled ligands have been used widely. 
Receptor binding assays can be applied to characterize the interaction between a receptor 
and its ligand but they provide little information about the downstream signalling events. 
Furthermore, the availability of labelled ligands may limit the use of the method. 
Functional assays measuring cellular levels of cAMP can be used in studies of GPCRs 
coupled to the Gαs or Gαi class of G proteins that activate or inhibit adenylyl cyclase, 
respectively (Hill et al 2010). The measurement of intracellular inositol phosphates or Ca2+ 
can be used for the assessment of PLC activity in relation to the activation of the Gαq class 
of G proteins (Liu et al. 2008, Emkey & Rankl 2009). Since GPCR activation alters the gene 
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transcription via the responsive elements for second messengers, cell-based reporter assays 
can be used for GPCR screening (Cheng et al. 2010). In reporter assays, the reporter gene 
constructs usually contain second messenger responsive elements upstream of a promoter, 
which regulates the expression of a selected reporter protein e.g. linked to a fluorescent 
protein.  
Recently, new cell-based methods to study GPCRs have been established, such as a label-
free dynamic mass redistribution (DMR) technology (Schröder et al. 2011). The DMR 
technology detects processes that occur when biomolecules change their localization within 
a cell, associated with mass relocation. The DMR technology has been applied to studies of 
GPCRs coupled to all four families of G proteins (Schröder et al. 2010). Another novel 
approach to study especially poorly characterized G12/13 coupled receptors is a transforming 
growth factor-α (TGFα) shedding assay, in which GPCR activation causes ectodomain 
shedding of a membrane-bound proform of alkaline phosphatase-tagged TGFα and its 
release into a conditioned medium (Inoue et al. 2012). Originally, the ectodomain shedding 
of TGFα was observed to take place downstream of LPA6 receptor signalling (Inoue et al. 
2011).  
G protein-independent functional assays include receptor internalization assays and β-
arrestin recruitment assays (Haasen et al. 2006, Siehler 2008, Zhang & Xie 2012). These 
assays often exploit the combination of high-resolution fluorescence microscopy and 
automated image analysis for monitoring fluorophore-labelled biomolecules in cells. Either 
ligands or β-arrestins can be labelled with a fluorophore in order to detect the 
internalization of the receptor. Alternatively, specific antibodies can be directed to the N- or 
C-terminus of the GPCR and co-internalized with the receptor. These primary antibodies 
can be detected with fluorophore-labelled secondary antibodies. Non-imaging-based β-
arrestin recruitment assays include bioluminescence resonance energy transfer, where the 
GPCR is tagged with a fluorescent protein tag whereas the β-arrestin is tagged with Renilla 
luciferase, or vice verca. After β-arrestin recruitment, the two tags come into close proximity 
and their interaction results in a detectable emission of light (Bertrand et al. 2002). 
 
2.4.2 [35S]GTPγS binding techniques 
Functional [35S]GTPγS binding techniques provide an opportunity to monitor the first step 
in the GPCR-G protein signalling cascade by measuring the guanine nucleotide exchange. 
After agonist binding, the GPCR will interact with a G-protein, GDP is released from the α 
subunit in the assay, it is replaced with a radiolabelled GTP analog. The substitution in the 
γ-phosphate renders [35S]GTPγS resistant to hydrolysis, resulting in the accumulation of 
radioactivity and this can be detected (Weiland & Jakobs 1994) (Figure 9). Classically 
[35S]GTPγS binding assays have been performed using membrane preparations (Lazareno 
1997).  
 
[35S]GTPγS autoradiography  
 
Receptor autoradiography generally refers to a method, in which either synthetic or natural 
ligands are labelled with radioactive isotopes, followed by their binding to specific 
receptors, their binding sites can be anatomically localized using a film or photoemulsion 
layer. The finding that receptorG-protein complexes are still able to function in tissue 
sections (Zarbin et al. 1983) led to the development of the [35S]GTPγS autoradiography 
method that provides an approach to detect agonist-driven activity at the receptorG 
protein axis in tissue sections (Sim et al. 1995, Sovago et al. 2001, Laitinen 2004). In addition 
to providing information about the receptor’s anatomical distribution, [35S]GTPγS 
autoradiography detects only active receptors in their native cellular microenvironment, 
and is often referred to as functional autoradiography. One advantage of the technique over 
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the classical receptor autoradiography is that several receptors can be studied 
simultaneously using a single radiolabelled compound.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. The principle of [35S]GTPγS binding assay. The symbol of radioactivity refers to the 35S 
of [35S]GTPγS, a radiolabelled analog of GTP that is also resistant to hydrolysis and remains 
bound to the G protein α subunit resulting in the accumulation of radioactivity (modified from 
Sovago et al. 2001). 
 
[35S]GTPγS autoradiography was first introduced in 1994 to detect the light-stimulated G 
protein activity in the Drosophila compound eye (Yarfitz et al. 1994), and was applied to 
brain cryostat sections in 1995 (Sim et al. 1995). Thereafter, several examples of successful 
detection of many receptor systems in the brain have been published, including cholinergic, 
opioidergic, serotonergic, adrenergic, dopaminergic, histaminergic, GABAergic, 
cannabinoidergic, and lysophospholipid receptors (Sovago et al. 2001, Laitinen 2004). 
Altogether, approximately 20 distinct GPCRs have been successfully studied using the 
method, and the method has been applied to brain sections of different species, including 
man (Sovago et al. 2005). The method seems largely restricted to studies of the GPCR 
subtypes that signal through the Gi class of G proteins. This may be explained by the 
relative abundance of Gi in many cells over all other classes of heterotrimeric G proteins 
and by the relatively higher intrinsic rates of basal GDPGTP exchange among the α 
subunits of this subclass (Laitinen 2004).  
The general procedure of [35S]GTPγS autoradiography is presented in Figure 10. It 
should be noted, that each assay protocol must be optimized for each particular receptor; 
e.g. assay buffer compositions and incubation times may vary. In order to detect agonist-
stimulated responses, the method requires a large excess of GDP to inactivate G protein α 
subunits and to reduce basal [35S]GTPγS binding (Sim et al. 1997, Sim-Selley & Childers 
2002). In [35S]GTPγS autoradiography, typically 1-2 mM of GDP is needed, in contrast to the 
membrane [35S]GTPγS binding assay, where micromolar concentration of GDP (1-10 μM) is 
sufficient. This is partly explained by the higher protein content of the tissue sections 
compared to membrane preparations as well as by the high degradative capacity of brain 
sections. In brain sections, practically all cellular enzymes, including the nucleotide 
32 
 
 
hydrolases capable of hydrolyzing GDP, are potentially preserved. Due to the high 
degradative capacity of brain sections in the presence of a high GDP concentration, high 
concentrations of agonists are also needed. Sodium is required in the assay buffer to reduce 
basal binding by inhibiting spontaneously active receptors whereas magnesium is required 
to promote agonist-stimulated G protein activation (Sim et al. 1997, Sim-Selley & Childers 
2002). The pH of the assay buffer must be appropriate to avoid tissue damage. Depending 
on the agonists used, other components can be included in the assay buffer. Bovine serum 
albumin (BSA, 0.1 - 0.5 %) needs to be included in the assay buffer to prevent lipophilic 
agonists, such as lysophospholipids and cannabinoids, from adsorbing to the tissue or 
containers. If one is examining peptide ligands, then protease inhibitors will be needed to 
prevent their degradation. The reducing agent dithiotreitol (DTT) can be included in the 
assay buffer to prevent non-specific binding of [35S]GTPγS  in tissue sections (Happe et al. 
2001). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Typical procedure of the [35S]GTPγS autoradiography method. Depending on the 
agonists used, the procedure might require some modification (modified from Sovago et al. 
2001).   
 
 
Preparation of tissue cryosections at -20 °C;  
storage of the sections at -80 °C until the assay day. 
Preincubation I (step 1, 20 min, RT) in the assay buffer containing Tris-HCl (pH 
7.40), MgCl2, NaCl, and EDTA to moisten the sections. 
On the assay day, sections are brought to room temperature (RT);  
thawing and drying of sections. 
Preincubation II, “GDP loading” (step 2, 60 min, RT) in the assay buffer 
supplemented with 1-2 mM GDP. 
Autoradiography incubation “[35S]GTPγS labelling” (step 3, 90 min, RT) in the 
assay buffer supplemented with 1-2 mM GDP, [35S]GTPγS, and agonists. 
Washing of the sections in buffer containing Tris-HCl (pH 7.40) and MgCl2 (2x5 
min, at 0 °C), and in deionized water (30 sec, at 0 °C). Drying of the sections. 
Film exposure for ~2-5 days. 
 
Development of the film. 
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[35S]GTPγS autoradiography has been proven to be suitable for studying brain lipid 
receptors, especially the Gi-coupled LPA1, S1P1, and cannabinoid CB1 receptors. In 
[35S]GTPγS autoradiography, the LPA-stimulated G protein activity is largely restricted to 
the developing white matter tracts in the brain of 4-week-old rats whereas S1P, as well as a 
S1P1 receptor-selective agonist will evoke a robust signal throughout the gray matter areas 
both in the developing and adult rat brain (Waeber & Chiu 1999, Laitinen 2004, Sim-Selley 
et al. 2009) (Figure 11). Among other lysophospholipids  when modified assay conditions 
were used (4 °C temperature, 3 h incubation time, 0.1 mM GDP)  LPI induced [35S]GTPγS 
binding response in the adult rat prefrontal cortex and hippocampus (Rojo et al. 2012). The 
cannabinoid CB1 receptor-mediated [35S]GTPγS binding response is prominent in several 
gray matter areas, including the cerebral cortex, hippocampus, caudate putamen, and the 
molecular layer of the cerebellum (Sim et al. 1996, Palomäki et al. 2007) (Figure 11), 
convergent with the mapping performed by the classical receptor autoradiography 
(Herkenham et al. 1991). In contrast to the abundantly expressed CB1 and S1P1 receptors, 
receptor densities for several classical GPCRs are low and [35S]GTPγS responses therefore 
more restricted (Figure 11). Although CB1 and S1P1 receptors are widely expressed in the 
brain and exogenous agonists for these receptors produce robust responses, endogenous 
responses in the brain are local. For example, it is believed that the endogenous 2-AG 
signals within a 20-μm-distance from its site of origin (Castillo et al. 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. [35S]GTPγS binding responses in horizontal brain sections of a 4-week-old rat evoked 
by lipid mediators (upper row) and classical neurotransmitters (lower row). Agonists used: LPA 
for LPA receptors, CP55,940 for cannabinoid receptors, S1P for S1P receptors, CCh 
(carbamylcholine) for muscarinic acetylcholine receptors, DAMGO for opioid receptors, and 5-HT 
for serotonin receptors. Abbreviations: Cbm, molecular layer of the cerebellum; cc, corpus 
callosum; CPu, caudate putamen; fi, fimbria of the hippocampus; Hip, hippocampus; SuG, 
superficial gray layer of the superior colliculus. Aaltonen 2008, unpublished.   
 
 
One characteristic of the functional autoradiography is [35S]GTPγS binding that is 
evident in several brain regions even without exogenously added agonists, i.e. activity 
under basal conditions. Endogenous receptor-activating ligands, such as neurotransmitters 
and neuromodulators, as well as their precursors may be retained in tissue sections or they 
may be formed during the incubations, contributing to the widespread and 
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heterogeneously distributed basal [35S]GTPγS binding (Laitinen 1999, Palomäki & Laitinen 
2006). A substantial portion of this basal labelling has been shown to derive from the 
endogenous formation of adenosine in brain sections during the incubations and 
consequent activation of the abundant and widely-distributed adenosine A1 receptors 
(Laitinen & Jokinen 1998, Laitinen 1999, Moore et al. 2000). Therefore, one needs to deplete 
adenosine either with adenosine deaminase or selective blockade of the A1 receptors with 
an antagonist (8-cyclopentyl-1,3-dipropylxanthine, DPCPX). Another source of basal 
binding in brain sections has been shown to be tonic LPA1 receptor activity, especially in 
the developing white matter tracts (Palomäki & Laitinen 2006). 
Recently, it was demonstrated that the comprehensive elimination of enzymatic 
hydrolysis of 2-AG in brain sections by irreversibly acting inhibitors leads to 2-AG 
accumulation and subsequent cannabinoid CB1 receptor activation that can be successfully 
revealed using [35S]GTPγS autoradiography (Palomäki et al. 2007). Evidently, brain sections 
preserve functional enzymatic machinery to generate endocannabinoids during the 
incubations. In addition to GPCR agonists and antagonists, enzyme activators and 
inhibitors thus represent promising novel approaches to study the life cycle of lipid 
modulators, i.e. a novel way of exploiting this technique.  
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3 Aims of the Study 
 
 
The general objective of the study was to deepen the understanding of lipid GPCR 
signalling in the CNS. The study comprised of two main parts; the first part involved the 
development and optimization of the methodology used for studying lipid-GPCR 
signalling and the second part focused on the characterization of the enzymatic pathways 
responsible for the lipid messenger synthesis and degradation. The second part especially 
focused on the lipid phosphate phosphatases as the regulators of LPAGPCR signalling 
and diacylglycerol lipases as the regulators of 2-AGGPCR signalling.  
 
 
The specific aims of this study were: 
 
1. To characterize and optimize [35S]GTPγS autoradiography method by mapping the 
rat brain regions with prominent [35S]GTPγS binding in basal conditions.  
 
2. To develop a LC/MS/MS method for the quantitative determination of LPA from 
brain tissue samples. 
 
3. To reveal the enzymatic pathways regulating the levels of signalling LPA in rat brain 
sections, especially to clarify if pharmacological manipulation of LPA-synthesizing 
or -degradating pathways would affect the tonic LPA1 receptor signal. 
 
4. To investigate if comprehensive pharmacological blockade of 2-AG hydrolysis 
would result in the DAGL-mediated 2-AG accumulation in mouse brain sections and 
whether DAGL-deficiency would alter the functionality of CB1 receptor-Gi axis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
 
4 General Experimental Procedures 
 
4.1 MATERIALS 
4.1.1 Chemicals  (Chapters 5–8) 
 
Chemicals used in the present study are presented in Table 6. All other chemicals were of 
the finest purity available. 
 
Table 6. Chemicals used in the present study and their targets/functions.  
Chemical Target 
receptor/enzyme 
or other function 
Origin 
Receptor agonists   
DAMGO  
([D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin) 
Opioid Tocris (Northpoint, UK) 
CP55,940   
((−)-3-[2-Hydroxy-4-(1,1-dimethylheptyl)-
phenyl]-4-[3-hydroxypropyl]cyclohexan-1-ol) 
Cannabinoid Tocris (Northpoint, UK) 
Neuropeptide Y Neuropeptide Y Tocris (Northpoint, UK) 
Histamine Histamine Fluka (Buchs, Switzerland) 
2-chloroadenosine Adenosine  Sigma (St. Louis, MO, USA) 
S1P (Sphingosine 1-phosphate)  S1P Biomol  
(Plymouth Meeting, PA, USA) 
(2S)-OMPT  
(1-oleoyl-2-methyl-sn-glycero-3-
phosphothionate) 
LPA3 Avanti Polar Lipids  
(Alabaster, AL, USA) 
16:0 LPA  
(1-palmitoyl-2-hydroxy-sn-glycero-3-
phosphate) 
LPA Avanti Polar Lipids  
(Alabaster, AL, USA) 
18:0 LPA  
(1-stearoyl-2-hydroxy-sn-glycero-3-
phosphate) 
LPA Avanti Polar Lipids  
(Alabaster, AL, USA) 
20:4 LPA  
(1-arachidonoyl-2-hydroxy-sn-glycero-3-
phosphate) 
LPA Avanti Polar Lipids  
(Alabaster, AL, USA) 
18:1 LPA  
(1-oleyl-2-hydroxy-sn-glycero-3-phosphate) 
LPA Sigma (St. Louis, MO, USA) 
AEA (Arachidonoylethanolamide, 
anandamide)  
Cannabinoid Cayman Chemical  
(Ann Arbor, MI, USA) 
2-AG (2-arachidonoyl glycerol)  Cannabinoid Cayman Chemical  
(Ann Arbor, MI, USA) 
   
Receptor antagonists/ 
inverse agonists 
  
Naloxone Opioid Tocris (Northpoint, UK) 
Thioperamide Histamine H3 RBI (Natick, MA, USA) 
AM251  
(N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamide) 
Cannabinoid CB1 Tocris (Northpoint, UK) 
BIIE 0246  
(N-[(1S)-4-[(Aminoiminomethyl)amino]-1-
[[[2-(3,5-dioxo-1,2-diphenyl-1,2,4-
triazolidin-4-yl)ethyl]amino]carbonyl]butyl]-
1-[2-[4-(6,11-dihydro-6-oxo-5H-
dibenz[b,e]azepin-11-yl)-1-piperazinyl]-2-
oxoethyl]-cyclopentaneacetamide) 
Neuropeptide Y Y2  Tocris (Northpoint, UK) 
      Continued 
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Table 6. Chemicals used in the present study and their targets/functions. Continued 
Chemical Target 
receptor/enzyme  
or other function 
Origin 
Receptor antagonists/ 
inverse agonists 
  
L-152,804  
(5,5-Dimethyl-2-(2,3,4,9-tetrahydro-3,3-
dimethyl-1oxo-1H-xanthen-9-yl)-1,3-
cyclohexanedione) 
Neuropeptide Y Y5  Tocris (Northpoint, UK) 
BIBP 3226 
(N-[(1R)]-4-[(Aminoiminomethyl)amino-1-
[[[(4hydroxyphenyl)methyl]amino]carbonyl]but
yl-α-phenylbenzeneacetamide trifluoroacetate) 
Neuropeptide Y Y1  Bachem  
(Torrance, CA, USA) 
DPCPX  
(8-cyclopentyl-1,3-dipropylxanthine) 
Adenosine A1 Sigma  
(St. Louis, MO, USA) 
Ki16425  
(3-(4-[4-([1-(2 chlorophenyl)ethoxy] carbonyl 
amino)-3-methyl-5-isoxazolyl]benzylsulfanyl 
propanoic acid)) 
LPA1/3 Sigma  
(St. Louis, MO, USA) 
VPC 23019 
((R)-phosphoric acid mono-[2-amino-2-(3-
octyl-phenylcarbamoyl)-ethyl] ester) 
S1P1/3  Avanti Polar Lipids  
(Alabaster, AL, USA) 
   
Enzyme activators/inhibitors   
Propranolol Non-specific LPP-inhibitor Biomol (Plymouth Meeting, 
PA, USA) 
Na3VO4 Non-specific LPP-inhibitor Sigma (St. Louis, MO, USA) 
THL (Tetrahydrolipstatin)  Non-specific lipase 
inhibitor 
Sigma (St. Louis, MO, USA) 
AlCl3 Component of AlFx- Merck  
(Darmstat, Germany) 
NaF Component of AlFx- Merck  
(Darmstat, Germany) 
MAFP (Methylarachidonoylfluorophosphonate)  Non-specific serine 
hydrolase inhibitor 
Cayman Chemical  
(Ann Arbor, MI, USA) 
JZL184 
(4-nitrophenyl-4-(dibenzo[d][1,3]dioxol-5 
yl(hydroxy)methyl)piperidine-1-carboxylate) 
Specific MAGL inhibitor Cayman Chemical  
(Ann Arbor, MI, USA) 
PIP2 (Phosphoinositol-4,5-bisphosphate) PLD-activator Avanti Polar Lipids  
(Alabaster, AL, USA) 
Oleate PLD-activator Sigma  
(St. Louis, MO, USA) 
Neomycin PIP2-depletor Sigma  
(St. Louis, MO, USA) 
1-butanol Non-specific PLD inhibitor Merck  
(Darmstat, Germany) 
Compound 4k 
(5-fluoro-2-indolyl des-chlorohalopemide) 
 
PLD-inhibitor University of Eastern 
Finland, Kuopio, Finland 
    
Other chemicals   
tert-butanol Control compound for 1-
butanol 
Merck  
(Darmstat, Germany) 
Nadolol Control compound for  
propranolol 
Sigma (St. Louis, MO, USA) 
Glycerol 3-phosphate LPA precursor  Sigma (St. Louis, MO, USA) 
PA (Phosphatidic acid)  LPA precursor Avanti Polar Lipids  
(Alabaster, AL, USA) 
PC (Phosphatidylcholine)  LPA precursor Sigma (St. Louis, MO, USA) 
BSA  
(Bovine serum albumin, fatty acid-free)  
Carrier protein Sigma (St. Louis, MO, USA) 
DTT (Dithiotreitol)  Reducing agent Sigma (St. Louis, MO, USA) 
      Continued 
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Table 6. Chemicals used in the present study and their targets/functions. Continued 
Chemical Target 
receptor/enzyme  
or other function  
Origin 
Other chemicals   
NEM (N-ethylmaleimide) Alkylating agent Sigma (St. Louis, MO, USA) 
GDP (Guanosine diphosphate)  Guanine nucleotide Sigma (St. Louis, MO, USA) 
GTPγS  
(Guanosine-5’-O-(3-thio)-triphosphate) 
Guanine nucleotide 
used for determining 
non-specific binding 
Sigma (St. Louis, MO, USA) 
[35S]GTPγS (Guanosine-5’-O-(3-
[35S]thio)-triphosphate) 
Radioisotope-labelled 
guanine nucleotide 
NEN Life Science Products Inc.  
(Boston, MA, USA) 
DFOM   
(Deferoxamine mesylate) 
Aluminium chelator Sigma (St. Louis, MO, USA) 
17:0 LPA  
(1-heptadecanoyl-2-hydroxy-sn-glycero-
3-phosphate) 
Internal standard Avanti Polar Lipids  
(Alabaster, AL, USA) 
AEA-d8  
(Arachidonoylethanolamide-d8) 
Internal standard Cayman Chemical  
(Ann Arbor, MI, USA) 
2-AG-d8  
(2-arachidonoyl glycerol-d8) 
Internal standard Cayman Chemical  
(Ann Arbor, MI, USA) 
Acetonitrile Solvent J.T. Baker  
(Deventer, The Netherlands) 
Methanol Solvent J.T. Baker  
(Deventer, The Netherlands) 
Chloroform Solvent Riedel-de Haen (Seelze, Germany) 
    
 
4.1.2 Animals (Chapters 5–7)   
4 week-old male Wistar rats were supplied by the National Laboratory Animal Centre 
(University of Eastern Finland, Kuopio, Finland). Approval for the harvesting of animal 
tissue was obtained from the local welfare officer of the University of Eastern Finland. The 
experiments did not involve any in vivo treatment. The animals were housed in groups of 
five to ten individuals per cage under standard laboratory conditions (12:12 h lightdark 
cycle, food and water ad libitum, 60% relative humidity). The rats were decapitated 79 h 
after lights on, and within the next 5 min, the whole brain was dissected out, dipped briefly 
in isopentane (chilled on dry ice) and stored at 80 °C. Horizontal, coronal or sagittal brain 
sections (20 μm thick) were cut according to Rat Brain Atlas (Paxinos & Watson 1998) at 19 
°C to 21 °C using a Leica cryostat, thaw-mounted onto Superfrost®Plus slides (Menzel-
Gläser, Germany), dried for 14 h at room temperature under a constant stream of air and 
stored thereafter at 80 °C.  
 
4.2 METHODS 
4.2.1 [35S]GTPγS autoradiography (Chapters 5, 7, 8) 
[35S]GTPγS autoradiography was performed using a three-step (Chapters 7 and 8) or a two-
step (Chapter 5) protocol. In the former procedure, the sections were processed in three 
sequential steps consisting of preincubation for 20 min (step 1), GDP-loading for 60 min 
(step 2) and [35S]GTPγS labelling (step 3) for 90 min. In the two-step protocol, the GDP-
loading step was omitted. All the steps in both protocols were performed at 20 °C using 
Tris-based buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 100 mM NaCl, 5 mM MgCl2). In 
the three-step protocol, steps 2 and 3 included 2 mM GDP, whereas in the two-step 
protocol, 2 mM GDP was present only during the autoradiography step, which additionally 
included 1 mM DTT and 32252 pM [35S]GTPγS in both protocols. For selected slides, 
chemicals under interest and 0.1% BSA were included in the assay during the step 3, or if 
indicated, during the step 1 or step 2. In addition, some slides in each experiment were 
incubated in the presence of 10 μM GTPγS (step 3) to determine non-specific binding. After 
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the 90 min autoradiography step, the slides were rinsed twice (5 min each time) in ice-cold 
washing buffer (50 mM Tris-HCl, pH 7.4 and 5 mM MgCl2), dipped for 30 s in ice-cold 
deionized water, air-dried and arranged into a cassette together with [14C] standards 
(Amersham, Little Chalfont, Bucks, UK) and exposed against a radiosensitive film (BioMax 
MR™, Kodak Scientific Imaging Film) for 25 days. After exposure, the films were 
developed for 34 min at 4 °C with Kodak D-19 developer.  
 
4.2.2 LC/MS/MS for LPA determination (Chapters 6, 7) 
 
Extraction of LPA for mass spectrometric determination  
 
Slides with two horizontal brain sections were incubated for 40 min in the presence of AlFx- 
(NaF 10 mM + AlCl3 50 μM) mimicking the [35S]GTPγS autoradiography. The control slides 
were incubated similarly in the assay buffer. After a 40 min incubation, slides were rinsed 
twice (2 min each time) in ice-cold washing buffer, dipped for 30s in ice-cold deionized 
water and air-dried. The modified extraction method of Bligh and Dyer (1959) was applied 
for the isolation of LPA from the tissue matrix. One sample consisted of pooled tissue 
obtained from four slides. The brain tissue was scraped manually from the slides with a 
spatula using the mixture of 50 mM Tris-HCl, pH 7.40 and methanol with a ratio of 1:4 
(v/v); this mixture also included an internal standard (17:0 LPA) used in the quantification. 
The tissue was transferred to a screw-capped Pyrex® borosilicate glass test tube. The 
mixture of 50 mM Tris-HCl, pH 7.40 and methanol (1:4, v/v) was added to the test tube to 
bring the volume up to 200 μl. Chloroform was added to yield a 
water/methanol/chloroform ratio of 1:4:2 (v/v/v) and the samples were shaken for 1 h with 
a vertical shaker (Heidolph Multi Reax, Heidolph Instruments GmbH & Co, Schwabach, 
Germany). To achieve the phase separation, 80 μl of chloroform and 80 μl of water were 
added. After vortexing for 1 min, the samples were centrifuged at 1800 x g for 15 min at 
room temperature. The upper aqueous layer was transferred to an HPLC sample vial.     
 
Liquid chromatography-tandem mass spectrometry (LC/MS/MS)   
 
The high-performance liquid chromatography (HPLC) system comprised of an Agilent 
1200 Series Rapid Resolution LC System (Agilent Technologies, Waldbronn, Germany) 
consisting of a solvent micro vacuum degasser, a binary pump, a thermostatted column 
compartment SL, and an autosampler SL. Ten microliter of sample solution were injected 
onto a reversed phase HPLC column (XBridge™ C8 2.1  50 mm, 2.5 μm) (Waters, Ireland) 
using gradient elution with 50 μM ammonium acetate + 1% triethylamine (TEA) (A) and 
1% TEA in 90% methanol (B) as follows: 06.0 min 20% B → 90% B, 6.010.0 min 90% B, 
10.010.1 min 90% B → 20% B, 10.015.0 min 20% B. The flow rate was 0.3 ml/min, column 
temperature was maintained at 40 ºC and the autosampler tray temperature was set to 10 
C.  
The mass spectrometric analysis was carried out with an Agilent 6410 Triple Quadrupole 
LC/MS equipped with an electrospray ionization source (ESI; Agilent Technologies, Palo 
Alto, CA, USA). The following ionization conditions were used: ESI negative ion mode, 
drying gas (nitrogen) temperature 300 ºC, drying gas flow rate 8 l/min, nebulizer pressure 
40 psi and capillary voltage 4000 V. Analyte detection was performed using multiple 
reaction monitoring (MRM) with the following transitions: m/z 409 → 153 for 16:0 LPA, m/z 
437 → 153 for 18:0 LPA, m/z 435 → 153 for 18:1 LPA, m/z 457 → 153 for 20:4 LPA, and m/z 
423 → 153 for 17:0 LPA. The fragmentor voltage was 160 V and collision energy 20 V, 
except 23 V for 17:0 LPA. Data were acquired by Agilent MassHunter Workstation 
Acquisition software (Agilent Technologies, Data Acquisition for Triple Quad., version 
B.01.03). 
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4.2.3 Statistical analysis (Chapters 5–8) 
Autoradiography films were digitized using a HP scanjet 7400c scanner. For the 
quantitative data, optical densities of the autoradiograms were measured using ImageJ, a 
freely available java-based image analysis software system developed in the National 
Institutes of Health, USA (http://rsb.info.nih.gov/ij/). Optical densities were converted to 
nCi/g using nonlinear transformation based on the greyscale values of [14C] standards. 
Quantitative data were calculated as nCi/g equivalents with non-specific binding 
subtracted from total binding.  
In LC/MS/MS experiments, an internal standard was used for quantification, and peak 
area ratios of the analyte to the IS were calculated as a function of the concentration ratios 
of the analyte to the internal standard using Agilent MassHunter software (Quantitative 
Analysis Version B.01.03). For Figure 25, the protein content of brain sections was 
determined by the Pierce BCA Protein Assay Kit with BSA as the standard. 
Unless otherwise stated, the statistical differences were determined using one-way 
ANOVA with Tukey’s multiple comparison post hoc test with ***p < 0.001, **p < 0.01, or *p < 
0.05 considered as statistically significant. All statistical data analyses were conducted 
using GraphPad Prism® (version 4.03 or 5.03) for Windows (San Diego, CA, USA).  
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5 [35S]GTPγS Binding Under Basal Conditions1 
 
 
 
Abstract: [35S]GTPγS autoradiography represents a powerful functional approach to detect 
receptor-dependent Gi protein activity in anatomically defined brain structures. Inherent in 
this technique, however, is the notable basal signal evident in several brain regions in the 
absence of receptor stimulation by exogenously added agonist. In the rat brain, much of 
this basal labelling derives from tonic activation of adenosine A1 and LPA1 receptors in the 
grey and white matter regions, respectively. Despite the elimination of the two receptor 
activities, prominent basal [35S]GTPγS labelling is still evident in discrete brain structures, 
possibly reflecting regional enrichment of Gi and/or constitutive receptor activity or the 
presence of still unknown endogenous ligands activating their orphan receptors. Here, the 
anatomical distribution of the enhanced basal signal was systematically mapped in brain 
sections of 4-week-old male Wistar rats. Regions with prominent basal [35S]GTPγS labelling 
represented neuroanatomically distinct structures, in particular various thalamic and 
hypothalamic nuclei. For instance, the paraventricular thalamic nucleus, the bed nucleus of 
the stria terminalis and the subfornical organ were highly labelled, as were the 
periaqueductal gray and the nucleus of the solitary tract. Pre-treatment with N-
ethylmaleimide, an alkylating agent preventing all known receptor-driven G protein 
activity in cryostat sections markedly decreased the basal binding in all examined regions. 
In preliminary screening, selective antagonists for various brain-enriched Gi-coupled 
receptors failed to suppress the basal signal in any of the studied regions.  
 
 
 
 
                                                 
1 Adapted with permission of Elsevier from: Aaltonen N, Palomäki VAB, Lecklin A, Laitinen JT. Neuroanatomical 
mapping ofjuvenile rat brain regions with prominent basal signal in [35S]GTPγS autoradiography. J Chem Neuroanat 
35: 233-241, 2008.    
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5.1 INTRODUCTION 
 
Inherent to the functional autoradiography is that there is a certain level of [35S]GTPγS 
binding evident in several brain regions even without exogenously added agonists, i.e. 
activity under basal conditions. A substantial portion of this basal labelling has been shown 
to derive from the endogenous formation of adenosine in brain sections during the 
incubations and consequent activation of the abundant and widely-distributed adenosine 
A1 receptors (Laitinen & Jokinen 1998, Laitinen 1999, Moore et al. 2000). Tonic adenosine A1 
receptor activity is prominent in the grey matter regions and is particularly evident in the 
molecular and granular cell layers of the cerebellum and in the cerebral cortex (Figure 12a). 
The adenosine signal can be efficiently blocked by the selective adenosine A1 receptor 
antagonist DPCPX or by the adenosine degrading enzyme adenosine deaminase (Laitinen 
& Jokinen 1998, Laitinen 1999, Moore et al. 2000). Recently, another source of basal binding 
in brain sections was shown to be tonic LPA1 receptor activity, especially evident in the 
developing white matter areas, e.g. the corpus callosum and the fimbria of the 
hippocampus, which in turn can be eliminated using a potent LPA1/3 receptor-preferring 
antagonist Ki16425 (Palomäki & Laitinen 2006) (Figure 12a). However, even after 
elimination of the two above-mentioned signals, prominent basal labelling is still notable 
deep in the brain in several midline structures (Figure 12b). As a prelude to ongoing studies 
aiming at further characterization and optimization of [35S]GTPγS autoradiography with 
brain sections, we have undertaken the first systematic anatomical mapping of the 
adenosine A1 and LPA1 receptor-independent basal [35S]GTPγS signal in brain sections of 4-
week-old male Wistar rats and identify the brain structures involved. 
 
 
 
 
 
 
 
 
 
 
 
      
 
Figure 12. (a) The adenosine signal is prominent throughout the majority of grey matter areas, 
especially in the molecular cell layer of the cerebellum (Cbm) and in the cerebral cortex (Cx) 
whereas the LPA signal is evident in the developing white matter tracts, such as the corpus 
callosum (cc) and the fimbria of the hippocampus (fi). Treatment of rat brain sections with the 
adenosine A1 receptor antagonist DPCPX and/or the LPA1/3 receptor antagonist Ki16425 reduces 
[35S]GTPγS binding compared to the control condition without any added ligands. (b) The effect 
of DPCPX and Ki16425 compared to the basal condition without added ligands in different levels 
of the rat brain. Note that even after elimination of tonic adenosine and LPA receptor signals, 
some prominent basal [35S]GTPγS labelling is evident, especially in several midline structures. 
Scale bar = 2 mm. 
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5.2 MATERIALS AND METHODS 
The materials and general methods are described in Chapter 4. 
 
5.2.1 Tissue staining 
To facilitate the identification of neuroanatomical structures, adjacent sections to those used 
in [35S]GTPγS autoradiography (eight individual animals) were stained with Luxol Fast 
Blue and Cresyl Violet staining according to Geisler et al. (2002). This method allows 
simultaneous demonstration of cell bodies and myelinated fibre tracts in the mammalian 
brain.  
 
5.3 RESULTS AND DISCUSSION 
5.3.1 Optimization of the assay conditions  
The three-step standard protocol for [35S]GTPγS autoradiography comprises of a 
preincubation for 20 min, GDP loading for 60 min, and [35S]GTPγS labelling for 90 min. For 
practical and economical reasons, we first tested whether the second step was necessary if 
one wished to visualize the basal labelling. These experiments indicated that [35S]GTPγS 
binding throughout the brain sections was higher without the GDP loading step. For 
example, quantitative comparison of optical density values (mean  SD, n=2) indicated that 
the two-step protocol resulted in 6.3 ± 2.1 % higher values for the cortex, 5.7 ± 2.0 % for 
caudate putamen and 4.8 ± 1.8 % for hippocampus. Nonetheless, the enhanced basal signal 
was clearly visible in the typical brain structures (data not shown). Additional experiments 
revealed that the inclusion of 1 mM DTT during the [35S]GTPγS labelling step clarified the 
boundaries of the labelled structures to some extent (data not shown). Different assay 
buffer compositions were also investigated, especially in the light of findings 
demonstrating that the use of a glycylglycine-based assay buffer instead of the more 
common Tris-based buffer resulted in reduction of overall basal binding (Happe et al. 
2001). In our experiments, however, basal binding was not significantly lower when a 
glycylglycine buffer was used instead of Tris buffer (data not shown). Based on these 
preliminary experiments, all subsequent studies were performed in Tris buffer using the 
two-step protocol consisting of preincubation for 30 min and [35S]GTPγS labelling for 90 
min. In addition, 1 mM DTT, 1 μM DPCPX and 0.5 μM Ki16425 were included in the 
[35S]GTPγS labelling step.     
5.3.2 Brain structures with enhanced basal [35S]GTPγS labelling  
In the brain sections of 4-week-old rats, the prominent regions with high basal [35S]GTPγS 
binding were largely localized near the midline and often in the close vicinity of the 
cerebral ventricles, representing phylogenetically conserved brain structures, including 
various thalamic and hypothalamic nuclei (Table 7, Figure 13, Figure 14). We also 
compared autoradiographs of 4-week-old animals to those of adult (12-week-old) animals 
and found that the same structures showed enhanced labelling in both age-groups under 
basal conditions (data not shown).  
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Figure 13. The prominent basal [35S]GTPγS signal is heterogeneously distributed and localizes to 
the deep brain structures. Luxol Fast Blue and Cresyl Violet staining was performed on adjacent 
sections. The number shown in the left indicates the distance (mm) of the first section in the 
row from the Bregma. Each of the stained sections is adjacent to the section shown in the left 
panel whereas the distance between other sections illustrated in this figure is 200300 μm. 
Structures in the parentheses indicate some of the areas with no prominent labelling. 
Abbreviations: AH, anterior hypothalamic area; BST, bed nucleus of the stria terminalis; CPu, 
caudate putamen (striatum); Cx, cerebral cortex; DM, dorsomedial hypothalamic nucleus; DR, 
dorsal raphe nucleus; Hip, hippocampus; IMD, intermediodorsal thalamic nucleus; IP, 
interpeduncular nucleus; LPB, lateral parabrachial nucleus; Me, medial amygdaloid nucleus; 
MHb, medial habenular nucleus; MPA, medial preoptic area; MPB, medial parabrachial nucleus; 
MPO, medial preoptic nucleus; Pa, paraventricular hypothalamic nucleus; PAG, periaqueductal 
gray; PH, posterior hypothalamic area; PV, paraventricular thalamic nucleus; Re, reuniens 
thalamic nucleus; Rh, rhomboid thalamic nucleus; S, subiculum; SFO, subfornical organ; SN, 
substantia nigra; Sol, nucleus of the solitary tract; sp5, spinal trigeminal tract; VMH, 
ventromedial hypothalamic nucleus. Scale bar = 2 mm. 
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Table 7. Adenosine A1 and LPA1 receptor-independent basal [35S]GTPγS binding in 4-week old 
male Wistar rat brain. Rat brain sections (horizontal cut) were processed for [35S]GTPγS 
autoradiography using a two-step protocol and the autoradiographs were digitized and 
quantified. The radioligand concentration was 32 pM in this set of incubations. Data are 
expressed as nCi/g equivalents with non-specific binding (determined with 10 μM GTPγS) 
subtracted from the total and are the mean ± S.E.M. from six individual animals (n = 6).          
 
Structure 
[35S]GTPγS binding 
(nCi/g) Structure 
[35S]GTPγS binding 
(nCi/g) 
Structures with relatively low 
and homogeneous basal 
binding  
 
Preoptic area 
 
Caudate putamen  208 ± 6 
Bed nucleus of the stria 
terminalis  596 ± 17 
Cerebral cortex  144 ± 7 Medial preoptic area  742 ± 33 
Hippocampus  175 ± 7 Medial preoptic nucleus  822 ± 43 
Subiculum  239 ± 9   
Substantia nigra  200 ± 10 Amygdala  
  Medial amygdaloid nucleus  761 ± 27 
Thalamus    
Medial habenular nucleus  363 ± 18 Midbrain  
Intermediodorsal thalamic 
nucleus  342 ± 13 Dorsal raphe nucleus  545 ± 28 
Paraventricular thalamic 
nucleus  455 ± 23 Interpeduncular nucleus  651 ± 12 
Reuniens thalamic nucleus  377 ± 25 Periaqueductal gray  363 ± 17 
Rhomboid thalamic nucleus  318 ± 15   
Subfornical organ  287 ± 19 Pons  
  Lateral parabrachial nucleus  561 ± 15 
Hypothalamus  Medial parabrachial nucleus  462 ± 18 
Anterior hypothalamic area  643 ± 38   
Dorsomedial hypothalamic 
nucleus  836 ± 28 Medulla oblongata  
Paraventricular hypothalamic 
nucleus  549 ± 39 Nucleus of the solitary tract  942 ± 44 
Posterior hypothalamic area  568 ± 48   
Ventromedial hypothalamic 
nucleus  795 ± 31 Spinal cord  
  Spinal trigeminal tract  393 ± 4 
 
 
The regions with prominent basal [35S]GTPγS labelling seem to belong to those 
participating in the regulation of primitive vital functions and behaviour. For instance, the 
nucleus of the solitary tract plays an important role in controlling cardiovascular, 
respiratory, gustatory, hepatic and renal mechanisms (Lawrence & Jarrott 1996). The 
subfornical organ participates in the regulation of cardiovascular system and electrolyte 
homeostasis as well as adjusting thirst (Noda 2006, Fry & Ferguson 2007). The bed nucleus 
of the stria terminalis is involved in emotional behaviour induced by stressful and 
anxiogenic stimuli (Forray & Gysling 2004, Choi et al. 2007). Many of the studied regions, 
including the habenular or the parabrachial nucleus, function as an important link between 
the forebrain and the brainstem (Sandyk 1991, Chen et al. 2004). The parabrachial nucleus 
also regulates taste sensation and gastrointestinal activity as well as cardiovascular and 
respiratory system (Benarroch 2006). The hypothalamus has an important role in the 
regulation of motivated behaviour and hormone release, as well as in the maintenance of 
body temperature. In line with details that can be observed from the autoradiographs of 
46 
 
 
previously published papers, several hypothalamic nuclei were intensively labelled under 
the basal conditions, supporting our earlier argumentation that non-optimal signal-to-noise 
ratios are expected for receptor-dependent responses due to the high basal [35S]GTPγS 
labelling in this region (Laitinen 2004).  
              
Figure 14. The adenosine A1 and LPA1 receptor-independent basal [35S]GTPγS labelling is largely 
concentrated over midline structures of the brain. The numbers (Lateral) in the figure indicate 
the distance (mm) of the first and last section from the midline of the brain. The distance 
between sections illustrated in this figure is 120 μm. A prominent basal [35S]GTPγS labelling is 
detectable in the same midline structures shown in the horizontal sections in Figure 12. The 
boundaries of the hypothalamic structures (arrow) are not as discrete as they are in the 
horizontal sections. Abbreviations: BST, bed nucleus of the stria terminalis; IP, interpeduncular 
nucleus; LPB, lateral parabrachial nucleus; MPB, medial parabrachial nucleus; PAG, 
periaqueductal gray; Sol, nucleus of the solitary tract; sp5, spinal trigeminal tract. Scale bar = 
2 mm. 
5.3.3 Sensitivity to NEM  
Since treatment of brain sections with pertussis toxin is not feasible (our unpublished 
observations), the sulfhydryl-alkylating reagent NEM has been successfully used to 
uncouple Gi-linked receptors from their cognate G proteins in brain sections due to its 
ability to irreversibly alkylate the sulfhydryl groups of cysteine residues, including those in 
the C-terminus of the Gi protein α-subunits. Treatment with NEM therefore reveals if 
members of the Gi class of G proteins are involved in certain signalling processes. In 
[35S]GTPγS autoradiography studies, both basal signal and agonist-induced responses are 
sensitive to NEM, as observed for several GPCRs (Waeber & Chiu 1999, Laitinen 2004, 
Palomäki & Laitinen 2006). In the present study, pre-treatment with NEM (1 mM) for 30 
min clearly decreased the overall labelling observed under basal conditions (Figure 15), 
suggesting that Gi activity likely accounts for the [35S]GTPγS binding to brain sections, 
including regions with high basal signal. Therefore, it is reasonable to speculate that the 
basal labelling is, at least partly, due to GPCR activity, and perhaps induced by so far 
unidentified receptor agonists and/or high local density of other types of proteins capable 
of binding [35S]GTPγS. Receptor-activating ligands might be endogenously present in 
sections or could be generated from their precursors during the incubations. It should be 
emphasized, however, that the heterogeneously distributed basal signal is inherent to the 
[35S]GTPγS autoradiography technique, and does not necessarily reflect the situation in the 
brain in vivo. 
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Figure 15. Treatment with the irreversible sulfhydryl-alkylating reagent N-ethylmaleimide (NEM) 
reduces overall [35S]GTPγS labelling and completely abolishes the basal labelling in [35S]GTPγS 
autoradiography. Horizontal rat brain sections were incubated for 10 min in assay buffer, 
followed by incubation for 30 min with 1 mM NEM in the same buffer. After a 10 min wash, 
[35S]GTPγS autoradiography was conducted using a two-step protocol. Abbreviations: BST, bed 
nucleus of the stria terminalis; LPB, lateral parabrachial nucleus; MPA, medial preoptic area; 
MPB, medial parabrachial nucleus; MPO, medial preoptic nucleus; PAG, periaqueductal gray; PV, 
paraventricular thalamic nucleus; sp5, spinal trigeminal tract. Scale bar = 2 mm.  
 
 
5.3.4 Constitutive receptor activity or orphan GPCRs and their ligands as a potential 
source of enhanced basal signal  
Some GPCRs have the ability to spontaneously adopt an active conformation in the absence 
of receptor-activating endogenous ligand, i.e. they display constitutive activity (Bond & 
Ijzerman 2006). Constitutive activity can be reversed with inverse agonists that have the 
ability to shift the equilibrium towards the inactive receptor conformation. For instance, the 
histamine H3 receptor, which can display high constitutive activity in rat brain preparations 
(Morisset et al. 2000, Rouleau et al. 2002), localizes to some extent in the same regions as the 
observed basal signalling. However, in our hands, the H3 receptor inverse agonist 
thioperamide was unable to suppress the basal binding in any of these regions (data not 
shown). With respect to other GPCRs, our previous studies have provided no evidence for 
the constitutive activity of the brain-enriched adenosine A1 or cannabinoid CB1 receptors in 
[35S]GTPγS binding assays (Laitinen 1999, Savinainen et al. 2003). However, these 
observations do not rule out the possibility that constitutive GPCR activity, mediated by 
still unidentified receptors, could be responsible for some of the labelling in brain regions 
with prominent basal signal.  
Periaqueductal gray is known to be an important mediator of opioid receptor-mediated 
analgesia (Gray et al. 2006). In our study, the opioid receptor antagonist naloxone was not 
able to reduce the basal binding significantly in this, or in any other brain region examined 
(data not shown) indicating that tonic opioid receptor activity was not responsible for the 
high basal [35S]GTPγS labelling in this brain region. Neither selective antagonists/ inverse 
agonists for cannabinoid CB1 and CB2 receptors nor the S1P receptor antagonist VPC 23019 
were able to reduce the basal signal detectably in any of the brain regions examined. 
Moreover, no reduction in basal labelling was achieved with the selective neuropeptide Y 
Y1 receptor antagonist BIBP 3226, the Y2 receptor antagonist BIIE 0246 or the Y5 receptor 
antagonist L-152,804, although these NPY receptor subtypes are known to be present in 
several brain regions, including various hypothalamic nuclei. In addition to the receptors 
examined in this study, Waeber and Moskowitz (1997) have tested the effect of several 5-
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HT receptor antagonists on basal binding, but none of the antagonists used (NAN-190, GR-
127,935, methiothepine) reduced the basal signal in the studied brain regions. Furthermore, 
a specific α2-adrenoceptor antagonist RX821002 was not able to reduce basal [35S]GTPγS 
binding (Happe et al. 2000).  
The hypothalamus appears to host most of the still orphan endoGPCRs, as well as many 
of the known GPCRs (Vassilatis et al. 2003). On the other hand, over 30 neurotransmitters 
or neuromodulators have been documented to be present in the nucleus of the solitary tract 
(Lawrence & Jarrott 1996), which was also the most intensely labelled structure in the basal 
conditions used in our study. Thus it is not surprising that although selective antagonists 
for various brain enriched receptors were tested in our experiments, none of them was able 
to decrease the basal signal in any of the studied regions. In addition, some ligands, 
especially those with a peptide structure may dissociate slowly from their receptors, 
contributing to prolonged biological activity (Haskell-Luevano et al. 1996). It might be 
possible that binding of such slowly dissociating ligands explain some of the basal 
[35S]GTPγS labelling.    
5.3.5 Regional enrichment of heterotrimeric G proteins and/or other classes of GTP-
binding proteins as a potential source of enhanced basal signal 
One contributor to the heterogeneously distributed basal signal could be a high local 
concentration of the heterotrimeric G proteins in a particular brain region. Although 
[35S]GTPγS autoradiography principally detects agonist-dependent activity of Gi-coupled 
receptors (Laitinen 2004) in brain sections and Gαo, the most abundant member of the Gi 
family of G proteins shows widespread distribution throughout the rat brain neuropil 
(Worley et al. 1986), other classes of heterotrimeric G proteins, namely Gs, Gq and G12 could 
also contribute to the heterogeneously distributed basal signal in a region-specific manner. 
Although not yet systematically studied, the so far published autoradiographs representing 
basal [35S]GTPγS binding allows one to draw the conclusion that the labelling in several 
regions with intense basal binding appears to be dramatically reduced in brain sections of 
Gαo-deficient mice (Jiang et al. 2001). This supports the view that the Gi class of G proteins, 
the brain-enriched Gαo in particular, is the major determinant of labelling under basal 
conditions of [35S]GTPγS autoradiography. It is not yet known to what extent other classes 
of GTP binding proteins, such as the monomeric G proteins might contribute to [35S]GTPγS 
binding to tissue sections under the assay conditions of autoradiography. In addition to the 
above-mentioned "classical" G proteins, several classes of cellular proteins can additionally 
bind and utilize GTP for functional purposes (Wennerberg & Der 2004), and are therefore 
broadly classified as GTP-binding proteins (G proteins). Since brain cryostat sections are 
expected to retain also such GTP-binding proteins, the presence of such proteins may in 
part, explain some of the basal signal in [35S]GTPγS autoradiography.  
 
5.4 CONCLUSIONS 
 
The present study has provided the first systematic neuroanatomical mapping of the 
adenosine A1 and LPA1 receptor-independent basal [35S]GTPγS signal in the developing rat 
brain. Our study reveals that the enhanced basal binding is mainly localized in the 
phylogenetically conserved brain structures, such as several thalamic and hypothalamic 
nuclei that develop at an early age. The basal signal could be diminished by incubation 
with the irreversible sulfhydryl-alkylating reagent, NEM, which is known to abolish all 
known agonist-induced G protein activity in [35S]GTPγS autoradiography. In contrast, 
selective antagonists towards various brain-enriched receptors failed to suppress the basal 
signal in any of the studied regions. The basal signal could reflect regional enrichment of 
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various members of the GTP-binding protein family and/or constitutive activity of 
unknown GPCRs or the presence of still unidentified ligands capable of activating their 
receptors. 
It may prove difficult to identify individual factors contributing to the heterogeneously-
distributed basal signal in brain cryosections. Nonetheless, attempts to identify these 
factors should be an important goal for further efforts to improve the signal-to-noise ratio 
of the method. Systematic approach to test several additional antagonists might be needed 
and based of the presently mapped anatomical structures, should now be more feasible. A 
more systematic manipulation of assay conditions such as buffer ion composition might 
also be worth testing in future experiments, as this might facilitate the detection of 
constitutive GPCR activity.  
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6 Development of LC/MS/MS Method for LPA Analysis2 
 
 
 
Abstract: A highly selective and sensitive liquid chromatography-tandem mass 
spectrometry (LC/MS/MS) method was developed for the determination of LPAs (16:0 LPA, 
18:0 LPA, 18:1 LPA, 20:4 LPA) in rat brain cryosections. After partitioning the LPAs from 
other lipophilic material present in the tissue with a liquid-liquid extraction, a reversed-
phase column and ion pair technique was used for separating analytes with a gradient 
elution. An internal standard (17:0 LPA) was included in the analysis. Detection and 
quantification of the LPAs were carried out with a triple quadrupole mass spectrometer 
using negative electrospray ionization (ESI) and multiple reaction monitoring (MRM). The 
artificial formation of LPAs from lysophosphatidylcholines during the sample preparation 
procedure and instrumentation was carefully studied during the method development. The 
method was validated; acceptable selectivity, accuracy, precision, recovery, and stability 
were obtained within the calibration curve range of 361790 fmol of LPAs. The 
quantification limit of the assay was 54 fmol injected into column for each LPAs. The 
method was applied to comparative studies of LPA levels in rat brain cryosections after the 
various chemical pre-treatments of the sections. 
 
 
 
 
 
 
 
 
 
 
                                                 
2 Adapted with permission of Elsevier from: Aaltonen N, Laitinen JT, Lehtonen M. Quantification of lysophosphatidic 
acids in rat brain tissue by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B 878: 1145-
1152, 2010. 
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6.1 INTRODUCTION 
 
Recent advances in LPA research have revealed its potential therapeutic and diagnostic 
usefulness as well as the need for development of selective and highly sensitive analytical 
methods, for instance in the diagnostics of the very malignant ovarian cancer (Xu et al. 
1998, Meleh et al. 2007). Several methods have been developed to analyze LPA levels in 
biological samples. LPA has been detected from plasma, serum and other body fluids as 
well as from tissue homogenates. In most cases, LPA is first extracted from the biological 
matrix using modified liquid-liquid extraction methods as described by Folch et al. (1957) 
or Bligh and Dyer (1959). Extraction procedures used together with strong acids (Shan et al. 
2008, Georas et al. 2007, Tokumura et al. 2009), however, raises the concern about artificial 
formation of LPA from LPC under highly acidic conditions (Scherer et al. 2009). There are 
several described methods for determining the total LPA content e.g. bioassay (Tigyi & 
Miledi 1992), immunoassay (Chen et al. 2000), and radioenzymatic assay (Saulnier-Blache et 
al. 2000) but there are some limitations in those methods. Bioassays determine the 
biological effects elicited by LPA, such as the changes in the calcium-dependent chloride 
currents in voltage-clamped Xenopus oocytes (Tigyi & Miledi 1992). Although sensitive, 
bioassays are susceptible to disturbance by interfering compounds present in biological 
samples. Immunoassay (Chen al. 2000) suffers from the poor selectivity of the antibody and 
finally the radioenzymatic assay (Saulnier-Blache et al. 2000) requires the use of radioactive 
reagents.  
A general approach used to quantify individual LPA species from biological samples has 
been gas chromatographic (GC) analysis (Xu et al. 1998, Sugiura et al. 1999, Nakane et al. 
2002). Nonetheless, as an indirect method, GC requires thin layer chromatography 
purification as well as hydrolysis and derivatization of non-volatile LPA prior to analysis 
and thus is extremely laborious and time-consuming. Moreover, some indirect analysis 
protocols have not included appropriate internal standards in the assay (Xu et al. 1998). 
HPLC (Holland et al. 2003) and capillary electrophoresis (Chen & Xu 2001) methods have 
also been used though light-scattering detection and indirect ultraviolet detection are rather 
insensitive and unselective.   
Higher sensitivity and selectivity is obtained by mass spectrometric (MS) detection. 
Some authors have reported analysis of phospholipids by flow injection directly coupled to 
MS (Xiao et al. 2001, Yoon et al. 2003). Unfortunately, flow injection can be problematic 
since there is no prior chromatographic separation to avoid ion suppression effects from 
highly abundant phospholipid species and other matrix components (Shan et al. 2008) and 
also artificial conversion of other lysophospholipids to LPA at the ion source has been 
demonstrated (Zhao & Xu 2009). However, high-throughput shotgun lipidomics provides a 
powerful tool for untargeted analysis of total lipid extracts, including hundreds of 
molecular species of glycerophospholipids, glycerolipids, and sphingolipids (Ejsing et al. 
2009, Ståhlman et al. 2009). Preferred methods for targeted quantifying of the levels of 
individual LPA species from biological samples are liquid chromatography-mass 
spectrometry (LC/MS) (Baker et al. 2001) and liquid chromatography tandem mass 
spectrometry (LC/MS/MS) methods (Georas et al. 2007, Shan et al. 2008, Tokumura et al. 
2009, Scherer et al. 2009). 
Previously, substantial amounts of LPA species were found in rat brain by GC analysis 
(Sugiura et al. 1999, Nakane et al. 2002). Here we report the highly selective and sensitive 
LC/MS/MS method for quantitative measurement of LPA species from rat brain 
cryosections. As far as we are aware, this is the first time that LPA has been measured from 
brain tissue by LC/MS/MS.   
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6.2 MATERIALS AND METHODS 
 
The materials and general methods are described in Chapter 4. 
 
6.2.1 Preparation of standards 
The stock solutions of 16:0 LPA, 18:0 LPA, 18:1 LPA and 20:4 LPA and internal standard 
(IS) (17:0 LPA) were prepared by dissolving the compounds in methanol. The stock 
solutions were stored at 20 °C. Standard working solutions were prepared daily in 
methanol to first obtain a concentration of 2.0 μM and 0.6 μM for IS. The dilutions from 
calibration standard working solutions were prepared in methanol to give concentrations 
of 0.02, 0.05, 0.1, 0.2, 0.5, and 1.0 μM. An internal standard was added into each sample to 
obtain a final concentration of 0.3 μM. Quality control (QC) sample working solutions (0.03, 
0.1, 0.3 and 0.8 μM) were prepared in methanol. An internal standard was added into each 
solution to obtain a final concentration of 0.3 μM. To prepare the calibration and QC 
samples, 100 μl of each particular standard solution, 80 μl of 50 mM Tris-HCl (pH 7.40), 
and 220 μl of methanol were mixed to obtain 400 μl of solution. Each calibration and QC 
sample was then prepared according to Chapter 4.2.2 starting from the chloroform addition 
into the sample. 
 
6.2.2 Assay validation 
This method was validated in terms of selectivity, linearity, precision, accuracy, recovery, 
and stability (Guidance for Industry 2001, van de Merbel 2008). LPAs are endogenous 
compounds and a brain matrix with no analytes is not available. Therefore 4% (w/v) BSA in 
Tris-buffer was used as a surrogate matrix (van de Merbel 2008). Homogenized rat brain 
tissue was used as the authentic biological matrix. The whole brain was homogenized in 50 
mM Tris-HCl (pH 7.40) buffer using a Soniprep 150 homogenizer (MSE Ultrasonic 
Disintegrator; MSE Scientific Instruments, Manor Royal, Crawley, Sussex, UK) and samples 
were prepared according to Chapter 4.2.2. The volume of the homogenate in each sample 
corresponded to that of the tissue cryosection samples.  
The selectivity of the method was assessed by analyzing reference standards, tissue 
samples, buffers, and solvents for interfering peaks at the retention times of LPAs. The 
standard addition method was used to further study the selectivity and matrix effect by 
spiking two concentrations of standards (0.2 and 0.4 μM) into the brain tissue homogenate 
to obtain regression curves for each LPA species (van de Merbel 2008). The slopes of the 
curves were compared to the slopes of standard curves prepared without tissue matrix 
using analysis of covariance (ANCOVA). Selectivity was also studied by diluting the tissue 
samples 1:2, 1:5 and 1:10 with methanol before injecting into LC/MS/MS (Schuhmacher et 
al. 2003) and comparing concentrations of diluted samples and undiluted samples. An in-
source fragmentation experiment with 18:1 LPC molecule (Little et al. 2006) was performed 
in order to probe ionization matrix effects by other molecular species, such as 
glycerophosphocholines and lysophosphatidylserines. The transition m/z 281 → 281 was 
utilized to monitor 18:1 fatty acid anion, which is an important fragment in all 
phospholipids, distinct from LPAs. Furthermore, a post-column infusion experiment was 
performed to evaluate the ion suppression after the injection of the tissue sample. The 
infusion setup consisted of a syringe pump and a post-column T-piece as reported 
elsewhere (Bonfiglio et al. 1999). 
The linearity of the assay for each of the analytes was assessed by analyzing the 
calibration curves from six concentrations of calibration samples in triplicate covering the 
range of 361790 fmol of LPA injected into the column. The calibration curve included 
samples without analytes including IS (a blank sample) and excluding IS (a zero sample). 
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Unweighted linear regression analysis was used to make the calibration curve. Correlation 
coefficients were also calculated. The lower limit of quantification (LLOQ) was determined 
by calculating precision and accuracy for five LLOQ samples that were independent of the 
calibration curve. The intra-day precision of the assay was assessed by calculating the 
relative standard deviation (RSD) for the analysis of QC samples in five replicates, and 
inter-day precision was determined by the analysis of QC samples on three days. Accuracy 
was assessed by calculating the deviation of the measured value from the nominal value, 
which compared the calculated and known concentrations. BSA was used as a surrogate 
matrix to the above mentioned experiments (van de Merbel 2008) and samples were 
prepared according to previous sections. QC samples including LLOQ were prepared in the 
presence of BSA and intra-day precision and accuracy were calculated as described above. 
The recovery of the analytes using brain tissue homogenate where two concentrations of 
standards (0.2 and 0.4 μM) had been spiked was calculated with the following equation: 
Recovery (%) = 100×(SU)/C. In equation S represents the measured concentration of spiked 
sample, U represents the measured concentration of non-spiked sample and C represents 
the nominal concentration of the analyte. 
The stability of the analytes was studied in three replicates using brain tissue 
homogenate samples. The concentrations of the stability samples were compared to those 
of freshly prepared samples. The freeze and thaw stability was determined after three 
freeze–thaw cycles. The short-term temperature stability was investigated by keeping the 
samples for 4 h at room temperature before sample preparation. The long-term stability 
was evaluated by analyzing samples which had been stored up to two months at 80 °C. 
The stock solution stability was investigated by comparing freshly prepared standards to 
standards prepared from a stock which had been frozen for 30 days and kept at room 
temperature for 6 h after thawing. The post-preparative stability was assessed by keeping 
the samples in an autosampler at 10 °C for 24 h. 
 
6.3 RESULTS AND DISCUSSION 
6.3.1 Method development 
During the early method development, several extraction procedures and test tube 
materials were tested. When modifications of chloroform-based liquidliquid extraction 
methods described by Bligh and Dyer (1959) and extraction with 1-butanol (Georas et al. 
2007, Scherer et al. 2009, Xiao et al. 2001, Baker et al. 2001) were compared, the best 
extraction efficiency and precision were obtained using a modified Bligh and Dyer method 
(data not shown). The majority of lipophilic material from the tissue matrix is removed by a 
single liquidliquid extraction step to the chloroform phase while the LPAs stay in the 
water phase. During those experiments, we observed that LPA could be adsorbed easily 
onto the surface of test tubes, especially when plastic materials were used. The peak areas 
were approximately 35% lower when extractions were performed in polypropylene 
microcentrifuge tubes (Sarstedt, Nümbrecht, Germany) compared to Pyrex® borosilicate 
glass tubes (SciLabware, Stone, Staffordshire, UK). Therefore all the following experiments 
were performed using glassware. In addition, a significant improvement was found in the 
precision and accuracy, especially in the case of 18:0 LPA, by washing glass test tubes with 
hydrochloric acid (6 M) between the experiments.   
Several authors have used extraction procedures with strong acids to move the LPAs 
into the lower organic phase of the Bligh and Dyer extract (Yoon et al. 2003, Georas et al. 
2007, Shan et al. 2008, Tokumura et al. 2009). This makes sample preparation laborious with 
a two-step extraction followed by separation and manipulation of chloroform extract. 
Moreover, one serious concern about acidification is the artificial formation of LPA by acid-
catalyzed hydrolysis of more abundant lysophospholipids. In our hands, treatment of the 
sample with 0.6 M hydrochloric acid in the presence of 18:1 LPC increased the amount of 
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18:1 LPA during sample preparation significantly (data not shown). Overall, there were 
several reasons for deciding to analyze the water phase. First, sample preparation was 
straightforward and quick to perform. Second, without using any pH adjustment with acid, 
the artificial formation of LPA from LPC during the sample preparation could be avoided. 
Finally, the majority of LPC remained in the lower phase, being absent from analysis and 
MS ion source where the loss of choline from LPC has been reported (Zhao & Xu 2009). 
Though the majority of LPCs were washed out into the chloroform during sample 
preparation, about 10 % of LPC still remained in the water phase which makes us to 
conclude that a chromatography step has to be included in the method (data not shown). 
Glycerophosphocholines, such as LPC, are also reported to cause LC/MS/MS ion 
suppression during the analysis of biological samples (Little et al. 2006).  
Different reversed phase columns and mobile phases were tested in order to obtain the 
best peak symmetry, selectivity, and resolution between LPAs and other lipid classes such 
as LPCs. Strongly retentive high resolution sub-2 μm stationary phases containing C8 and 
C18 were initially tested resulting in narrow and symmetric peaks. Unfortunately, the 
peaks started to broaden considerably after only a few injections and the column 
performance deteriorated, probably due to irreversible attachment of LPAs to the stationary 
phase. Similar results were obtained with bridged ethylsiloxane/silica hybrid technology 
reversed phase C8 and C18 columns (XBridge, Waters, Ireland). In reversed phase columns, 
sample retention depends on three characteristics of the column: type and concentration of 
the bonded phase and column surface area. Very hydrophobic analytes, like LPAs, are 
strongly retained, and in some cases their elution from a strong column (e.g. narrow bore 
columns with small internal volumes) may not be possible, even with mobile phases 
containing high percentages of organic solvent. We achieved improved chromatographic 
performance with a C8 column with a larger particle size (3.5 μm) and pore size of 300 Å 
(Zorbax 300 SB-C8, Agilent Technologies, Palo Alto, CA, USA). In this case, the less strong 
wide pore column allowed the convenient elution of the sample without loss of column 
performance. However, retention times of LPAs and LPCs were overlapping with the 
mobile phase gradients in use. 
Initially, the mobile phase consisted of acetate buffer and acetonitrile:isopropanol (5:2, 
v/v). During method development, several types of gradients were tested, but resolution 
between LPAs and LPCs could never be achieved. We found a wide pore reversed phase 
column (300 Å) and methanol together with acetate buffer to sharpen chromatographic 
peaks and also give resolution between LPAs and LPCs. Different solvents are enriched on 
the surface of the bonded phase to different degrees. Among the commonly used reversed 
phase organic solvents, methanol is adsorbed less than acetonitrile, making the system less 
retentive, and more suitable for LPA analysis. To further improve the resolution between 
LPAs and LPCs, we tested ion pairing reagents such as triethylamine (TEA) and N,N-
dimethylhexylamine. Ion-pair chromatography provides an additional opportunity for 
achieving selectivity. Poor chromatographic peak symmetries were found with 10 mM TEA 
probably due to the simultaneous retention of LPAs by both reversed-phase and ion-pair 
processes. Instead, a high concentration (1%) of TEA was found to improve peak 
symmetries due to retention being determined by the ion-pairing properties, and it also 
increased the intensity of the MS signal. TEA has been reported to promote the formation of 
molecular ion and diminish the response of adduct ion (Schug & McNair 2002). In addition, 
it was further hypothesized that mobile phase additives with higher proton affinity would 
aid in formation of negative ions by extracting hydrogen ions in negative mode ESI (Schug 
& McNair 2002). A narrow bore column in favour of a wide pore reversed phase column 
was chosen to our final ion-pair chromatography method since this further improved 
column efficiency and selectivity, and therefore also improved resolution between LPAs 
and LPCs. 
It should be noted, however, that a high concentration of TEA may contaminate the 
instrument to some extent which could be seen especially in the subsequent measurements 
55 
 
 
in the positive ion mode (Hughes et al. 2007). Therefore careful cleaning of the instrument 
is needed after the measurements and the use of project-specific capillaries is highly 
recommended. After the measurements we cleaned the instrument carefully with mixture 
of water and acetonitrile supplemented with formic acid (1%). A mass spectrometer spray 
chamber was rinsed carefully with a mixture of isopropanol and water. In addition, after 
the project the HPLC instrument was cleaned with a 50:50 mixture of methanol and 
potassium phosphate buffer (100 mM, pH 5.0). We also cleaned the capillary with a mixture 
of isopropanol and water and replaced the electrospray nebulizer needle and the LC filter 
element (5 μm). By these cleaning procedures, the residual TEA (m/z 102) was almost 
completely removed from the instrument and there was no effect (e.g. reduced sensitivity) 
of following measurements in the positive ion mode. 
Mass spectrometric detection was performed using a highly selective MRM technique in 
the negative ion mode. Using full-scan MS experiments, the deprotonated molecular ions 
[M – H]- for 16:0 LPA, 18:0 LPA, 18:1 LPA, 20:4 LPA and IS (17:0 LPA) were found to be m/z 
409, m/z 437, m/z 435, m/z 457, and m/z 423, respectively. A specific and sensitive assay was 
developed by monitoring transitions to the most intensive product ions. The following 
transitions were used: m/z 409 → 153 for 16:0 LPA, m/z 437 → 153 for 18:0 LPA, m/z 435 → 
153 for 18:1 LPA, m/z 457 → 153 for 20:4 LPA, and m/z 423 → 153 for 17:0 LPA (Figure 16), 
where an ion at m/z 153 is formed by loss of water from the ion at m/z 171.  
 
6.3.2 Selectivity 
In order to determine the selectivity of the method, the standards and tissue samples 
prepared with the sample preparation method were analyzed (Figure 17). The solvents did 
not contribute any interfering peaks or background in any of the standard chromatograms. 
However, in the chromatograms of tissue samples, additional peaks were observed with 
the same parent-to-daughter ion transitions as the LPA species (Figure 17), which has 
previously been reported by Shan et al. (2008). These peaks are likely due to loss of choline 
from the LPC molecule in the MS ion source (Zhao & Xu 2009).  
When two concentrations of standards (0.2 and 0.4 μM) were added into the brain tissue 
homogenate and the slopes of the regression curves were compared to those prepared 
without tissue matrix, the slopes were found to be statistically equal for other LPA species, 
except for 18:0 LPA (Figure 18). This was taken as evidence of the absence of significant 
matrix effect or interference induced by the brain matrix. In the case of 18:0 LPA, 
absorption of the analyte on the surface of the test tube may explain the results to some 
extent. When tissue samples were diluted 1:2, 1:5 or 1:10 with methanol before injecting into 
LC/MS/MS, the concentrations of diluted samples were found to be constant due to 
simultaneous dilution of internal standard. This further ensures our observation that there 
is no matrix effect or interference, which could cause systematic error to the results (data 
not shown). Furthermore, no significant ion suppression at the retention time of analytes 
was found in a post-column infusion study where remarkable ion suppression occurred at 
a retention time of 0.5 min but this was normalized by the retention time of 3.0 min (data 
not shown). In-source fragmentation of 18:1 LPC gave transition of m/z 281 → 281 (Figure 
16) which was used to optimize the resolution between LPA and other species like ion 
suppression-causing glycerophosphocholines (Little et al. 2006). 
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Figure 16. Product ion mass spectra and molecular structures with proposed fragmentation of 
(A) 16:0 LPA (m/z 409 →100–1000), (B) 18:0 LPA (m/z 437 →100–1000), (C) 18:1 LPA (m/z 
435 →100–1000), (D) 20:4 LPA (m/z 457 →100–1000), (E) 17:0 LPA (m/z 423 →100–1000), 
and (F) 18:1 LPC (m/z 281 →100–1000). One microliter of standard solution in methanol (1:10 
dilution from stock solutions, ~20 μM) was injected directly into the LC/MS/MS using an 
isocratic mobile phase consisting of 30% of 1% TEA in 50 μM ammonium acetate and 70% of 
1% TEA in 90% methanol delivered at 0.3 ml/min. 
 
 
6.3.3 Linearity, precision, accuracy, and recovery  
The six point calibration curves were highly linear over the range of 361790 fmol of LPA 
injected into column. The calibration curve parameters with standard errors and regression 
coefficients are summarized in Table 8. The LLOQ with acceptable accuracy (± 10%) and 
precision (≤ 15% RSD) was 54 fmol of LPA injected into the column. Previously, the 
detection limits for LPA species achieved with LC/MS/MS analysis have been in the range 
of 0.010.03 μM (200600 fmol/injection) (Meleh et al. 2007) whereas with flow injection, a 
detection limit as low as of 0.31.0 nM (620 fmol/injection) (Yoon et al. 2003) has been 
reported. However, only Shan et al. (2008) have reported a quantification limit for 
LC/MS/MS method (160500 fmol/injection). With the radioenzymatic assay, a detection 
limit of 200 fmol has been reported (Saulnier-Blache et al. 2000).  
The precision and accuracy of all QC samples were within the acceptable range (Table 9). 
The method was accurate and precise between runs and within individual runs at each QC 
level for all the LPAs. The method was accurate and precise at all studied levels also when 
(A)
(B)
(C)
(D)
(E)
(F)
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QC samples were determined in the presence of the surrogate sample matrix [4% (w/v) 
BSA, m/V]. No statistically significant differences (one-way ANOVA with Tukey’s multiple 
comparison post hoc test with p<0.05 considered as statistically significant) were found 
between results of QC samples with or without surrogate matrix at any concentration level 
(data not shown). The recoveries for 16:0 LPA, 18:0 LPA, 18:1 LPA and 20:4 LPA were 
found to be 104%, 69%, 92%, and 86%, respectively.   
 
 
 
 
Table 8. The linear range, calibration curve parameters with standard errors and regression 
coefficients of 16:0 LPA, 18:0 LPA, 18:1 LPA and 20:4 LPA (n=3). Unweighted linear regression 
analysis was used to make the calibration curve. LLOQ was determined by calculating precision 
and accuracy for five LLOQ samples that were independent of the calibration curve.  
 
Compound Linear range 
(fmol) 
Regression parameters 
Slope ± S.T.D error      Intercept ± S.T.D error   
R2 LLOQ (fmol) 
16:0 LPA 36-1790 1.0007 ± 0.0131 -0.0002 ± 0.0210 0.999 54 
18:0 LPA 36-1790 0.6322 ± 0.0110 0.0117 ± 0.0156 0.999 54 
18:1 LPA 36-1790 0.7878 ± 0.0158 -0.0177 ± 0.0253 0.999 54 
20:4 LPA 36-1790 0.7355 ± 0.0171 -0.0151 ± 0.0273 0.998 54 
 
 
 
Table 9. Within-run and between-day precision and accuracy for 16:0 LPA, 18:0 LPA, 18:1 LPA, 
and 20:4 LPA and their nominal values at each QC level.  
 
Compound Nominal 
conc. (μM) 
Intra-day precision and accuracy Inter-day precision 
Mean  
(n = 5) (μM) 
RSD (%) Mean accuracy 
(%) 
Mean (n = 3 
days)  (μM) 
RSD (%) 
16:0 LPA 0.03 0.03 5.0 92 0.03 22 
 0.1 0.1 3.6 85 0.1 11 
 0.3 0.3 2.3 90 0.3 5.4 
 0.8 0.8 1.6 94 0.8 5.2 
       
18:0 LPA 0.03 0.03 14 104 0.03 33 
 0.1 0.1 2.8 103 0.1 10 
 0.3 0.3 2.4 114 0.3 12 
 0.8 1.0 1.2 120 0.9 9.4 
       
18:1 LPA 0.03 0.03 6.5 108 0.03 17 
 0.1 0.1 4.0 89 0.1 12 
 0.3 0.3 3.0 89 0.3 9.1 
 0.8 0.7 1.2 92 0.8 6.9 
       
20:4 LPA 0.03 0.03 4.5 100 0.03 17 
 0.1 0.1 2.1 83 0.1 11 
 0.3 0.3 3.5 85 0.3 11 
 0.8 0.7 1.3 85 0.8 11 
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Figure 17. Representative MRM chromatograms of (A) standard sample of 16:0 LPA (0.1 μM, 
retention time (RT) 5.23 min), (B) 18:0 LPA (0.1 μM, RT 5.74 min), (C) 18:1 LPA (0.1 μM, RT 
5.38 min), (D) 20:4 LPA (0.1 μM, RT 5.08 min), and (E) internal standard (IS) 17:0 LPA (0.3 
μM RT 5.50 min). Endogenous LPA content was measured from a rat brain homogenate and 
brain cryosections. Representative MRM chromatograms of a rat brain homogenate of (G) 16:0 
LPA (0.17 μM), (H) 18:0 LPA (0.20 μM), (I) 18:1 LPA (0.11 μM), (J) 20:4 LPA (0.04 μM), and 
(K) IS (0.3 μM). Representative MRM chromatograms of a rat brain cryosections of (M) 16:0 
LPA (0.17 μM), (N) 18:0 LPA (0.19 μM), (O) 18:1 LPA (0.16 μM), (P) 20:4 LPA (0.08 μM), and 
(Q) IS (0.3 μM). Additional peaks on MRM channels of LPAs in brain homogenate and 
cryosections were due to artificial formation of LPAs from LPCs in MS ionization chamber (Zhao 
& Xu 2009). The transition m/z 281 → 281 monitored 18:1 fatty acid anion and it was used to 
optimize the resolution between LPA and ion suppression causing lipids (Little et al. 2006). 
Representative MRM chromatograms of (F) 18:1 LPC standard (8 μM, RT 6.75 min and 8.35 
min), (L) tissue homogenate, and (R) tissue section. In the chromatograms, the individual LPAs 
are indicated with the arrow.       
Standard Tissue
16:0 LPA
m/z 409153
18:0 LPA
m/z 437153
18:1 LPA
m/z 435153
20:4 LPA
m/z 457153
(A)
(B)
(C)
(D)
17:0 LPA
m/z 423153
(E)
18:1 LPC
m/z 281281
(F)
 homogenate sample Tissue section sample
(G)
(H)
(I)
(J)
(M)
(N)
(O)
(P)
(K) (Q)
(L) (R)
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Figure 18. The matrix effect was studied with the standard addition method. Two concentrations 
of standards (0.2 and 0.4 μM) were spiked into the brain tissue homogenate to obtain a 
regression curve (triangles). Standard curve using the same concentrations was prepared 
without tissue matrix (squares). The standard addition method shows no matrix effect on 16:0 
LPA (A), 18:1 LPA (C), and 20:4 LPA (D). Statistically significant difference was found between 
slopes of homogenate and reference standards of 18:0 LPA (B). This matrix effect is probably 
due to the adsorption of the analyte on the surface of the test tube. The statistical equality of 
the slopes (p<0.05 considered as statistically significant difference) was determined using 
analysis of covariance (ANCOVA) (mean ± SD, n=3).    
 
6.3.4 Stability 
There was no significant degradation of LPAs after three freezethaw cycles (24 h interval 
between the cycles) in comparison with freshly prepared samples (10 to +17% for other 
LPAs and +37 % for 18:0 LPA). The short-term temperature stability showed no 
degradation of LPAs but, instead, increased levels of LPAs 24101% after 4 h storage at +20 
°C. The increasing amount of LPAs after storage at +20 °C has been previously described 
(Scherer et al. 2009). LPAs may have been formed enzymatically in the brain tissue when 
stored at +20 °C before the enzymatic machinery is switched off by addition of methanol 
and chloroform into the sample. The LPA concentrations in 30 and 60 days of long-term 
stability samples were within the range of 17 to +10% for other LPAs but up to 42% for 
18:0 LPA. The overall divergent results of 18:0 LPA are likely to be due to adsorption of the 
analyte onto the surface of test tubes. The stock solutions of LPAs in methanol were stable 
for 30 days when stored at 20 °C and kept at room temperature for 6 h after thawing. Post-
preparative stability samples were found to be stable when they were stored for 24 h at 10 
°C in the autosampler.  
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6.3.5 Application 
In preliminary experiments with rat brain cryosections, the following endogenous LPA 
levels were found: 3.2 ± 0.4 for 16:0 LPA, 5.8 ± 1.8 for 18:0 LPA, 2.6 ± 0.6 for 18:1 LPA, and 
1.2 ± 0.4 for 20:4 LPA (nmol/g protein in tissue, mean ± SD of three replicate samples from 
two individual animals, n=6). According to GC analysis (Nakane et al. 2002), the four LPA 
species followed in our LC/MS/MS method account for 93% of LPA species in rat brain. 
Previously, in the GC analysis 18:1 LPA was found to be the predominant LPA species in 
rat brain homogenate (Nakane et al. 2002). Based on our findings, 18:0 LPA seems to 
predominate; this may be due to differences in the method and the age of the rats used (we 
used young 4-week-old rats). In preliminary experiments, the concentrations of LPA 
species were above the LLOQ of the method and all the measured concentrations were 
within the range of the method.  
 
6.4 CONCLUSIONS 
 
A highly selective and sensitive method using LC/MS/MS was developed for the 
determination of LPA species in rat brain cryosections. As far as we are aware, this is the 
first report where the LPA content of brain tissue has been measured using LC/MS/MS. 
From the analytical point of view, LPAs are a demanding group of compounds since, for 
example, artificial formation of LPA from LPCs has been demonstrated during sample 
preparation and within the instrumentation. To prevent the artificial formation of LPA, we 
used a single step extraction procedure without any strong acid treatment to remove 
lipophilic material from the water phase, which was then analyzed. This sample pre-
treatment also removed most of the lipids causing the matrix effect and the method was 
found to be highly selective. Since residual LPC remained in the water phase after sample 
preparation, additional peaks were observed at the same parent-to-daughter ion transitions 
as the LPA species. Therefore, we developed a chromatographic method based on a narrow 
bore reversed phase column and ion-pair technique to optimize the efficiency of the column 
and to achieve resolution between LPAs and LPCs. Mass spectrometric detection was 
performed using a highly selective MRM technique in the negative ion mode. The method 
was validated and acceptable accuracy, precision, recovery, and stability were obtained for 
concentrations within the range of the calibration curve for all of the studied LPAs. 
According to the validation results and data from the preliminary study, we conclude that 
the LC/MS/MS method described in this paper is applicable for the targeted quantitative 
analysis of LPA species in rat brain sections.  
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7 Identification of Enzymatic Pathways Degrading LPA 
in Brain Sections3  
 
 
Abstract: The lifetime of the signalling pool of LPA is controlled by the equilibrium 
between synthesizing and degrading enzymatic activity. In the current study, we have 
characterized these enzymatic pathways in rat brain by pharmacologically manipulating 
the enzymatic machinery required for LPA synthesis and degradation. In rat brain 
cryosections, the lifetime of bioactive LPA was found to be controlled by Mg2+-independent, 
NEM-insensitive phosphatase activity, attributed to LPPs. Pharmacological inhibition of 
this LPP activity amplified LPA1 receptor signalling, as revealed using functional 
autoradiography. Although two LPP inhibitors, sodium orthovanadate and propranolol, 
locally amplified receptor responses, they did not affect global brain LPA phosphatase 
activity (also attributed to Mg2+-independent, NEM-insensitive phosphatases), as confirmed 
by Pi determination and by LC/MS/MS. Interestingly, the phosphate analog, aluminium 
fluoride (AlFx) not only irreversibly inhibited LPP activity thereby potentiating LPA1 
receptor responses, but also totally prevented LPA degradation, however this latter effect 
was not essential in order to observe AlFx-dependent potentiation of receptor signalling. 
We conclude that vanadate- and propranolol-sensitive LPP activity locally guards the 
signalling pool of LPA whereas the majority of brain LPA phosphatase activity is attributed 
to LPP-like enzymatic activity which, like LPP activity, is sensitive to AlFx but resistant to 
the LPP inhibitors, vanadate and propranolol. 
 
 
 
 
 
 
 
 
 
 
                                                 
3 Adapted from Aaltonen N, Lehtonen M, Varonen K, Arrufat Goterris G, Laitinen JT. Lipid phosphate phosphatase 
inhibitors locally amplify lysophosphatidic acid LPA1 receptor signalling in rat brain cryosections without affecting 
global LPA degradation. BMC Pharmacology 12:7, 2012.  
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7.1 INTRODUCTION 
 
 
Previous studies have demonstrated that brain sections retain the capacity to generate 
endogenous GPCR agonists, such as adenosine and LPA, during autoradiography 
incubations, resulting in tonic adenosine A1 and LPA receptor activity in anatomically 
defined brain regions (Chapter 5, Laitinen 1999, Palomaki & Laitinen 2006). The LPA-
evoked [35S]GTPγS binding response in rat brain sections reflects LPA1 receptor activity, as 
it is sensitive to the LPA1/3-selective antagonist Ki16425 and is restricted to the developing 
white matter tracts (Chapter 5, Waeber & Chiu 1999, Laitinen 2004). This labelling pattern 
faithfully mirrors the known expression pattern of LPA1 receptors in the developing rat 
brain (Allard et al. 1998, Weiner et al. 1998, Handford et al. 2001, Cervera et al. 2002). 
It was recently demonstrated that a comprehensive elimination of the enzymatic 
hydrolysis of the endocannabinoid 2-AG in brain sections leads to 2-AG accumulation and 
subsequent cannabinoid CB1 receptor activation, as successfully revealed using functional 
autoradiography (Palomaki et al. 2007). Using this approach, we have characterized the 
enzymatic pathways and their role in tonic LPA1 receptor activity by pharmacologically 
manipulating the enzymatic machinery required for LPA degradation. The two degradative 
pathways generating inorganic phosphate (Pi) as a result of LPA degradation are depicted 
in Figure 19.   
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Figure 19. The two enzymatic pathways generating inorganic phosphate (Pi) as a result of LPA 
degradation. Abbreviations: G, glycerol; GP, glycerol phosphate; LPA, lysophosphatidic acid; 
LPL, lysophospholipase; LPP, lipid phosphate phosphatase; MAG, monoacylglycerol; MAGL, 
monoacylglycerol lipase.  
 
7.2 MATERIALS AND METHODS 
 
The materials and general methods are described in Chapter 4. 
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7.2.1 Determination of Pi and glycerol 
To estimate LPA-degrading phosphatase activity under the assay conditions mimicking 
functional autoradiography, triplicate slides with two or three horizontal brain sections 
underwent an autoradiography-mimicking protocol (except that DPCPX, GDP and the 
radioligand were omitted). The experiments with Na3VO4, propranolol, and nadolol (as a 
negative control for propranolol) were performed with and without NEM pretreatment. 
The protocol consisted of a 10 min pre-incubation in the assay buffer, a 30 min incubation in 
the assay buffer with or without 5 mM NEM, then a washing step with assay buffer, and 
finally a 90 min incubation in the presence of chemicals of interest as well as 0.1% BSA and 
1 mM DTT. In NEM-treated sections, Mg2+ was omitted from the assay buffer. In 
experiments with NaF and AlFx, the protocol consisted of two sequential 40 min 
incubations (steps 1 and 2) and finally a 90 min incubation (step 3) in the presence of the 
chemicals of interest as well as 0.1% BSA and 1 mM DTT. The LPA species used was 18:1 
LPA. In all experiments, after the final 90 min incubation step, the postincubation buffer 
was collected quantitatively and the Pi content was determined in duplicate using the 
Fiske-Subbarow method, as described in Esmann (1988) after TCA-precipitation of BSA 
which interferes with method. Absorbances (λ = 700 nm) were read with a Tecan 
Spectrafluor microplate reader. 
To clarify the enzymatic routes responsible for LPA degradation in our experimental 
setting, Pi formation was determined using enzyme-coupling fluorescent method (Vazquez 
et al. 2003). The glycerol content was determined using a coupled enzyme reaction (Free 
Glycerol Reagent, Sigma, Cat.# F6428) with the exception that H2O2 production was 
coupled to peroxidase-dependent formation of the fluorescent dye resorufin (Navia-
Paldanius et al. 2012). Briefly, rat cerebellar membranes (1 μg/well on a 96-well plate), 
prepared as described in Saario et al. (2004), were pretreated with the serine hydrolase 
inhibitors MAFP (1 μM) or JZL184 (100 μM) for 30 min and then incubated with or without 
18:1 LPA, GP, or (2S)-OMPT (10 μM final concentration). The fluorescence (λex = 530 nm, λem 
= 590 nm) was monitored kinetically for 90 min at 10 min intervals using Tecan Infinite 
M200 fluorometer. 
 
7.3 RESULTS AND DISCUSSION 
7.3.1 Tonic LPA1 receptor activity under basal conditions of [35S]GTPγS autoradiography 
is not due to PLD or autotaxin activity  
Our previous study suggested that tonic LPA1 receptor activity in rat brain sections might 
be due to LPA generated via PLD activity, based on the sensitivity of this response to 1-
butanol (Palomäki & Laitinen 2006). However, 1-butanol is known to have several cellular 
off-targets and it is an inefficient PLD inhibitor, and therefore butanol-sensitivity alone is 
invalid as a proof for PLD involvement in a given cellular process or vice versa. Therefore, 
as the initial step of the present studies, we explored in more detail the possible enzymatic 
pathways that could generate LPA under the assay conditions employed.  
We first used various approaches to address the role of PLD, but in addition to the 1-
butanol-sensitivity of this response, found no additional evidence for the involvement of 
the PC-PLD  PA-PLA1/2 LPA pathway as a source of tonic LPA1 signalling. A summary 
of these studies is presented in Figure 20. Briefly, we found that exogenous addition of the 
PLD substrate PC or the LPA precursor PA failed to boost LPA1 receptor signalling. 
Similarly, the PLD activators oleate and PIP2 did not enhance LPA1 receptor activity, and 
the PIP2-depletor, neomycin, failed to reduce activity. Although 1-butanol has been 
previously demonstrated not to affect LPA1 receptor signalling in response to exogenous 
LPA (Palomäki & Laitinen 2006), we found here that 1-butanol readily blunted the 
responses to sub-threshold concentrations of LPA. Finally, the selective PLD inhibitor, 
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compound 4k (Monovich et al. 2007, Su et al. 2009), did not reduce tonic LPA1 receptor 
activity.  
We next examined whether tonic LPA1 activity in brain sections is due to LPA formed as 
a result of ATX activity. However, we found that exogenously added ATX substrate LPC 
did not boost tonic LPA1 receptor activity (Figure 20). In addition, LPA could theoretically 
be generated either from glycerophosphate or from MAG in reactions catalyzed by 
glycerophosphate acyl transferase or monoacylglycerol kinase, respectively. In brain 
sections, however, catabolic rather than de novo synthesizing pathways are likely to be 
dominating. In previous experiments, neither exogenous 2-AG, (partially converted to 1(3)-
AG during the incubations) nor inhibitors of 2-AG degradation were able to induce 
[35S]GTPγS binding in the LPA1 receptor-enriched white matter areas of rat brain sections 
(Palomaki et al. 2007), suggesting that monoacylglycerol kinase was not involved. Neither 
exogenous glycerol-3-phosphate was able to induce LPA1 receptor mediated [35S]GTPγS 
binding, providing no evidence of involvement of glycerophosphate acyl transferase (data 
not shown). Collectively, these studies indicate that with compounds used, we could not 
affect LPA-generating pathways in brain sections. We next explored if the tonic LPA1 
receptor activity could be boosted by inhibitors of LPA degradation. 
 
7.3.2 The LPP inhibitors Na3VO4 and propranolol locally amplify LPA1 receptor 
signalling without affecting global LPA degradation  
The LPP-mediated degradation of LPA is susceptible to the phosphatase inhibitor sodium 
orthovanadate (Na3VO4) (Simon et al. 2002) and to propranolol (Roberts et al. 1998, Simon 
et al. 2002), better known as a classical β-adrenoceptor blocking agent. Another β-blocker, 
nadolol, has no demonstrable LPP inhibiting capacity (Simon et al. 2002) and therefore can 
serve as a useful control compound. We tested the effects of these compounds on basal 
LPA1 receptor signalling. Treatment of brain sections with propranolol (1 mM) or Na3VO4 
(100 μM) resulted in stimulated [35S]GTPγS binding responses that were restricted to the 
white matter areas of 4 week-old rat brain (Figure 21a). The observed labelling pattern was 
fully reproduced by the addition of exogenous LPA (50 μM) and all the evoked responses, 
including the tonic LPA1 receptor activity observed under basal conditions, were abolished 
by treatment with the LPA1/3 receptor selective antagonist Ki16425 (5 μM) (Figures 21a and 
b). As expected, treatment with nadolol (1 mM) had no effect on basal LPA1 receptor 
signalling (Figure 21c). Both Na3VO4 and propranolol, but not nadolol, amplified the LPA-
evoked (0.5 μM to 50 μM) binding responses (Figure 21c). Since propranolol and vanadate 
amplified LPA1 receptor signalling only when present in the [35S]GTPγS labelling step, 
these drugs presumably inhibit LPPs in a reversible manner. 
To rule out the direct agonism of propranolol and vanadate at the LPA1 receptor, we 
performed classical filtration-based [35S]GTPγS binding assay and found that neither 
compound was able to stimulate [35S]GTPγS binding to the rat cerebellar membranes, 
whereas exogenous LPA evoked a dose-dependent response (data not shown). We 
additionally observed that the LPA3 receptor-preferring agonist (2S)-OMPT (0.5 μM to 50 
μM) induced only a weak response in the brain of a 4-week old rat when compared to 
signal achieved with exogenous LPA (10 μM) (data not shown). This lends further support 
to the argument that observed LPA-evoked signalling is reflecting the activity of the 
myelin-enriched LPA1 receptors instead of LPA3 receptors that are expressed to a lesser 
degree in the brain (Choi et al. 2010).      
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Figure 20. Evidence indicating that tonic LPA1 receptor activity under basal conditions of 
[35S]GTPγS autoradiography is not due to PLD or autotaxin activity. Inclusion of the LPA 
precursors phosphatidic acid (PA) (present in step 3) (a), or phosphatidylcholine (PC) in step 3 
(b) does not boost tonic LPA1 receptor activity. The PLD activators oleate (step 3) (c), and PIP2 
(step 3) (d) do not enhance tonic LPA1 receptor activity, and the PIP2-depletor neomycin 
(present in steps 2 and 3) (e) does not reduce it. The selective PLD inhibitor, compound 4k 
(c4k) (steps 13), does not reduce tonic LPA1 receptor activity (f). The non-specific PLD 
inhibitor 1-butanol (step 3) blunts the response evoked by exogenous LPA while the control 
compound tert-butanol does not have any effect (step 3) (g). Incubation of brain sections with 
the autotaxin substrate LPC (step 1 or 3) does not affect tonic LPA1 receptor activity (h) (cc, 
corpus callosum). Scale bars = 5 mm.  
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Figure 21. Vanadate and propranolol evoke LPA-mimicking [35S]GTPγS binding response that is 
sensitive to LPA1/3 receptor antagonist. (a) Test chemicals were included during the [35S]GTPγS 
labelling step (step 3). Treatment with propranolol or Na3VO4 results in G protein activity in the 
LPA1 receptor enriched white matter tracts, a response that is mimicked by exogenous LPA. The 
LPA1/3 receptor antagonist Ki16425 abolishes all the evoked responses in the white matter 
regions, including the tonic LPA1 signal observed under basal conditions (cc, corpus callosum). 
Scale bar = 2 mm. The eight-point [14C] standard used in the quantification is shown at the 
bottom of the image. (b) and (c) Quantitative data of the binding responses including the dose 
response for exogenous LPA with or without the simultaneous treatment with the inhibitors. 
Autoradiography films were digitized and [35S]GTPγS binding was quantified from the corpus 
callosum of coronal rat brain sections. Significance level: (b) ***p < 0.001 compared to the 
treatment without Ki16425 (c) ***p < 0.001 compared to control in each LPA concentration 
(n=6).  
 
 
The LPPs catalyze the hydrolysis of the phosphate group of their lipid substrates 
resulting in the generation of Pi. The measurement of the released Pi offers a 
straightforward way to monitor LPP activity (McDermott et al. 2006). Studies with LPA (50 
μM) indicated that LPP-like phosphatase activity accounted for the majority of LPA 
degradation, as  93% of the LPA-derived Pi was formed as a result of Mg2+-independent, 
NEM-resistant phosphatase activity (Figure 22). In the routine assay buffer containing Mg2+, 
46 ± 1 % (mean ± SEM, n=3) of exogenous LPA (50 μM, corresponding to 47.5 nmol 
potentially available Pi per slide) was degraded during the 90 min incubation whereas in 
the Mg2+-free assay buffer supplemented with NEM (5 mM), the respective figure was 44 ± 
3 %. However, neither the LPP inhibitors Na3VO4 (100 μM), propranolol (1 mM), nor 
nadolol (1 mM) affected total LPA phosphatase activity in a statistically significant manner, 
assessed at the bulk level of brain sections (Figure 22). In line with this, when the LPA 
content of brain sections treated with Na3VO4 or propranolol was analyzed using 
LC/MS/MS, there was no significant accumulation of LPA when compared to control 
sections that were incubated in the absence of these inhibitors (data not shown). In brain 
sections, LPP activity appears to locally control the lifetime of the signalling pool of LPA, 
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and LPPs must therefore reside in close proximity to the LPA1 receptors, as propranolol and 
vanadate had no effect on LPA degradation when assessed at the bulk brain level. 
 
 
 
Figure 22. Brain tissue dephosphorylates LPA through LPP-like phosphatases that are resistant 
to propranolol and Na3VO4. Slides with three horizontal rat brain sections underwent the 
autoradiography-mimicking incubation protocol, (a), or were pretreated with NEM (5 mM) 
followed by the autoradiography-mimicking protocol with the exception that Mg2+ was omitted 
from the incubation buffer (b). Following a 90 min incubation in the presence of 0.1% BSA 
together with the indicated combinations and concentrations of the compounds, the assay 
buffer was quantitatively collected and the Pi content was determined. Note that the bulk of LPA 
degradation is due to NEM-resistant and Mg2+-independent phosphatase activity (compare a and 
b) and that Na3VO4, propranolol or nadolol do not affect basal or LPA-derived Pi generation in a 
statistically significant manner. Significance level: Each bar indicated with ¤ shows a significant 
difference (p < 0.001) to the corresponding bar indicated with # while there is no significant 
difference between the bars marked with the same symbol (n=3). 
 
7.3.3 Aluminium fluoride amplifies LPA1 receptor signalling and totally prevents LPA 
degradation  
We undertook a search for additional inhibitors in an attempt to identify compounds that 
could comprehensively target the global pool of LPA phosphatases in brain sections. 
Sodium fluoride (NaF) is commonly used as a phosphatase inhibitor and aluminium 
fluoride (AlFx) acts as a transition stage phosphate analog also capable of inhibiting several 
phosphatases (Li 2003). AlFx forms spontaneously in aqueous solutions in the presence of 
Al3+ and Fl ions. We pretreated brain sections with NaF or AlFx in order to test whether 
these compounds could affect LPA receptor activity and/or LPA degradation. Interestingly, 
when sections were pretreated with AlFx (AlCl3 50 μM + NaF 10 mM), a stimulated 
[35S]GTPγS binding response throughout the LPA1 receptor-enriched white matter regions 
was evident (Figures 23a and b). This labelling pattern was fully mimicked by addition of 
exogenous LPA (0.5 μM to 50 μM) (Figures 23a and b), and was blocked by Ki16425 (5 μM) 
(Figures 23a and c). Similarly, pretreatment of brain sections with NaF (10 mM) resulted in 
stimulated [35S]GTPγS binding responses throughout the white matter regions (Figure 23a). 
Pretreatment with these compounds was sufficient to evoke LPA1 receptor signalling, 
suggesting that, in contrast to the reversibly acting inhibitors Na3VO4 and propranolol (that 
needed to be present during the [35S]GTPγS labelling step), AlFx and NaF inhibited LPP 
activity in an irreversible manner. AlFx is known to mimic the chemical structure of Pi and 
therefore affects the activity of several phosphoryl transfer enzymes (Li 2003). As a 
phosphate analog, AlFx might bind to the Pi-recognizing binding pocket of the LPPs and 
by this mechanism lead to irreversible inhibition. 
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Figure 23. AlFx
 and NaF evoke LPA-mimicking [35S]GTPγS binding response that is sensitive to 
LPA1/3 receptor antagonist. (a) AlFx
 (NaF 10 mM + AlCl3 50 μM) was included during the 40 min 
preincubation step (step 1), NaF was included in step 2, and LPA in step 3, whereas Ki16425 
was present throughout all steps. Treatment with AlFx
 and NaF results in region-specific G 
protein activity that is restricted to the LPA1 receptor-enriched white matter tracts, a response 
that is mimicked by exogenous LPA and that is sensitive to Ki16425 (cc, corpus callosum; fi, 
fimbria of the hippocampus). Scale bar = 5 mm. (b) and (c) Quantitative data of the binding 
responses. Autoradiography films were digitized and [35S]GTPγS binding was quantified from 
corpus callosum of the coronal rat brain sections. Significance level: (b) ***p < 0.001 
compared to control in each LPA concentration (c) ***p < 0.001 compared to the treatment 
without Ki16425 (n=6).  
 
 
We wished to explore in more detail the mode of inhibition of these compounds, as well as 
the behaviour of NaF in our experimental setting. This was justified by the fact that 
aluminium is a common constituent of glassware and F can etch it from the glass. 
Deforoxamine mesylate (DFOM) is an aluminium and iron(III) chelator that can be used in 
experimental settings to reveal if aluminium is present in the system. When brain sections 
were treated with DFOM (50 μM), the responses to AlFx and NaF (10 mM) in functional 
autoradiography were totally abolished (Figure 23a). It is noteworthy that DFOM needed to 
be added together with AlFx or NaF in order to achieve this reversal; if added after 
pretreatment with AlFx or NaF, DFOM was ineffective (data not shown). These studies 
indicate that AlFx acts as an irreversible inhibitor of brain LPP activity thereby amplifying 
tonic LPA1 receptor activity. The general phosphatase inhibitor, NaF per se, did not inhibit 
LPPs, but mimicked the action of AlFx based on the ability of F to etch Al3+ from the glass 
slides.   
We were curious to examine whether AlFx could also inhibit LPA degradation at the 
bulk brain level. When sections were pretreated with AlFx but then omitted from all 
subsequent steps, AlFx readily facilitated LPA1 receptor signalling (Figure 23, Figure 24a), 
but such a pretreatment did not inhibit LPA degradation in a statistically significant 
manner. Degradation of exogenous LPA (50 μM) alone yielded 22.6 ± 1.2 nmol Pi per slide 
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whereas pretreatment with AlFx followed by incubation with exogenous LPA yielded 21.4 
± 0.4 nmol Pi per slide (mean ± SEM, n=3). However, when added together with LPA, AlFx 
totally (and NaF partially) blocked the formation of LPA-derived Pi, thus providing 
evidence of the ability of these compounds to inhibit the vanadate- and propranolol-
insensitive pool of LPA phosphatases in a reversible manner (Figure 24b). Treatment with 
DFOM (50 μM) totally prevented the ability of AlFx and NaF to inhibit the degradation of 
LPA (Figure 24b), indicating that AlFx-, rather than NaF, was the active compound. 
 
 
 
 
 
Figure 24. AlFx
 (not NaF) generates the LPA1 receptor-mediated response; AlFx
 also blocks the 
LPA phosphatase activity. (a) AlFx
 (NaF 10 mM + AlCl3 50 μM) was included during the 40 min 
pre-incubation step (step 1), NaF was present in step 2 whereas deferoxamine mesylate 
(DFOM) was present throughout steps 13 and in addition during a 10 min pre-incubation prior 
to AlFx
 treatment. Both NaF and AlFx
 induce [35S]GTPγS binding in the LPA1 receptor-enriched 
white matter areas. The responses to AlFx
 and NaF are totally abolished with the aluminium 
and iron(III) chelator DFOM (cc, corpus callosum; fi, fimbria of the hippocampus). Scale bar = 5 
mm. (b) Slides with two horizontal brain sections underwent the three-step autoradiography-
mimicking protocol. AlFx
 (NaF 10 mM + AlCl3 50 μM) and NaF were present during the 90 min 
incubation step (step 3). DFOM was present in steps 2 and 3. After the final incubation step, the 
assay buffer was quantitatively collected and the Pi content was determined. Note that NaF 
partially and AlFx
 totally inhibit LPA-derived Pi formation and that DFOM reverses these actions. 
Significance level: ***p < 0.001 and **p < 0.01 compared to the treatment with LPA alone 
(n=3). 
 
 
To further explore the consequences of total inhibition of LPA phosphatase activity, AlFx-
treated brain sections were incubated for 40 min in autoradiography buffer, the buffer was 
removed and tissue LPA content extracted using chloroform-methanol, followed by 
LC/MS/MS analysis. Four LPA species with different acyl substitutions (16:0 LPA, 18:1 
LPA, 18:0 LPA and 20:4 LPA) were examined in the present study. The relative abundances 
of the four LPA species in brain sections incubated under control conditions were 20:4 LPA 
 16:0 LPA < 18:1 LPA < 18:0 LPA. The amounts of three of these species (16:0 LPA, 18:1 
LPA and 20:4 LPA) were significantly increased after AlFx treatment when compared to 
control sections (Figure 25). These experiments indicate that total blockade of LPA 
phosphatase activity with AlFx treatment resulted in accumulation of several endogenous 
LPA species at the bulk brain level. However, no such bulk LPA accumulation was 
required to observe the AlFx-evoked potentiation of LPA1 receptor signalling. 
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Figure 25. Treatment with AlFx
 results in accumulation of several endogenous LPA species in rat 
brain sections. The slides with two horizontal brain sections were treated with AlFx
 (NaF 10 mM 
+ AlCl3 50 μM) for 40 min followed by extraction of LPA species. The samples were analyzed 
with LC/MS/MS for four endogenous LPA species. The amounts of three of these LPA species are 
increased in a statistically significant manner in AlFx
-treated sections as compared to control 
sections. Significance level: ***p < 0.001 and **p < 0.01 compared to control (t test, n=3). 
    
 
7.3.4 The LPA → MAG → glycerol pathway efficiently degrades exogenous LPA  
In addition to the LPA → MAG → glycerol pathway (Figure 19), another Pi-generating 
pathway for LPA degradation involves its deacylation to form glycerophosphate which is 
further dephosphorylated by glycerophosphatases to glycerol (the LPA → GP → glycerol 
pathway) (Figure 19). Since there are two degradative pathways for LPA that potentially 
release Pi, we wished to clarify which pathway would account for LPA degradation in our 
model. We performed kinetic monitoring of Pi production from exogenous LPA and 
glycerol 3-phosphate (GP) after incubation with rat cerebellar membranes in a 96-well-
format. In this setting, cerebellar membranes generated Pi from LPA (10 μM) but there was 
no Pi generation from GP (10 μM) (Figure 25a), indicating that the Pi formed from LPA in 
our experimental setting is principally due to LPP/LPP-like activity. As a further proof, we 
used the dephosphorylation-resistant thio-analog of LPA, (2S)-OMPT, that is also an LPA3 
receptor.-preferring agonist. As expected, there was no Pi generation from (2S)-OMPT (10 
μM) (Figure 26a). 
Since both of the two Pi-releasing pathways for LPA degradation finally produce 
glycerol, we assessed cerebellar membrane-dependent glycerol generation from exogenous 
LPA in brain tissue. MAGL is believed to be mainly responsible for the MAG → glycerol 
conversion. In addition, ABHD6 and ABHD12 have been identified to hydrolyze brain 
endocannabinoid 2-AG (Blankman et al. 2007), and together the three serine hydrolases 
account for ~99% of the brain 2-AG hydrolase activity (Savinainen et al. 2012). It is therefore 
likely that in addition to MAGL, ABHD6 and ABHD12 are involved in the degradation of 
both 1- and 2-monoacylglycerols. To delineate the relative contributions of the three 
hydrolases, we pretreated cerebellar membranes with two serine hydrolase inhibitors, 
methylarachidonoylfluorophosphonate (MAFP) and JZL184. The former is a potent, non-
selective inhibitor of MAGL (Saario et al. 2004, Savinainen et al. 2010) that also inhibits 
ABHD6/ABHD12, whereas the latter is a MAGL-selective inhibitor (Long et al. 2009). As 
expected, in rat cerebellar membranes incubated together with LPA (10 μM), glycerol 
production closely matches Pi generation (Figures 26a and 26b), indicating that MAG → 
glycerol conversion takes place under the assay conditions employed. With MAFP 
pretreatment (1 μM), LPA-derived glycerol production was decreased by 91% (Figure 26b). 
With JZL184 pretreatment (100 μM), the corresponding reduction was 71% (Figure 26b). 
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The selectivity of the inhibitors towards MAGL likely explains the difference in the 
inhibition of glycerol production from LPA between the two inhibitors. Since there was no 
Pi generation from exogenous glycerol 3-phosphate, it seems that LPA is predominantly 
degraded by the LPA → MAG → glycerol pathway in our experimental setting whereas the 
LPA → GP → glycerol pathway plays a minor role. According to our findings, both 
phosphohydrolases (LPPs/LPP-like) as well as MAGL and related hydrolases 
(ABHD6/ABHD12) seem to be active.  
Previously, NEM-insensitive LPA phosphohydrolase activity was studied in the nuclear 
fraction isolated from rabbit cerebral cortex (Baker et al. 2000). This activity was found to be 
present also in the microsomal fraction. In the nuclear fraction, phosphohydrolase activity 
was found to be sensitive to NaF (50 mM) but virtually insensitive to propranolol (0.5 mM). 
Dephosphorylation by phosphohydrolases was found to be more active route for LPA 
degradation when compared to deacylation by lysophospholipases. It was also indicated 
that followed by dephosphorylation of LPA, monoacyl product is rapidly converted to 
glycerol by monoglyceride lipase. These findings support our present findings concerning 
the active pathways involved in LPA degradation in brain as well as the existence of LPP-
like, propranolol- and vanadate-insensitive phosphohydrolase activity.    
 
 
 
 
 
Figure 26. Rat cerebellar membranes principally metabolize LPA via the LPA → MAG → glycerol 
pathway. (a) Rat cerebellar membranes (1 μg/well) were incubated in the absence (basal) or 
presence of LPA, glycerol 3-phosphate (GP), or the phosphatase-resistant LPA analog (2S)-
OMPT. Pi generation was kinetically monitored for 90 min using a fluorescent assay. Rat 
cerebellar membranes generate Pi from exogenous LPA but not from exogenous GP or (2S)-
OMPT. Significance level: ***p < 0.001 compared to basal (n=4 for basal and LPA, n=3 for GP 
and (2S)-OMPT). (b) Rat cerebellar membranes were pretreated for 30 min with DMSO or the 
broad-spectrum serine hydrolase inhibitor MAFP or the MGL-specific inhibitor JZL184. This was 
followed by 90 min incubation in the absence (basal) or presence of LPA. Glycerol generation 
was kinetically monitored for 90 min using a fluorescent assay. Rat cerebellar membranes 
readily generate glycerol from exogenous LPA; this response is largely blocked by MAFP and 
partially so by JZL184. Significance level: ***p < 0.001 compared to either basal (a) or as 
indicated (b) (n=4). 
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7.4 CONCLUSIONS 
 
The two most important pathways to generate LPA are thought to be LPA generation either 
from lysophospholipids by autotaxin or from phosphatidic acid by the PLD → PLA1/2 
pathway. Our findings indicated, however, that tonic LPA1 activity in brain sections was 
not due to LPA generated as a result of autotaxin or PLD activity, since exogenous 
precursors of LPA as well as various compounds reported to affect autotaxin and/or PLD 
activity failed to affect the basal tone of LPA1 receptor activity. We observed that in brain 
sections, the lifetime of bioactive LPA is controlled by Mg2+-independent, NEM-insensitive 
phosphatase activity attributable to LPPs. Pharmacological inhibition of this LPP activity by 
AlFx, propranolol or sodium orthovanadate amplified basal and LPA-stimulated LPA1 
receptor signalling, as revealed using functional autoradiography. We conclude that LPP 
acts locally to control the lifetime of the signalling pool of LPA in the vicinity of LPA1 
receptors whereas the majority of brain LPA phosphatase activity is attributable to 
additional LPP-like enzymatic activity. LPP-like enzymatic activity, like LPP activity, is 
sensitive to AlFx but appears to be resistant to the two other LPP inhibitors, vanadate and 
propranolol. Finally, we demonstrated that degradation of exogenous LPA is almost 
entirely channelled via the LPA → MAG → glycerol pathway and that MAGL accounts for 
the majority of oleylglycerol-hydrolyzing activity in brain tissue. The Pi- and glycerol-
generating enzymatic routes involved in LPA degradation are summarized in Figure 27. 
 
 
 
 
 
 
                
 
  
 
 
 
 
 
Figure 27. Summary of the inorganic phosphate (Pi)- and glycerol-generating enzymatic 
pathways potentially involved in brain tissue-dependent LPA degradation. The width of the 
arrows indicates the relative activity of the pathway in the present experimental setting. 
According to the present study, the LPA → MAG → glycerol pathway is predominantly 
responsible for LPA degradation in rat brain whereas the LPA → GP → glycerol pathway plays a 
minor role. The majority of brain LPA phosphatase activity is attributed to LPP-like enzymatic 
activity. The blunt arrows indicate the enzyme inhibition. Abbreviations: ABHD, α/β-hydrolase 
domain-containing protein; G, glycerol; GP, glycerol phosphate; LPA, lysophosphatidic acid; 
LPL, lysophospholipase; LPP, lipid phosphate phosphatase; MAG, monoacylglycerol; MAGL, 
monoacylglycerol lipase, MAFP; methylarachidonoylflurophosphonate.  
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8 Identification of Enzymatic Pathways Generating 2-
AG in Brain Sections4  
 
 
 
Abstract: The principal brain endocannabinoid, 2-AG, is enzymatically produced by 
postsynaptic neurons and then activates presynaptic CB1 receptors in a retrograde manner. 
The primary pathway for 2-AG generation is believed to be conversion from the DAGs by 
two sn-1-specific lipases, DAGLα and DAGLβ. Previous studies with DAGL-deficient mice 
indicate that DAGLα is the major enzyme needed for retrograde synaptic 2-AG signalling. 
The current study investigated whether the CB1 receptor-mediated Gi protein activity is 
altered in brain cryosections of DAGL-deficient mice when compared to wild-type mice 
and whether the sn-1-specific DAGLs are able to generate 2-AG in brain cryosections. 
Functional autoradiography indicated that brain regional CB1 receptor-Gi-activity largely 
remained unaltered in DAGLα-knockout and DAGLβ-knockout mice when compared to 
wild-type littermates. Following comprehensive pharmacological blockade of 2-AG 
hydrolysis, brain sections generated sufficient amounts of 2-AG to activate CB1 receptors 
throughout the regions endowed with these receptors. As demonstrated by LC/MS/MS, this 
pool of 2-AG was generated via tetrahydrolipstatin-sensitive enzymatic pathways distinct 
from DAGLα or DAGLβ. We conclude that in addition to the sn-1-specific DAGLs, 
additional 2-AG-generating enzymatic pathways are active in brain sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
4 Adapted with permission of Elsevier from: Aaltonen N, Riera Ribas C, Lehtonen M, Savinainen JR, Laitinen JT. Brain 
regional cannabinoid CB1 receptor signalling and alternative enzymatic pathways for 2-arachidonoylglycerol 
generation in brain sections of diacylglycerol lipase deficient mice. Eur J Pharm Sci 51:87-95, 2014. 
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8.1 INTRODUCTION 
 
 
Convincing evidence has been provided to show that DAGLα is the major enzyme 
involved in the biosynthesis of 2-AG needed for retrograde synaptic signalling. It was 
observed that the retrograde synaptic suppression was absent in several brain regions of 
DAGLα-KO mice whereas it remained intact in the brain of DAGLβ-KO mice (Gao et al. 
2010, Tanimura et al. 2010, Yoshino et al. 2011). Furthermore, there were up to 80 % 
reductions in 2-AG levels in DAGLα-KO mice brain whereas in the brains of DAGLβ-KO 
mice, the 2-AG levels remained unaltered (Tanimura et al. 2010, Yoshino et al. 2011), or 
were reduced up to 50 % (Gao et al. 2010). However, despite the chronic reduction in 2-AG 
levels, there was no evidence of CB1 receptor up-regulation in the studied brain regions, as 
evidenced by unaltered levels of mRNA (Gao et al. 2010) and Western blotting of receptor 
protein (Tanimura et al. 2010). However, it has not been studied whether the brain regional 
CB1 receptorGi signalling axis remains intact in DAGL-deficient mice.  
We previously demonstrated that pharmacological elimination of 2-AG hydrolytic 
activity in rat brain sections leads to an accumulation of endogenous 2-AG and subsequent 
CB1 receptor activation, as revealed using [35S]GTPγS autoradiography (Palomäki et al. 
2007). It was postulated that the DAGL activity generated 2-AG in sufficient amounts to 
activate CB1 receptors. The 2-AG accumulation was susceptible to two recognized inhibitors 
of the DAGLs, tetrahydrolipstatin (THL) and compound RHC80267, and CB1 receptor 
activity was modestly amplified by two DAGL activators, calcium and glutathione 
(Palomäki et al. 2007). Since only nonselective pharmacological tools were previously 
available to explore the possible role of DAGLs, we were curious to extend these findings 
by examining whether 2-AG accumulation takes place in cryosections of DAGLα-KO or 
DAGLβ-KO mice brain when compared to WT brain and whether there would be 
alterations in the functionality in CB1 receptor-Gi axis between the genotypes. 
 
8.2 MATERIALS AND METHODS 
 
The materials and general methods are described in Chapter 4. 
8.2.1 DAGL-deficient mice 
Frozen brains of DAGLα-KO, DAGLβ-KO and WT mice were a gift from Dr. Masanobu 
Kano, University of Tokyo, Tokyo, Japan and from Dr. Kenji Sakimura, Niigata University, 
Niigata, Japan. The generation of the DAGL-KO mice has been described by Tanimura et al. 
(2010). The brains were removed from 3 to 6 months old mice representing combination of 
both males and females of all genotypes. The mice were sacrificed by decapitation, and 
within the next 3 min, the whole brain was dissected out, dipped briefly either in 
isopentane (chilled on dry ice) or in liquid nitrogen, and stored at 80 °C. Both isopentane 
and liquid nitrogen were used to freeze the brains in order to compare the two freezing 
methods. Since our preliminary experiments demonstrated that there was no difference in 
the outcome between the brains processed in these two different ways (data not shown), a 
combination of both brain types were used in following experiments. Horizontal brain 
sections (20 μm thick) were cut at 20 °C using a Leica cryostat, thaw-mounted onto 
Superfrost®Plus slides (Menzel-Gläser, Germany), dried for 12 h at room temperature 
under a constant stream of air and stored thereafter at 80 °C.  
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8.2.2 LC/MS/MS for eCB determination 
 
Sample preparation   
 
Triplicate slides each with five brain sections underwent the autoradiography-mimicking 
protocol (except that DPCPX, GDP, DTT and radioligand were omitted). The protocol 
consisted of 20 min pre-incubation in the assay buffer, 60 min incubation in the assay buffer 
with or without the lipase inhibitors and 0.5% (w/v) BSA, and finally a 90 min incubation in 
the assay buffer supplemented with 0.1% (w/v) BSA. Between the steps, the slides were 
rinsed either twice (after the first step) or once (after the second step) with the assay buffer. 
After the final 90 min incubation step, the postincubation buffer was quantitatively 
collected. The slides were rinsed twice (2 min each time) in ice-cold washing buffer, dipped 
for 30 s in ice-cold deionized water and air-dried.   
To determine the 2-AG and AEA content, the brain sections were moistened with 
methanol and the tissue was scraped manually from the slides with a spatula into a plastic 
test tube. To determine 2-AG and AEA content in the incubation buffer, 500 μl of 
incubation buffer was transferred to a plastic test tube. Extraction of the analytes from the 
sample matrix has been previously described (Lehtonen et al. 2011). Briefly, 500 μl of ice-
cold methanol was added to samples, which were then homogenized with a Soniprep 150 
homogenizer (MSE Ultrasonic Disintegrator; MSE Scientific Instruments, Manor Royal, 
Crawley, Sussex, UK). Samples were transferred into screw-capped glass test tubes and the 
lipids were extracted by adding chloroform and water to yield a 
methanol/chloroform/water ratio of 1:2:1 (v/v/v). Samples were centrifuged at 1500 x g for 
10 min at 10 °C to obtain a sharp phase separation. The upper aqueous layer was discarded 
and the lower organic layer was transferred to a screw-capped glass test tube. This liquid 
extraction was repeated once, and the organic layers were combined. The sample was then 
evaporated to dryness under nitrogen at room temperature and the residue was 
reconstituted in 50 μl of ice-cold acetonitrile. The sample was dissolved for 5 min and then 
20 μl of water was added. After centrifugation at 10 000 x g for 10 min at 10 °C, the 
supernatant was transferred to an HPLC sample vial for LC/MS/MS analysis, as described 
below. 
 
Liquid chromatography/tandem mass spectrometry (LC/MS/MS)   
 
The LC/MS/MS instrumentation used in the eCB analysis has been previously described 
(Lehtonen et al. 2011). The HPLC system consisted of an Agilent 1200 Series Rapid 
Resolution LC System (Agilent Technologies, Waldbronn, Germany) with a solvent micro 
vacuum degasser, a binary pump, a thermostatted column compartment, and an 
autosampler. The mass analysis was made with an Agilent 6410 Triple Quadrupole MS 
equipped with an electrospray ionization source (Agilent Technologies, Palo Alto, CA, 
USA). Ten microliters of the sample solution were injected onto a reversed-phase HPLC 
column (Zorbax Eclipse XDB-C18 Rapid Resolution HT 2.1 mm x 50 mm, 1.8 μm) (Agilent 
Technologies, Palo Alto, CA, USA) using an isocratic mobile phase consisting of 
H2O/acetonitrile/formic acid (33:67:0.1, v/v/v), delivered at 150 μl/min. Column temperature 
was maintained at 40 °C and the autosampler tray temperature was set at 10 °C. The 
following ionization conditions were used: ESI positive ion mode, drying gas (nitrogen) 
temperature 300 °C, drying gas flow rate 10 l/min, nebulizer pressure 50 psi, and capillary 
voltage 4000 V. Detection was performed using multiple reaction monitoring with the 
following transitions: m/z 348 → 62 for AEA, m/z 356 → 63 for AEA-d8, m/z 379 → 287 for 
2-AG, and 387 → 294 for 2-AG-d8. Fragmentor voltage and collision energy for AEA, AEA-
d8, 2-AG, and 2-AG-d8 were 120 and 10 V, 120 and 12 V, 130 and 8 V, and 125 and 10 V, 
respectively. Dwell time was 100 ms for each transition, and mass resolutions for MS1 and 
MS2 quadrupoles were 2.4 and 1.2 FWHM, respectively, for AEA, and 0.7 and 0.7 FWHM, 
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respectively, for AEA-d8, 2-AG, and 2-AG-d8. Deuterated internal standards, AEA-d8 and 
2-AG-d8, were used for quantification, and peak area ratios of the analyte to the internal 
standard were calculated as a function of the concentration ratios of the analyte to the 
internal standard.  
 
8.3 RESULTS AND DISCUSSION 
8.3.1 The functionality of CB1 receptorGi-axis remains unaltered in DAGLα-KO and 
DAGLβ-KO mice when compared to WT animals.  
We assessed basal and CB1 receptor-dependent G protein activity in cryosections of 
DAGLα-KO, DAGLβ-KO and WT mice by analyzing selected CB1 receptor-enriched brain 
regions (Herkenham et al. 1991), i.e. the cingulate cortex, caudate putamen, globus pallidus, 
somatosensory cortex, substantia nigra, cerebellar molecular layer, hippocampus-overall, 
hippocampus-CA1, hippocampus-CA3, and hippocampus-dentate gyrus, in a quantitative 
manner. There were no statistically significant differences in basal G protein activity in 
examined brain regions in the DAGLα-KO, DAGLβ-KO and WT mice (Figures 28a and b). 
Pretreatment with the broadly-acting serine hydrolase inhibitor MAFP (10 μM) induced a 
robust [35S]GTPγS binding response throughout the CB1 receptor-enriched brain regions 
(Figure 28a). Evidently, after comprehensive blockade of 2-AG hydrolysis, mice brain 
cryosections were able to generate sufficient amounts of 2-AG to activate CB1 receptors. 
Previously, by classical filtration based [35S]GTPγS binding assay it was demonstrated that 
MAFP has no direct effect on CB1 receptor activation (Savinainen et al. 2003, Palomäki et al. 
2007). No statistically significant differences were observed in the MAFP-evoked CB1 
receptor response between the genotypes (Figure 28b).  
The synthetic CB1 receptor agonist CP55,940 induced concentration-dependent (0.5 μM, 5 
μM, 50 μM) [35S]GTPγS binding responses in the studied brain regions (Figure 28a). The 
dose-response for CP55,940 was chosen to extend up to 50 μM due to the high degradative 
capacity of brain sections, where millimolar concentrations of GDP are needed to observe 
agonist-driven Gi protein activity (Laitinen 2004). No statistically significant difference was 
observed in CP55,940-evoked regional CB1 receptor activity between DAGLβ-KO and WT 
mice whereas in certain hippocampal regions of DAGLα-KO mice (hippocampus-overall, 
hippocampus-CA3 and hippocampus-dentate gyrus), sub-maximal concentrations of 
CP55,940 evoked a statistically significant increase in CB1 receptor activity (Figure 28b). In 
agreement with the previous findings with rat brain cryosections (Palomäki et al. 2007, 
Aaltonen et al. 2013), the observed labelling patterns evoked by both MAFP and CP55,940 
were abolished with the CB1 receptor-selective antagonist AM251 (1 μM),  confirming that 
responses were mediated via the CB1 receptors (Figure 29).   
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Figure 28. Blockade of endocannabinoid hydrolysis by the irreversibly acting inhibitor MAFP 
evokes CP55,940-mimicking [35S]GTPγS binding responses throughout the CB1 receptor-
enriched brain regions of DAGLα-KO, DAGLβ-KO and WT mice brain sections. MAFP was included 
during step 2 whereas CP55,940 was included during the [35S]GTPγS labelling step. (a) In basal 
conditions, there is no difference in [35S]GTPγS labelling between the genotypes. Treatment 
with MAFP induces G protein activity in the CB1 receptor-enriched brain regions; this response is 
similar in the three genotypes. The MAFP-evoked response is dose-dependently mimicked by 
CP55,940 (Cx, cerebral cortex; CPu, caudate putamen; Hip, hippocampus; Cbm, molecular 
layer of the cerebellum). Scale bar = 2 mm. (b) Quantitative data of the [35S]GTPγS binding 
responses. No statistically significant difference is observed in basal or MAFP-evoked G protein 
activity between WT and DAGLα-KO or DAGLβ-KO mice. In certain hippocampal structures, 
treatment with CP55,940 induces increased binding response in DAGLα-KO mice when 
compared to WT mice (*p < 0.05) (n=5). 
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Figure 29. [35S]GTPγS binding responses evoked by MAFP and CP55,940 are sensitive to CB1 
receptor-selective antagonist AM251. MAFP was included during the step 2 whereas CP55,940 
and AM251 were included during the [35S]GTPγS labelling step (Cx, cerebral cortex; GP, globus 
pallidus; Hip, hippocampus; SN, substantia nigra). Scale bar = 2 mm. 
 
Previous studies with DAGL-deficient mice revealed that both global and regional 2-AG 
levels in brain were significantly reduced and that 2-AG mediated retrograde synaptic 
suppression was absent in DAGLα-KO mice brain (Gao et al. 2010, Tanimura et al. 2010, 
Yoshino et al. 2011). One would expect that chronic and extensive 2-AG reduction would 
lead to up-regulation of CB1 receptors as a compensatory response. However, mRNA 
expression pattern and protein levels of CB1 receptors were found to be normal in the 
studied brain regions (Gao et al. 2010, Tanimura et al. 2010). In contrast, global genetic 
knockout of MAGL resulted in a dramatic increase in 2-AG levels in the nervous system 
that lead to a reduction of CB1 receptor density, as well as pharmacological tolerance to the 
cannabinoid agonists, indicating desensitization of CB1 receptors (Chanda et al. 2010, 
Taschler et al. 2011). Down-regulation of CB1 signalling was also observed in some, but not 
all regions following chronic treatment of mice with the selective MAGL-inhibitor JZL184 
(Schlosburg et al. 2010). Likewise, chronic treatment of rats with ∆9-THC significantly 
reduced cannabinoid agonist-stimulated responses in several brain regions enriched with 
the CB1 receptors whereas acute ∆9-THC treatment had no such effect (Sim et al. 1996). Our 
present findings indicate that agonist-induced CB1 receptor signalling is unaltered in all 
tested brain regions of DAGLβ-KO mice and in the majority of tested brain regions of 
DAGLα-KO mice as compared to their WT littermates. In certain hippocampal regions of 
DAGLα-KO mice brain, however, increased CB1 receptor activity was observed. Evidently, 
in the majority of brain regions, the loss of DAGL does not affect the functionality of the 
CB1-receptor-Gi/o axis or the receptor density but it is conceivable that in hippocampus, 
chronic reduction of 2-AG leads to activation of compensatory mechanisms. Previously, 
hippocampus has been demonstrated to be one of the brain structures that is very sensitive 
to desensitization and down-regulation of CB1 receptors both in mice (Sim-Selley et al. 2006, 
McKinney et al. 2008, Schlosburg et al. 2010) and humans (Hirvonen et al. 2013) and 
similarly this structure might also be susceptible to receptor up-regulation. Nonetheless, the 
chronic reduction of 2-AG levels in the CNS does not seem to induce any major 
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compensatory effects to such an extent as seen after the chronic elevation of 2-AG levels 
described in several animal models.   
 
8.3.2 Mice brain sections generate 2-AG via THL-sensitive enzymatic pathways distinct 
from DAGLα or DAGLβ. 
To investigate the origin of 2-AG capable of activating the CB1 receptors in MAFP-treated 
sections, brain sections of DAGLα-KO, DAGLβ-KO and WT mice were treated with MAFP 
or with the combination of MAFP and the established DAGL inhibitor THL using 
autoradiography-mimicking conditions. After the incubation, the tissue and buffer lipids 
were extracted using chloroform-methanol and 2-AG and AEA levels were determined 
with LC/MS/MS. Pretreatment with MAFP (10 μM) resulted in an approximately 9-fold 
increase in the tissue 2-AG content (Figure 30a) and an approximately 100-fold increase in 
2-AG levels in the incubation buffer (Figure 30b). Inclusion of THL (10 μM) blocked the 2-
AG generation in MAFP-treated sections; this was evident in both tissue and incubation 
buffer samples (Figures 30a and b). There were no statistically significant differences in 2-
AG levels between WT and DAGLα-KO or DAGLβ-KO mice in any of the tested conditions 
(Figures 30a and b). These results indicate that in the present experimental setting, brain 
sections generate 2-AG via THL-sensitive enzymatic pathways distinct from DAGLα or 
DAGLβ. In addition to MAGL, MAFP potently inhibits other serine hydrolases including 
the AEA-degrading enzyme FAAH (McKinney and Cravatt 2005). When relative levels of 
AEA were determined after pre-incubation with MAFP (10 μM), there was an 
approximately 7-fold increase in the AEA content when compared to basal situation in 
tissue samples (Figure 31a) and an approximately 3-fold increase in incubation buffer 
samples (Figure 31b). Treatment with THL (10 μM) had no effect on the MAFP-induced 
increases in AEA levels (Figures 31a and b). There were no statistically significant 
differences in AEA contents between WT and DAGLα-KO or DAGLβ-KO mice in any of 
the tested conditions (Figures 31a and b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Mouse brain sections generate 2-AG via THL-sensitive enzyme pathway(s) distinct 
from DAGLα or DAGLβ. (a) and (b) Slides with five horizontal sections of DAGLα-KO, DAGLβ-KO 
and WT mice brain underwent the three-step autoradiography-mimicking incubation. MAFP and 
THL were present during the 60 min incubation step (step 2). (a) The tissue was scraped from 
the slides and lipids extracted using chloroform-methanol followed by 2-AG determination with 
LC/MS/MS. (b) After the final incubation step, the assay buffer was quantitatively collected and 
lipids extracted using chloroformmethanol followed by 2-AG determination with LC/MS/MS. 
Significance level: **p < 0.01 (n=4). 
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Figure 31. Treatment with MAFP results in AEA accumulation in brain sections of DAGLα-KO, 
DAGLβ-KO and WT mice in THL-insensitive manner. (a) and (b) Slides with five horizontal 
sections of DAGLα-KO, DAGLβ-KO and WT mice brain underwent the three-step 
autoradiography-mimicking incubation. MAFP and THL were present during the 60 min 
incubation step (step 2). (a) The tissue was scraped from the slides and lipids extracted using 
chloroformmethanol followed by determination of relative content of AEA with LC/MS/MS. (b) 
After the final incubation step, the assay buffer was collected and lipids extracted using 
chloroform-methanol followed by determination of relative content of AEA with LC/MS/MS. 
Significance level: *p < 0.05 (n=4). 
 
 
In the comparison of 2-AG and AEA levels between unprocessed cryosections of 
DAGLα-KO, DAGLβ-KO and WT mice brains, the sections were thawed, the tissue lipids 
were extracted using chloroformmethanol and the endocannabinoid content was 
determined with LC/MS/MS. Unexpectedly, we found approximately 2-fold elevated levels 
of 2-AG in sections of DAGLα-KO brain when compared to WT and DAGLβ-KO brain 
(Figure 32a). There was no statistically significant difference in the 2-AG content between 
the sections of WT and DAGLβ-KO brain (Figure 32a). When AEA levels were determined, 
there were no statistically significant differences in the AEA content between the three 
genotypes (Figure 32b).  
Although MAFP elevates tissue levels of both 2-AG and AEA under the conditions 
employed, our previous studies indicated that treatment of brain sections with URB597, a 
potent and specific inhibitor of FAAH, failed to mimic MAFP in evoking the CB1 receptor 
activity response (Palomäki et al. 2007). This is true also for another FAAH inhibitor, PF-750 
(our unpublished observation). Furthermore, exogenous AEA, even in the presence of 
URB597, generated only relatively weak responses as opposed to the robust responses 
evident in MAFP-treated sections (Palomäki et al. 2007). These data strongly argue against 
the possibility that the observed responses were mediated by AEA, the other major CB1 
receptor-activating eCB recognized to date. Moreover, we recently demonstrated that the 
potency of the MAGL-selective inhibitor JZL184 is not sufficient to afford visualization of 
the eCB-driven CB1 receptor activity (Aaltonen et al. 2013). However, this is possible using 
a truly potent MAGL-selective inhibitor (JJKK-048) (Aaltonen et al. 2013) indicating that 2-
AG is the endocannabinoid responsible for activating CB1 receptors in brain sections. 
However, not even comprehensive elimination of MAGL activity is sufficient to generate 
the full MAFP-mimicking response, as MAGL accounts for 85 % of brain 2-AG hydrolysis 
and additional hydrolases (ABHD6 and ABHD12) remain active after selective MAGL-
blockade (Blankman et al. 2007, Savinainen et al. 2012). Only MAFP seems to be capable of 
comprehensively prevent brain 2-AG hydrolysis.   
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Figure 32. Tissue 2-AG content is higher in unprocessed brain sections of DAGLα-KO mice when 
compared to WT and DAGLβ-KO mice, there is no difference in tissue AEA content between the 
genotypes. (a) and (b) Slides with five horizontal cryosections of DAGLα-KO, DAGLβ-KO and WT 
mice brain were thawed, tissue scraped from the slides, and lipids extracted using chloroform-
methanol followed by endocannabinoid determination with LC/MS/MS. Note the difference to 
figures 30 and 31; no incubations have been conducted with this set of slides. Significance 
level: **p < 0.01 compared to wild-type (n=4). 
 
 
Accumulation of 2-AG, but not that of AEA, was sensitive to THL, indicating that mouse 
brain has THL-sensitive enzymatic machinery that is able to generate 2-AG in sufficient 
amounts to activate CB1 receptors. Since there was no statistically significant difference in 
the 2-AG contents between the genotypes in MAFP-treated brain sections, we conclude that 
this pool of 2-AG is not being generated via DAGLα or DAGLβ. These results therefore 
indicate that alternative THL-sensitive enzymatic pathways capable of generating 2-AG are 
active in brain cryosections. Since previous reports indicated that both global and regional 
2-AG levels in brain were significantly reduced in DAGLα-KO mice brain (Gao et al. 2010, 
Tanimura et al. 2010, Yoshino et al. 2011), currently observed ability of brain sections of 
DAGLα-deficient mice to generate 2-AG, as well as increase in 2-AG levels in unprocessed 
brain sections of DAGLα-KO mice, are unexpected. Since we measured 2-AG and AEA 
contents in brain sections that were incubated at room temperature for a prolonged period 
of time, and it has been demonstrated that post-mortem rat brain can generate 2-AG 
rapidly after decapitation (Sugiura et al. 2001), the eCB contents likely reflect the 
biochemical reaction taking place in dead neural tissues. It is possible that lipids leak out 
from damaged or dead cells in brain sections and 2-AG is produced by enzymes other than 
DAGLs. In DAGL-KO mice, the activities of these enzymes might have been elevated in 
order to compensate for the lack of DAGLs. It has been demonstrated that there were no 
changes in mRNA or protein levels of DAGLα in DAGLβ-KO and vice versa (Gao et al. 
2010), suggesting that the lack of one isotype is not inducing up-regulation of the other 
isotype. Alternative pathways for 2-AG generation could include conversion from 2-
arachidonoyl lysophosphatidic acid by a phosphatase or generation from 2-arachidonoyl-
phospholipids by sequential actions of PLA1 and lyso-PLC (Piomelli 2003, Bisogno 2008). 
However, these pathways are apparently not involved in the 2-AG generation required for 
retrograde synaptic suppression (Tanimura et al. 2010), though there is evidence indicating 
that sn-1-DAGLα is not involved in hippocampal inhibitory synaptic transmission that is 
believed to be mediated by 2-AG (Min et al. 2010b). We assume that the pool of 2-AG 
generated in mice brain cryosections is different from the DAGLα-dependent pool that is 
used for retrograde 2-AG signalling in the living brain. We therefore wish to emphasize 
that brain cryosections do not represent a physiological model for eCB generation or 
retrograde signalling in the living brain. However, this study clearly demonstrates that as 
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well as the sn-1 specific DAGLs, additional 2-AG generating enzymatic pathways are active 
in brain sections. 
It should be noted that in addition to their signalling functions, eCBs have been indicated 
to possess supplemental roles (Piomelli 2003, Alger & Kim 2011). A detectable amount of 2-
AG is present in non-stimulated brain without permanent activation of CB1 receptors 
(DiMarzo and Petrosino 2007, Gao et al. 2010, Tanimura et al. 2010) reflecting that not all of 
the 2-AG is used for retrograde signalling. Since 2-AG acts at the crossroads of multiple 
biochemical pathways of lipid metabolism, it is likely that a proportion of 2-AG generated 
in brain serves as a lipid intermediate in these pathways. Moreover, although the signalling 
pool of 2-AG is apparently operating between post- and presynaptic neurons, another pool 
might be present in other cell types and not be involved in retrograde signalling. It has been 
demonstrated that mouse microglia (Walter et al. 2003, Carrier et al. 2004, Witting et al. 
2004) as well as astrocytes (Walter et al. 2004) have the capacity to produce 2-AG. Thus, it 
might be that non-neuronal cell types account for the production of 2-AG in brain 
cryosections. Further studies are therefore warranted in order to identify the cell types 
generating this alternative pool of 2-AG in brain tissue. Finally, it is noteworthy that in 
some brain regions highly enriched with the CB1 receptors (such as the substantia nigra) 
(Herkenham et al. 1991), DAGLα is only sparsely expressed, as evidenced by weak 
labelling with the DAGLα antibodies in immunohistochemical studies (Uchigashima et al. 
2007, Tanimura et al. 2010). This further supports the existence of alternative biochemical 
routes that could generate CB1 receptor-activating eCBs in brain regions with sparse 
DAGLα expression.  
 
 
8.4 CONCLUSIONS 
 
The present findings indicate that the functionality of the CB1 receptorGi-axis remains 
unaltered in various brain regions of DAGLα-KO and DAGLβ-KO mice when compared to 
WT animals. Furthermore, we demonstrate that mice brain cryosections are able to generate 
sufficient amounts of 2-AG to activate CB1 receptors throughout the brain regions endowed 
with these receptors. As demonstrated by LC/MS/MS, this pool of 2-AG is generated via 
THL-sensitive enzymatic pathway(s) but evidently not via DAGLα or DAGLβ. This pool of 
2-AG must therefore be different from the DAGLα-dependent pool that is used for 
retrograde 2-AG signalling in living brain. We conclude that in addition to DAGLs, brain 
tissue has additional THL-sensitive enzymatic sources capable of generating 2-AG. 
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9 General Discussion 
 
9.1. General comparison of LPA and eCB signalling  
The present study provides novel information about regulation of LPA and eCB signalling 
systems in brain tissue. Though both LPA and eCBs are bioactive lipids that signal through 
specific GPCRs, they are usually discussed separately in the literature. There is apparent 
similarity between the two lipid systems, but certain differences can also be found. 
From the historical point of view, LPA and eCB research has been evoked from different 
origins. The natural source of cannabinoids, the Cannabis sativa plant, has been used for 
millennia for its intoxicating and medicinal properties. Identification of the active 
component of Cannabis sativa (Gaoni & Mechoulam 1964) and further efforts to explain 
cannabinoid actions in the body led to the discovery of cannabinoid receptors and their 
endogenous ligands, the eCBs. The LPA research was initiated upon the early observations 
that members of the endogenous phospholipid class of compounds can act as extracellular 
effectors in modulating blood pressure (Sen et al. 1968, Tokumura et al. 1978). From the first 
observations, it took three decades until the first LPA receptor was cloned. The first 
cannabinoid receptor was cloned in 1988 (Devane et al. 1988) whereas the first LPA receptor 
was cloned approximately ten years later, in 1996 (Hecht et al. 1996). The discovery of the 
specific receptors instigated an intense research activity on both fields. 
Currently, there are more GPCRs identified for LPA (six receptors) (Table 2) than for 
eCBs (two receptors). In addition to the currently recognized receptors, there might be 
other receptors for both LPA and eCBs among the large group of orphan GPCRs; so far 
more candidates have appeared for LPA. According to phylogenetic models of GPCRs, 
LPA receptors appear to have evolved from two distinct lineages whereas CB1 and CB2 
receptors evolved from a single lineage (Figure 3) (Shimizu 2009). The LPA signalling is 
mediated via all four main G protein subfamilies whereas eCB receptors principally signal 
via Gi type G proteins. Due to a larger number of receptors and signalling partners, LPA 
signalling is somewhat more complicated than eCB signalling. In the brain, the CB1 receptor 
is one of the most abundant GPCRs showing a robust expression pattern in the gray matter 
areas (Herkenham 1991). The LPA1 receptor is considered to be the primary LPA receptor 
in the brain but it shows restricted expression pattern mainly in white matter tracts of the 
developing brain (Choi et al. 2010). The role of eCB signalling as a modulator of 
neurotransmission is rather well understood whereas the role of LPA in neurotransmission 
largely remains to be elucidated. Both LPA and eCBs play major roles in brain 
development. 
Studies on receptor and enzyme knockout animals have revealed certain differences 
between LPA and eCB functions. The CB receptor knockouts as well as knockouts of eCB-
synthesizing and -degrading enzymes show a normal phenotype (Zimmer et al. 1999, 
Buckley et al. 2000, Buckley et al. 2008, Tanimura et al. 2010, Gao et al. 2010, Chanda et al. 
2010, Yoshino et al. 2011, Tascler et al. 2011). The LPA1 receptor knockouts, instead, show 
50% embryonic lethality (Contos et al. 2000) whereas ATX knockouts as well as LPP3 
knockouts are embryonically lethal (Tanaka et al. 2006, Escalante-Alcade et al. 2003). The 
embryonic lethality occurs also when another lysophospholipid receptor, S1P1, is knocked 
out (Liu et al. 2000). Based on these observations one could conclude that lysophospholipid 
signalling is more essential for development than eCB signalling. In post-natal life, it seems 
that eCB-mediated signalling become especially important during disease.  
Following the discovery of receptors mediating the actions of eCBs and LPA, the 
characterization of their biosynthetic and degradative enzymes has provided essential 
information about the functionality of these lipid systems and has remarkably increased the 
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knowledge on how exogenous agents can affect these systems. Enzymatic networks reveal 
the closeness of the systems to each other; theoretically, when 2-arachidonoyl-LPA is 
dephosphorylated by phosphatase activity, the product will be 2-AG (Figure 33). The 
enzymatic conversion of 2-arachidonoyl-LPA to 2-AG has been demonstrated to take place 
in brain homogenates (Nakane et al. 2002) but currently, there is no direct evidence to link 
the LPPs to cannabinoid signalling (Brindley & Pilquil 2009). In aggressive cancer cells, the 
2-AG-hydrolyzing enzyme MAGL generates lipid precursors for the production of LPA 
(Nomura et al. 2010). MAG acts as a substrate for COX and by COX activity, MAGL 
products can also be used for eicosanoid production (Nomura et al. 2011) (Figure 33), 
linking both LPA and eCB systems to the eicosanoid system.  
 
 
   C20:4 LPA    C20:4 MAG (2-AG)                     C20:4 (AA)                    Eicosanoids 
 
 
 
 
 
 
 
Figure 33. The interconnection between three lipid-GPCR signalling systems involving LPA, 
endocannabinoid and eicosanoid signalling. C20:4 LPA can be converted to 2-AG by a 
phosphatase activity. The hydrolysis of 2-AG produces AA, which can be used as a precursor for 
the eicosanoid production (modified from Brindley & Pilquil 2009). 
  
 
The dysregulation of LPA and eCB signalling is involved in the pathology of several 
common diseases (Tables 3 and 4). In the majority of these diseases, however, the main 
functions of LPA and eCBs are opposite. In cancer, LPA generally induces cancer 
progression whereas eCBs suppress cancer. LPA evokes pain whereas eCBs relieve pain. 
Both LPA and CB-receptors are widely expressed in the body, which makes it challenging 
to achieve an organ-specific effect by using exogenous receptor agonists or antagonists. 
Lipid GPCRs likely bind their ligands laterally via the lipid bilayer (Hanson et al. 2012, 
Hurst et al. 2010, Hurst et al. 2013), suggesting that exogenous ligands should be first 
targeted to the cell membrane. Furthermore, the ligands are susceptible to the rapid 
enzymatic degradation. These issues challenge the development of lipid ligands and for 
drug discovery purposes, receptor agonists or antagonists either for LPA or eCB receptors 
are not currently the principal targets. Instead, allosteric modulators as well as enzyme 
inhibitors for lipid biosynthetic and degradative enzymes are under intense investigation. 
There are several pharmacological inhibitors developed especially targeting the eCB-
degrading enzymes (Table 5) but currently only few compounds exist which inhibit LPA 
synthesis or degradation. There are certain requirements for a pharmacological inhibitor 
until it can be used as a drug; for instance, it should be potent, selective over other 
enzymes, soluble, stable in vivo, and preferentially orally active. Only a few inhibitors 
developed so far meet these requirements, for many their in vivo profile has not been made 
publicly available. Much of work still needs to be done to fully utilize the therapeutic 
potential of these lipid systems.  
 
9.2. Studying the life cycle of LPA and 2-AG 
Brain sections presumably preserve the functional enzymatic machinery required for 
synthesis and degradation of lipid GPCR ligands, in a suitable microenvironment along 
with their native signalling partners. In the present study, a novel pharmacological 
LPPs 
LPP-like 
phosphatases 
MAGL 
ABHD6 
ABHD12 
LPA receptors Cannabinoid 
receptors
Eicosanoid 
receptors
COX 
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application of functional autoradiography was utilized in studies of the enzymatic 
pathways responsible for the lipid messenger synthesis and degradation in brain sections. 
For additional information, functional autoradiography was combined with supporting 
methods. The accumulation of endogenous compounds in tissue sections was verified by 
combining the results of functional autoradiography with a sophisticated LC/MS/MS 
analysis. Additionally, the degradation of LPA and 2-AG was studied by assaying their 
degradation products. The measurement of Pi has been previously used when determining 
degradation of adenine and guanine nucleotides during autoradiography incubations 
(Laitinen et al. 2001, Laitinen 2004). Here, this approach was utilized for the first time for 
studying LPA degradation. The determination of glycerol is a straightforward way to 
monitor the degradation of glycerophospholipids and was utilized when studying the 
enzymatic pathways involved in the degradation of LPA.   
 
Characterization of the [35S]GTPγS autoradiography method  
 
[35S]GTPγS autoradiography measures the first step in the receptor-Gi protein signalling 
cascade, the guanine nucleotide exchange. Inherent to the method is [35S]GTPγS binding 
under basal conditions that may possibly mask some receptor responses. Adenosine is 
continuously generated in brain sections during the incubations and it can cause an A1 
receptor-dependent [35S]GTPγS binding response predominantly in grey matter areas 
(Laitinen 1999, Moore et al. 2000). The primary source for adenosine in brain sections is 
degradation of adenine nucleotides such as ATP (Laitinen 1999). It has been demonstrated 
that adenosine A1 receptors exhibit no constitutive activity in the absence of agonist 
(Savinainen et al. 2003). Thus either the adenosine A1 receptor-selective antagonist DPCPX 
or the adenosine-hydrolyzing enzyme adenosine deaminase need to be routinely included 
in the protocol to eliminate this adenosine-derived signal. In addition to the adenosine A1 
receptors, LPA1 receptors have been observed to be tonically active in brain sections 
contributing to the white matter-enriched [35S]GTPγS binding in basal conditions. This 
labelling can be eliminated by using an LPA1/3 receptor-selective antagonist (Palomäki & 
Laitinen 2006).  
In the present study, the majority of the adenosine A1 and LPA1 receptor-independent 
basal labelling was found to be located in the brain regions participating in the regulation 
of primitive vital functions and behaviour, such as in thalamic and hypothalamic nuclei. 
Due to the sensitivity to NEM, the basal signal appears to be Gi protein-mediated. The 
sensitivity to NEM cannot be construed as an absolute proof of involvement of Gi proteins, 
since in addition to cysteine in the C-terminus of Gi, NEM has the potential to alkylate 
cysteines in other proteins (Laitinen 2004). In principle, basal labelling could reflect regional 
enrichment of various members of the G protein family, that could bind [35S]GTPγS also in 
a manner independent of any interaction with GPCR. Furthermore, constitutive activity of 
unknown GPCRs or the presence of still unidentified ligands capable of activating their 
receptors could affect basal labelling. Interestingly, the majority of currently orphan 
receptors are considered to be located in the hypothalamus, which was the region that was 
most intensively labelled under basal conditions. None of the antagonists used in this study 
could abolish the basal labelling, indicating that it is not induced by the activity of 
histamine H3, cannabinoid CB1/CB2, S1P1, or neuropeptide Y1/Y2/Y5 receptors. Since LPA1 
receptors are expressed and the [35S]GTPγS binding response is clearly visible in the 
juvenile brain (Laitinen 2004, Choi et al. 2010), we performed the present studies using 
brain sections of young, 4 week-old rats. A preliminary comparison indicated that identical 
brain structures were also labelled in the adult rat brain. However, a more detailed study 
would be needed to make it possible to conduct a quantitative comparison of the regional 
signal intensity between young and adult animals. It should be emphasized that the male 
Wistar rats were sacrificed at one particular circadian time (89 hrs after lights on a 12:12 
hour lightdark cycle). Although not yet studied, factors such as diet, sex and the circadian 
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time could in principle affect the distribution and/or intensity of the basal [35S]GTPγS 
labelling. It should be emphasized, that the current anatomical mapping does not 
necessarily reflect the situation in the brain in vivo. 
In addition to white matter-enriched LPA1 receptors, [35S]GTPγS autoradiography is 
suitable for studying other Gi-coupled lipid receptors, including S1P1 and CB1 receptors. 
The activation of both S1P1 and CB1 receptors induces robust responses, predominantly in 
gray matter areas (Waeber & Chiu 1999, Laitinen 2004, Sim-Selley et al. 2009). In contrast to 
the LPA1 receptor, receptors for S1P or endocannabinoids display no tonic activity visible in 
functional autoradiography. Our unpublished results indicate that brain sections are not 
capable of generating S1P during the incubations, whereas they do seem to be able to 
generate LPA and 2-AG. The generation of S1P requires phosphorylation of sphingosine by 
sphingosine kinase (Pyne et al. 2009); it is likely that catabolic rather than de novo 
synthesizing pathways are active in brain sections. If one wishes to clarify the pathways 
that require kinase activity, methods based on living cells presumably would be needed. 
Furthermore, since functional autoradiography detects receptor-mediated G protein 
activity, detection of G protein-independent, e.g. β-arrestin-mediated, GPCR activity would 
require some additional technique. 
  
[35S]GTPγS autoradiography as a pharmacological approach to study enzymatic activity regulating 
lipid GPCR signalling 
 
Traditionally, functional autoradiography has been performed using exogenous receptor 
agonists or antagonists. In addition to exogenous ligands, endogenous lipid mediators pre-
existing in the sections or generated during the incubations, are able to activate their 
cognate receptors and induce the [35S]GTPγS binding response. The use of pharmacological 
inhibitors of enzymes that degrade these ligands or, alternatively, stimulators of their 
biosynthetic enzymes, provides a novel way to extend the usefulness of the method.  
2-AG is known to be efficiently generated in the post-mortem rat brain tissue after 
decapitation (Sugiura et al. 2001). Previously, brain sections were found to efficiently 
degrade 2-AG (Savinainen et al. 2001). Further studies indicated that the elimination of 2-
AG degradative pathways by MAFP evoked accumulation of endogenous 2-AG and the 
subsequent CB1 receptor activation as revealed using [35S]GTPγS autoradiography 
(Palomäki et al. 2007). Prolonging the pre-incubation time prior to MAFP treatment had no 
effect on the [35S]GTPγS binding responses evoked by the subsequent MAFP treatment 
(Palomäki et al. 2007), and it was postulated that 2-AG pre-existing in the sections had 
become depleted during the prolonged pre-incubation and the endocannabinoid, activating 
the CB1 receptors, had been synthesized during the incubations. Since it is a broadly-acting 
serine hydrolase inhibitor, MAFP blocks virtually all 2-AG-degradating enzymes, and 
during the following 90 minute [35S]GTPγS labelling step, 2-AG-synthesizing enzymes have 
sufficient time in which to operate. The current study attempted to clarify wether the 
MAFP-evoked response was due to DAGL activity by using brain sections of DAGLα-KO 
and DAGLβ-KO mice. Unexpectedly, the obtained results indicate that some THL-sensitive 
enzymes other than DAGLs are responsible for 2-AG generation in brain sections. Since 
DAGLα-mediated 2-AG generation is believed to be responsible for the retrograde synaptic 
signalling, it is likely that cell types other than neurons are responsible for synthesizing the 
2-AG in brain sections.   
An additional goal was to identify compounds that could boost the tonic LPA1 signal in 
brain sections and in this way increase the understanding of the regulation of the brain 
LPA-GPCR signalling. Since known precursors of LPA as well as various compounds 
reported to affect the autotaxin and/or PLD activity failed to affect the basal tone of LPA1 
receptor activity, the tonic LPA1 activity in brain sections is apparently not due to LPA 
generated by autotaxin or PLD activity. Instead, it was possible to manipulate the tonic 
LPA activity by pharmacologically inhibiting LPA degradation. The results indicated that 
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LPPs guard the signalling pool of LPA but the majority of LPA degradation in brain 
sections is due to other, LPP-like, enzymes. The LPP activity served to limit the actions of 
endogenously generated LPA but not exogenously applied LPA. AlFx, propranolol and 
vanadate were found to inhibit LPPs; AlFx in an irreversible manner and propranolol and 
vanadate in a reversible manner. Additionally, the results suggested that AlFx  is able to 
inhibit the LPP-like enzymes in a reversible manner. The three inhibitors used are rather 
unspecific towards LPPs, due to the the lack of commercially available specific inhibitors of 
LPPs. However, inhibitor-induced [35S]GTPγS binding responses were restricted to the 
LPA1 receptor-enriched white matter areas, no responses were observed in other brain 
regions. Furthermore, the observed [35S]GTPγS labelling was sensitive to a LPA1/3 receptor-
specific antagonist, evidence for the absence of unspecific responses.   
The presently described approach is well suited for studying the lipid class of 
compounds, which are synthetized on demand and rapidly enzymatically degraded. The 
approach is not likely to be applicable for classical hydrophilic vesicle pre-packed 
neurotransmitters, as previously demonstrated with muscarinic cholinergic receptors 
(Palomäki et al. 2007). It should be noted that different enzymatic routes may be active in 
vivo than in vitro. Brain sections do not tend to represent a physiological model but provide 
a platform for studies of metabolic pathways regulating the lifetime of bioactive lipids, 
especially when combined with analytical methods.  
 
LC/MS/MS as a method to quantify LPA levels in the brain tissue 
 
It was wished to provide direct evidence that the endogenous LPA could accumulate in 
brain sections followed by a treatment with pharmacological inhibitors of LPA degradation. 
In previous reports, LPA content in the brain tissue had been determined by gas 
chromatography (GC) (Xu et al. 1998, Sugiura et al. 1999, Nakane et al. 2002), but this was 
an indirect method requiring first thin layer chromatographic purification, and then GC, all 
rather time-consuming. There have been a few existing LC/MS/MS methods published in 
the literature for the determination of LPA from biological fluids (Georas et al. 2007, Shan et 
al. 2008, Tokumura et al. 2009, Scherer et al. 2009) but not from the brain tissue. There have 
also been some limitations in the previously published methods, and so an LC/MS/MS 
method was developed that was optimized to the current experimental demands.  
From an analytical point of view, LPAs are a demanding group of compounds, and 
several important issues were encountered during the method development. LPA is sticky, 
binding to many surfaces, e.g. test tubes and chromatographic columns. It was noticed that 
LPA may easily bind to several test tube materials (e.g. polypropylene microcentrifuge 
tubes and certain glass test tubes) and residual LPA might lead to variations in the results. 
When Pyrex® borosilicate test tubes were used and washed with hydrochloric acid 
between the experiments, sufficient repeatability was obtained. With several 
chromatographic columns tested, LPA evidently bound to the columns and their 
performance deteriorated after a few runs. With a C8 column with a large particle size (3.5 
μm) and a pore size of 300 Å, it was possible to obtain good chromatographic performance.  
In the development of analytical methods, it is important to find means to eliminate 
interfering compounds prior to the detection. LPC, a compound that is present in high 
concentrations in tissues, can be converted to LPA during sample preparation and within 
the instrumentation, especially if acidic extraction conditions are used. LPC is also known 
to induce an ion suppression effect. There was some concern that in some previously 
published methods, LPC and the artificially formed LPA may have affected the results 
(Scherer et al. 2009, Zhao & Xu 2009). We first extracted LPC into a separate phase from 
LPA and finally removed the residual LPC by chromatographic separation. When the C8 
column was combined with an ion pair reagent in the mobile phase, LPCs were separated 
from LPAs. It was demonstrated that the chromatographic separation prior to detection 
was necessary and thus the direct flow injection could not be utilized. 
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The present method was validated and found to be suitable for LPA analysis from the 
brain tissue. In addition to brain tissue, the method could be applied to studies of other 
biological samples after optimization of the extraction procedure to each particular tissue or 
fluid. It is essential to have quantitative methods to determine endogenous lipids in 
experimental settings. Importantly, lipids could be used as biomarkers to predict certain 
diseases; e.g. there are published reports describing the use of LPA as a biomarker in the 
diagnosis of ovarian cancer (Xu et al. 1998, Meleh et al. 2007). 
 
Future perspectives  
 
The present anatomical mapping of adenosine A1 and LPA1 receptor-independent 
[35S]GTPγS labelling in basal conditions represented the first step in the improvement of the 
signal-to-noise ratio of the method. In future experiments, a systematic approach with 
various receptor antagonists would be needed to reveal which factors contribute to the 
basal labelling. The described anatomical mapping should facilitate these efforts. The 
constitutive receptor activity can be affected by sodium concentration, and testing different 
ion composition of the incubation buffer would provide information whether constitutive 
activity could affect the basal labelling. It is noteworthy that there might be orphan 
receptors activated by currently unknown ligands in the mapped brain regions. The present 
mapping provides a potential anatomical location of these orphan receptors and may 
facilitate the search for endogenous ligands capable of activating these receptors.  
The present results indicate that there are LPP-like enzymatic routes existing in the brain 
that are capable of degradating LPA. Further identification of these routes would be needed 
in future experiments. Likewise, a more detailed characterization of the 2-AG-generating 
enzymes in the brain would be beneficial. The use of brain sections from animals having 
both DAGLα and DAGLβ knocked-out would strengthen the conclusion about the 
existence of DAGL-independent routes that are able to generate 2-AG in the brain.  
There is a clear need for the development of specific and potent inhibitors targeting 
enzymes that regulate the lifetime of bioactive lipids. Currently, there are more 
specific/unspecific inhibitors reported to target the eCB system than to target the LPA 
biosynthetic/degradative enzymes. It seems that enzyme-selective inhibitors represent 
potential drug molecules. In experimental systems, specific inhibitors would provide direct 
evidence for the involvement of a particular enzyme without concerns about activation of 
compensatory mechanisms that may take place in transgenic animals. Since both LPA and 
2-AG are involved in the regulation of many organ systems as well as in the pathology of 
several diseases, defining the mechanisms of their synthesis/degradation is especially 
important for understanding these processes.  
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10 Conclusions  
 
The first aim of the present study was to develop and optimize the methodology used for 
studying lipid-GPCR signalling and the second aim was to characterize the enzymatic 
pathways responsible for the lipid messenger synthesis and degradation. The main 
technique utilized throughout the study was functional autoradiography; this was 
exploited in a novel way to examine the enzymatic pathways that regulate the brief lifetime 
of bioactive lipids. 
 
 
 
The main conclusions of the present study are as follows: 
 
 
1. The majority of the adenosine A1 and LPA1 receptor-independent basal [35S]GTPγS 
labelling in the juvenile rat brain sections were located deep in the brainstem as well 
as in several thalamic and hypothalamic nuclei. The basal signal appeared to be G 
protein-mediated and could reflect regional enrichment of various members of the 
GTP-binding protein family, constitutive activity of unidentified GPCRs and/or the 
presence/synthesis of receptor ligands.   
 
2. A LC/MS/MS method was developed for quantitative determination of LPA species 
from brain tissue samples. Special attention was paid to the separation of interfering 
compounds prior to detection. 
 
3. LPPs degrade the signalling pool of LPA in rat brain sections. In addition to LPPs, 
there seemed to be alternative LPP-like enzymes existing in the brain that degrade 
LPA at the bulk brain level.  
 
4. The CB1 receptor-dependent Gi-activity remained unaltered in several brain regions 
of DAGL-deficient mice when compared to WT mice. Alternative enzymes other 
than DAGLs appeared to be responsible for synthesizing 2-AG in brain sections.  
 
5. The enzymatic machinery synthesizing and metabolizing membrane-derived lipid 
mediators was well preserved in brain cryosections. Especially when combined with 
analytical methods, functional autoradiography could be used as a pharmacological 
tool to reveal the enzymatic pathways that regulate lipid-GPCR signalling.  
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Receptor Signalling
Bioactive lipids act as important 
signalling molecules both in the 
central nervous system and the 
periphery. Bioactive lipids are 
produced by multistep enzymatic 
pathways and after they exert 
their effect by activating their 
specific receptors, they are rapidly 
enzymatically degraded. Altered 
lipid signalling is linked to the 
pathology of several serious diseases. 
In the present study, functional 
autoradiography was applied in a 
novel way to examine the enzymatic 
pathways that synthesize and 
degrade signalling lipids in brain 
sections.
